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Abstract 
 
Preterm delivery occurs in 10% of all births. It is the major cause of infant death and handicap in the 
developed countries and accounts for 65% of neonatal deaths and 50% of childhood neurological 
disabilities. At the end of pregnancy, „pro-labour‟ factors begin to mediate remodeling of the cervix 
resulting in cervical ripening and dilatation, uterine contractility and decidual/fetal membrane 
activation. The amnion plays an important role in the onset of human labour. It is a major site for 
prostaglandins (PG) and inflammatory cytokine synthesis which increases both before and during 
labour. Amnion derived inflammatory cytokines and prostaglandins contribute to the relaxation of the 
lower uterine segment and to cervical ripening. Oxytocin (OT) and oxytocin receptor (OTR) are 
classically considered to play a fundamental role in the mechanism of labour as OT stimulates uterine 
contractions and OTR antagonists are clinically used as tocolytics. The increase in OT and OTR 
expressions were observed in tissues other than myometrium, including the breast cells, decidua and 
amnion. However, amnion is not a contractile tissue and therefore the physiological role of the 
OT/OTR is less obvious. We hypothesised that the regulation of OT/OTR in human amnion is linked 
to NF-κB activity and plays an important role in the onset of labour.  
We have demonstrated that in human amnion, labour induces expression of both OT and OTR 
expression. Using specific inhibitors and siRNA target knockdown studies, we have shown that unlike 
the myometrial OTR, OT binding to OTR in human amnion drives the receptor to couple with Gαi2 
and Gαi3, but not Gαq. This subsequently triggers the sequential activation of ERK, p38 MAPKs and 
NF-κB signalling cascades leading to PG and proinflammatory cytokine/chemokine synthesis. This 
suggests that OT not only induces uterine contractions but also plays a role in triggering the onset of 
labour by mediating the proinflammatory effects in the amnion.  
These proinflammatory effects of OT were suppressed by an OTR-specific antagonist, ornithine 
vasotocin (OVT), indicating that OT exerts its effects predominantly via OTR. However, the 
commonly used OTR antagonist, atosiban, had no effect on OT induced proinflammatory effects. 
Unexpectedly, atosiban treatment alone resulted in activation of inflammatory mediators such as 
MAPKs and NF-κB leading to downstream pro-labour gene expressions via Gαi. Activation of such 
inflammatory processes within the uterus initiates labor, whereas exposure to inflammation may be 
associated with fetal brain damage in preterm and term infants. Therefore, atosiban could exacerbate 
inflammation in the context of preterm birth and potentially have an effect on neonatal outcome. With 
this in mind the future development of OTR antagonists to prevent preterm birth will need to take into 
account the effects upon differential OTR G-protein coupling. 
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1.1. Pregnancy and parturition 
1.1.1. Normal labour: phases of parturition 
Human parturition is a complex sequence of events that involves four different physiologic phases [1]. 
For most of human pregnancy the myometrium remains in a state of functional quiescence, allowing 
development of the fetus. During this first parturitional phase putative inhibitors, such as progesterone, 
prostacyclin, relaxin, nitric oxide, parathyroid hormone-related peptide, calcitonin gene-related 
peptide, adrenomedullin, and vasoactive intestinal peptide, keeps the uterus in a quiescent state [2]. 
The mechanisms through which these agents act vary but in general, they lead to increased 
intracellular cyclic adenosine monophosphate (cAMP) levels resulting in a decrease in calcium 
release and reduction of myosin light chain kinase activity, which is required for contraction of 
myofilaments. At the end of the first trimester, progesterone production is taken over by the placenta 
and there is luteal regression. In many species, labour is initiated by progesterone withdrawal 
although this does not occur in the human [3]. Pharmacological inhibition of progesterone action 
however, increases myometrial contractility and causes cervical ripening [4, 5].  
Towards the end of pregnancy, there is a relatively gradual change from myometrial quiescence to a 
more contractile state. The transformation of the uterine muscle from quiescent to contractile occurs 
during the second „activation‟ phase in response to uterotropins and is thought to involve increased 
synthesis of contraction-associated proteins (CAP) including proteins encoding ion channels, 
connexin-43, prostaglandins (PG) and oxytocin receptors (OTR) [6, 7]. Activation prepares the uterus 
for labour and alters it from a relatively insensitive organ to a sensitive organ, primed for stimulated 
contractions. It is possible that there are two phases of upregulation of pro-labour proteins. Proteins 
such as OTR, PG receptors and gap junctions are upregulated during the third trimester whilst 
inflammatory-type mediators are upregulated in the 2-3 weeks prior to labour. 
In the third „stimulation‟ phase of parturition, the uterus can be stimulated by uterotonins including 
PGs, CRH and oxytocin (OT). It is accepted that the nonapeptide hormone oxytocin plays a key role 
in the stimulation process, and there is growing evidence for its contribution to the activation process 
as well. The biochemical events within the uterus resemble an inflammatory reaction [8]. Labour is 
associated with increased synthesis of cytokines and PGs and an influx of neutrophils into the uterus. 
Chemotactic cytokines, such as IL-8, attract protease secreting neutrophils into the fetal membranes 
and cervix. This leads to remodelling and ripening. Prostaglandins have been used to drive cervical 
ripening to induce labour. PGE2 is able to promote cervical changes that resemble a normal 
physiologic ripening seen prior to labour. It is thought to involve stimulation of collagenolytic activity 
in cervical tissue [9]. This leads to relaxation of the lower segment of the uterus and stimulate 
fundally dominant contractions.  
21 
 
The fourth „involution‟ phase of parturition includes the uterine involution that follows the delivery of 
the fetus and the placenta, which has been found to be primarily mediated by oxytocin.  
1.1.2. Preterm labour 
Preterm birth refers to delivery that occurs at gestational age less than 37 weeks. It occurs in 9% in 
high-income countries compared to 15% in the poorest countries [10]. Despite the advancing 
knowledge of the risk factors and mechanisms involved in preterm labour and increasing public health 
and medical interventions, there has been a marked rise in preterm birth rate in highly industrialised 
countries [11]. Preterm labour (PTL) is one of the main causes of perinatal morbidity and mortality. It 
accounts for 75% of perinatal mortality and more than half of morbidity (both short-term and long-
term), including cerebral palsy, deafness, blindness and chronic lung disease [12]. However, most of 
neonatal disorders and deaths are accounted for by births before 32 weeks of gestation [13]. Preterm 
birth can be categorised into spontaneous preterm labour, spontaneous rupture of the membranes, and 
delivery for maternal or fetal indications [14], where approximately 30-35% of preterm labour are 
indicated, 40-45% with spontaneous preterm labour and 25-30% with preterm premature rupture of 
memebranes (PPROM) [15].  
1.1.2.1. Risk factors of preterm labour and methods of prediction 
Predicting preterm labour takes various factors into consideration including risk factors, fetal 
fibronectin, cervical length,bacterial vaginosis, and presence of other biomarkers such as cytokines, 
chemokines, and oesteriol [15, 16]. Risk factor scoring using standardised questionnaire has been 
utilised to identify women at risk of preterm birth and gauge the intensity of their prenatal care [17-
19]. The use of risk factors for prediction of preterm labour has great potential as early identification 
of risk can lead to risk-specific treatments [20]. Risk scoring system has been successful at identifying 
women at higher risk of preterm labour on the basis of patient‟s previous history of preterm labour. It 
has been estimated that the recurrence risk of preterm labour increases by 15-50% in women with 
previous preterm delivery depending on the gestational age of the delivery [15, 21]. There is an 
inverse correlation between the number of gestational age of the previous preterm birth and the risk of 
another preterm birth. Other maternal risk factors include low and high maternal age, race, and 
socioeconomic status. Black women have 2-3 fold higher risk of early preterm birth compared to 
women from other racial groups [22]. Low socioeconomic status and educational status have been 
shown to be associated with preterm birth [23, 24], but the mechanisms involved are unknown. In 
addition, there are evidences that suggest gene polymorphism associated with increased risk of 
preterm labour. It has been reported that maternal carriage of the rare tumour necrosis factor (TNF)-2 
allele leads to approximately 2 fold increase in the risk of spontaneous preterm delivery with the mean 
gestational age at delivery of 32.9 weeks for cases compared to 39.3 weeks in control subjects [25].  
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Another risk factor is multiple pregnancies. In the case of twins, approximately 60% are born preterm, 
with 40% due to spontaneous labour or PPROM at gestational age less than 37 weeks and others due 
to maternal or fetal disorders. The relative risk for preterm birth is substancially higher for triplets 
than for twins as almost 90% of triplets are born preterm [26]. The underlying mechanism for this 
increase is preterm risk is not always clear, but uterine over-distension resulting in contractions and 
PPROM is one of the suggested causative mechanisms [27]. Bleeding in early pregnancy, specifically 
in second and third trimesters, has been associated with increase in spontaneous preterm delivery [28]. 
Smoking is also related to preterm birth as previous studies have demonstrated that tobacco use 
increases the risk of preterm birth by about 2-fold [29]. However, these risk factors have variable 
sensitivities and predictive values and thus the use of risk scoring system has limited success in 
reducing preterm birth [19].  
Intrauterine infection is the most important mechanism leading to preterm birth and it accounts for 25-
40% of all preterm births [30]. Systemic or intrauterine infection in several different pregnant animal 
models has been shown to result in preterm labour [31-33], which provides evidence supporting the 
role of infection in preterm labour. The mechanisms through which intrauterine infection leads to 
preterm labour resemble that of the innate immune response [27]. Microorganisms can gain access via 
multiple routes including accidental introduction during an invasive procedure, spreading through 
fallopian tubes, ascending from the vagina or cervix, and dissemination via haematogenous route 
through the placenta [30]. They are then detected by pattern-recognition receptors such as TLRs, 
which trigger a signalling cascade resulting in release of inflammatory cytokines and chemokines [15]. 
These in turn lead to PG synthesis and matrix-degrading enzymes to stimulate uterine contractions 
and PPROM [27].  
Bacterial vaginosis has been associated with up to 3-fold increase in the risk of preterm birth [34]. It is 
a disorder characterized by changes in vaginal microbiome. Presence of clue organisms such as 
mobiluncus and bacteroides, high vaginal pH, and profuse white discharge are used for diagnosis [35]. 
There is  a significantly higher incidence of bacterial vaginosis in black women than white women, 
this may contribute to the higher risk of preterm labour in black women [36]. 
Biological fluids have been used to predict preterm birth. There have been numerous studies to assess 
the value of biomarkers, however, only few have shown clinical usefulness [20]. One of the most 
powerful biochemical predictor/biomarker of preterm birth is fetal fibronectin. It is glycoproteins 
produced by the fetal membranes to maintain the attachment of placenta and membranes to uterine 
deciduas [37]. Presence of fetal fibronectin in cervicovaginal fluid of women undergoing routine 
screening at 24-26 weeks of gestation is normally considered an indication that they are at 
substantially higher risk of preterm delivery [38]. Increase in fetal fibronectin from under 40 ng/ml to 
100 ng/ml and over has been associated with a progressive increase in the risk of preterm birth [38]. 
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Meta-analysis confirmed that the fetal fibronectin screening has high negative predictive value, 
meaning that there is a strong correction between absence of fetal fibronectin and lower risk of 
preterm labour [39]. 
Prior to the onset of labour, the cervix undergoes remodelling where it shortens, softens and dilates, 
which occurs in both term and preterm parturition [27]. In 1965, it was first reported that a short cevix 
is a risk factor for preterm labour and delivery [40] and since then there has been numerous studies 
confirming this finding [41-43]. Shortening of cervix is one of the earliest indicators of labour onset. 
Cervical length of less than 25 mm after 24 weeks of gestation increases the relative risk of preterm 
labour [44], and thus  routine cervical length assessment is considered to be useful for prediction of 
preterm labour in high risk pregnancies. The combination of fetal fibronectin and cervical length 
assessment is thought to provide better predictive values [45]. 
1.1.2.2. Preventing preterm labour 
Management of preterm birth has been developed target PTL before the onset of labour as well as 
established PTL.  Preventing preterm labour before labour onset involves enhanced prenatal care in 
combination with nutritional interventions and patient education, screening and treatment of 
infections, progestin supplementation, and cervical cerclage [11].  
There are contrasting evidences on the role of enhanced prenatal care in preventing preterm labour. 
Increasing the availability and frequency of prenatal care generally failed to reduce preterm births, 
however, few reported that enhancement of prenatal care by adding patient education and maternity 
care coordination result in lower premature labour and improved fetal outcome [46, 47]. Despite such 
promising results from initial observational studies, randomized, controlled trials showed that 
enhanced prenatal care is not effective in preventing preterm birth [48, 49]. These differences may be 
due to the variance in the enhancements to prenatal care, patient risk characteristics, and rate of 
hospital admission for preterm labour. With such inconsistencies in different reports, it is difficult to 
prove the effectiveness of prenatal care in preventing preterm labour. 
As previously mentioned, infection has been shown to be strongly associated with preterm birth. 
Screening and treatment of intrauterine infections during early pregnancy has been used as 
preventative measures. There are several lines of evidence supporting the use of antibiotics in preterm 
birth. In the case of bacteriuria, analysis of randomized clinical trials showed that the antibiotic 
treatment led to significantly reduction in preterm delivery as well as occurrence of low birth weight 
[50]. Randomised controlled trials suggest that the use of antibiotics in bacterial vaginosis and 
abnormal vaginal flora resulted in a decrease in preterm birth [51]. However, administration of broad-
spectrum antibiotics had conflicting results. A broad-spectrum antibiotic, erythromycin, had beneficial 
effects in women with bacterial vaginosis as well as PPROM [52, 53], but co-amoxiclav was found to 
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be associated with neonatal morbidity [53]. There are studies showing that antibiotics for bacterial 
vaginosis increase the risk of PTL. In recurring bacterial vaginosis, administration of intravaginal 
clindamycin has been shown to increase the rate of PTL which may be due to the selectivity of the 
antibiotics enabling virulent growth of E.coli and bother bacterial known to be associated with PTL 
[54]. The conflicting results on the use of antibiotics to prevent preterm birth are mainly due to the 
wide variety of antibiotics available. This would be particularly important finding among black 
women, who have higher incidences of bacterial vaginosis than women for other ethnicity. 
Progesterone decline has been shown to precede the onset of labour. Thus a number of studies were 
designed to evaluate the effect of progestin supplementation in the prevention of preterm birth. The 
use of 17 alpha-hydroxyprogesterone caproate has been shown to significantly reduce the occurrence 
and recurrence of preterm birth [55, 56]. Progesterone has also been implicated in reducing the risk of 
spontaneous early preterm birth in women with short cervix [57]. In randomised trial, intravaginal 
progesterone administration to women with a sonogrphic short cervix led to 45% reduction in the rate 
of PTL before 33 weeks, 38% reduction in PTL at < 35 weeks and 50% reduction in PTL < 28 weeks 
[58, 59]. but not in women with a history-indicated cerclage [60]. However, administration of 17 
alpha-hydroxyprogesterone caproate seems less effective in prevention of prematurity in multiple 
pregnancy [61] and established preterm labour. The progestin supplement regime requires weekly 
injections and as the improvements were variable, it is no longer used regularly.  
Cervical cerclage has been a traditional treatment for an incompetent or structurally weak cervix [11]. 
Several studies have demonstrated a clear association between short cervix and the risk of PTL. 
Placement of cervical suture was aimed to correct the weekness that occurs in the mechanisms that are 
required to retain the conceptus in the uterus [62]. Emergency cerclage has been reported to prolong 
pregnancy by 4-5 weeks (ranging from 1 day-18 weeks) [63], and history- or ultrasound-indicated 
cervical cerclage appears to have lower complication rates [64]. Highest efficacy of cervical cerclage 
reducing preterm birth was observed with a multifactorial approach, where cervical cerclage was used 
in combination with antibiotics, bed rest, and other tocolytics such as prostaglandin synthesis inhibitor, 
indomethacin [65, 66]. There are reports of contradictory conclusions which illustrated that placement 
of a cerclage is ineffective in reducing the rate of spontaneous preterm birth. Randomised controlled 
trials showed the insertion of Shirodkar suture in women with a short cervix at 22-24 weeks of 
gestation or McDonal cerclage of ultrasonographic short cervix does not reduce prematurity nor 
improve perinatal outcomes [67, 68].  
Various tocolytic drugs for treatment of established preterm labour have been developed. Use of 
tocolytics aim to prevent preterm labour for women at risk of preterm birth and may postpone 
delivery long enough to improve neonatal outcome. Previous randomized trial data suggest that 
tocolytics can delay labour for up to 48 hours [69, 70]. This allows time for antenatal corticosteroid 
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administration for fetal lung maturity, which significantly reduces neonatal respiratory distress 
syndrome, intraventricular hemorrhage, and mortality [71]. It allows in utero transfer to a hospital that 
has facilities to provide neonatal intensive care which can potentially improve neonatal outcomes [72]. 
Tocolytics are also used in cases of uterine hyperstimulation, resulting in fetal distress and can 
facilitate external cephalic version at term. However, if aiming to prolong pregnancy for over a week, 
tocolytics have limited efficacy.  
Currently available tocolytic drugs target preterm labour in a reactive way when uterine contractility 
and preterm labour have already started. The classes of drugs used as tocolytics include nitric oxide 
donors (glycerol trinitrate) [73], calcium channel blockers (such as nifedipine) [74], beta-mimetics 
(such as terbutaline) [75], magnesium sulphate [76], cyclo-oxygenase inhibitors [77] and oxytocin 
receptor antagonists [78]. Figure 1.1 shows their mechanism of action.  
 
Figure 1.1. Mechanisms of action by tocolytics. (modified from [79]) 
 
Nitric oxide (NO) is produced during oxidation of amino acids catalysed by NO synthase. It acts as a 
strong vasodilator and has been suggested to be associated with cyclic guanosine monophosphate 
(cGMP) generation and uterine relaxation [80]. The ability of NO to suppress uterine contractility was 
more predominant in non-labouring tissues in comparison to labouring tissues, indicating that NO is 
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most potent during pregnancy and it loses its inhibitory effect with the onset of labour to enable 
uterine contractions [80]. Nitroglycerine is a typical nitric oxide donor, which has been used to relax 
the uterus. In the meta-analysis of randomised controlled trials, nitroglycerine had no effect at 
delaying labour or improving fetal outcome [73]. NO donors are not used in clinic despite its ability to 
reduce prematurity, due to significantly higher risk of side effects compared to other tocolytics [79].  
Calcium-channel blockers are agents that interfere with the transfer of calcium ions in cell membranes. 
They are non-specific smooth muscle cell relaxants commonly used to treat hypertension. In 
myometrial cells, calcium-channel blockers decrease intracellular free calcium concentration by 
preventing influx of calcium ions and drive myometrial relaxation [81]. Human myometrium in vitro 
studies showed great promise in the use of calcium-channel blockers to manage preterm labour [82]. 
The most widely used calcium-channel blocker is nifedipine. A meta-analysis of randomised trials 
reported that nifedipine reduced the number of deliveries for 7 days and reduced neonatal morbidity 
[74]. Since then, there has been growing evidence supporting the efficacy of nifedipine in the 
management of preterm labour, which suggested that it is a promising tocolytic agent with easy route 
of administration and fewer side effects [83]. However, it is to be used with caution in patients with 
cardiovascular conditions as it may increase the risk of pulmonary oedema and cardiac failure [84]. 
Tocolytic betamimetics have been used routinely in clinical practice since 1980s [79]. They are used 
to activate adenyl cyclase to increase cAMP production. This increase in cAMP leads to a reduction 
of intracellular calcium and decrease in activity as well as phosphorylation of myosin light-chain 
kinase, thus inducing uterine relaxation [85]. Despite the initial studies reporting the efficacy of 
betamimetics in delaying preterm birth for two days, there were significant maternal side effects [75, 
84]. Their use has been replaced by oxytocin receptor antagonists and nifedipine as they have similar 
efficacy with significantly less maternal side effects. 
Magnesium sulphate has been reported to have relaxant effect in human uterine contractility. It is 
considered to be a calcium antagonist as it reduces intracellular calcium levels and the process of 
contraction [81]. However, a meta-analysis reported that it had no beneficial effect on preterm labour 
and its use in higher doses was associated with increased infant mortality [76]. There is lack of 
evidence to recommend this drug as a first-line tocolytic agent, but there is growing evidence that 
suggests magnesium sulphate provides fetal neuroprotection. This was first reported by Nelson et al. 
where they found that administration of magnesium sulphate protected premature infants against 
cerebral palsy [86]. Magnesium can reduce threats to preterm brain as it can reduce vascular 
instability and lesses hypoxic damage whilst providing protection against cytokine or excitatory 
amino acide damage [87]. Randomised, placebo-controlled trials followed to support the use of 
magnesium sulphate to lower the risk of cerebral palsy in infants [88-90].  
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Prostaglandins have been consistently reported to play a central role in the onset of labour. 
Prostaglandin-synthase inhibitors were designed to block the production of PGs by interfering with 
the activity of cyclooxygenase (COX) isoforms. The most widely used COX inhibitor is indomethacin, 
which is a non-specific COX inhibitor that has been reported to reduce birth before 37 weeks of 
gestation and increase gestational age compared to both placebo and other tocolytics [77]. However, 
its use is restricted due to its potential adverse effects on the fetus as well as the mother. The use of 
indomethacin has a potential risk of neonatal necrotising enterocolitis, premature closure of the ductus 
arteriosis and decrease in urine production [27, 77, 84]. Collectively, these studies indicate that 
indomethacin is an effective tocolytic drug for short-term effect in pregnancies below 32 weeks. 
Specific COX-2 inhibitors such as nimesullide or rofecoxib have been developed but are not 
recommended for use in clinical practice due to their side effects [91]. Rofecoxib has been shown to 
be associated with incread rate of PPROM as well as the risk of preterm delivery [92].  
Oxtocin receptor antagonists (OTR-A) are another type of tocolytic agent currently available. The 
only OTR-A used in clinical practice is atosiban, which has been reported to have controversial 
efficacy. However, alternative OTR-A are still under development. More details about this particular 
type of tocolytic agent will be discussed further later on in this chapter. 
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1.2. Anatomy of tissues in pregnancy and labour 
The gestational tissues are made up of tissues from both maternal and fetal origin. The maternal 
tissues consist of the uterus (myometrium, cervix and deciduas), and fetal tissues consist of fetal 
membranes (amnion and chorion) and placenta (Fig. 1.2). The interactions between these tissues are 
important in maintenance of pregnancy as well as the onset of labour. 
 
 
 
Figure 1.2. The gestational tissues of the human uterus. The gross anatomy of the intrauterine tissues 
comprised of the uterus, fetal membranes, fetus, and cervix (Modified from [93]).   
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1.2.1. The uterus 
The uterus is a muscular organ which is capable of accommodating a growing fetus throughout 
pregnancy by hypertrophy and stretch. It then provides a contractile force towards the end of gestation 
to aid the expulsion of the fetus. There are three main parts of the uterus; the myometrium, the cervix 
and the decidua [94].  
The myometrium is the major muscular layer of the uterus, predominantly composed of bundles of 
smooth muscle fibres connected by collagen fibres, which are called fasciulata. The seemingly 
random arrangements of these fibres provide the driving force behind the waves of contractions in 
every direction during labour, thus referred to as the engine room of parturition [95]. Therefore the 
proceses involved in the onset of labour ultimately result in activation of this tissue. The myometrium 
can be divided into three topographically separate segments; the fundus (top), corpus (upper) and 
isthmal (lower) segments. At the time of active labour, the contractions begin at the fundal region 
travel downwards towards the lower, isthmal segment in a wave-like motion [96]. The spatial 
difference in this contractile activity is associated with the significant differences in gene expression 
between the fundal and isthmal segments [97]. There are increases in procontractile gene expression 
(such as oxytocin receptor and connexin-43) [98], whereas the lower segments has greater expression 
of corticotrophin-releasing hormone receptor R1 to aid relaxation of the uterus [99], and COX-1 and -
2 to promote PG synthesis that subsequently results in cervical ripening [98].  
The cervix is the lower cylindrical portion of the uterus which consists of collagen fibre, connective 
tissue and blood vessels. During most of pregnancy, the cervix remains rigid and tightly closed [100], 
whereas towards the time of labour, it undergoes a major remodelling process called cervical ripening. 
The ripening of the cervix occurs in both term and preterm parturition. It occurs concurrently with the 
activation of the myometrium, and it resembles a proinflammatory process with infiltration of 
macrophages and neutrophils [101]. This leads to cytokine release as well as production of enzymes 
necessary for cervical ripening. Collagenases, elastases, and matrix metalloproteinases release result 
in the breakdown of the connective tissue and collagen fibres, ultimately enabling the softening and 
shortening of the cervix prior to the passage of the fetus [102].  
The outer layer of the uterus is referred to as the endometrium. During pregnancy, endocrine events 
driven by progesterone and other stimuli transform the endometrium to form the maternal component 
of the placenta, the decidua. It acts as an interface to the embryo, enabling the exchange of nutrients, 
gas and waste. Moreover, it is also considered to regulate the maternal-fetal immune-tolerance during 
pregnancy [103]. The decidua itself can be divided into three regional layers defined by their role in 
the implantation of the embryo. The region closest to the site of placentation, interacting with the 
trophoblast is called decidua basalis.  The decidua capsularis is a layer that forms around the growing 
embryo within the uterine cavity, enclosing it to the endometrium. The third layer is called decidua 
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parietalis, which forms a lining inside the whole of uterine cavity. The decidua consists of a distinct 
population of leukocytes and specialised lymthocytes (uterine natural killer cells) that leads to 
production of cytokines and growth factors for angiogenesis, vascular stability and placental growth 
[104].  
1.2.2. Fetal membranes and placenta 
Fetal membranes are comprised of the amnion and the chorion (Fig. 1.3), and encapsulate the growing 
fetus and amniotic fluid. They act as a barrier against ascending infections and play a role in the 
exchange of nutrients along with the placenta. The amnion is the innermost layer of the fetal 
membranes, which is in contact with the amniotic fluid and helps provide the tensile strength required 
to the fetal sac. There are five different layers of amnion. The innermost layer of amnion is made of 
non-ciliated cuboidal epithelial cells attached to the amniotic basement membrane. The amniotic 
basement membrane combined with the fibroblast layer surrounded in a mass of reticulin form the 
bulk of the amnion and represent the strongest structure of the amnion. The innermost layer, amnion 
mesenchyme, is immediately apposed to the chorion but not fused. The amnion is devoid of muscular, 
vascular and innervated tissue, thus it contributes to the onset of labour via production of cytokines, 
chemokines and prostaglandins. The mechanical stretch of amnion is also thought to have a role in the 
onset of labour [105]. 
 
Figure 1.3. Schematic diagram of human fetal membranes. The amnion consists of a single epithelical cell 
layer and a mesenchyme with basement membrane and fibroblast layer.The chorion consists of reticular layer, 
basement membrane and trophoblast cells (Modified from [106]).  
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The chorion forms the outer layer of the fetal membranes. It is comprised of three layers; the 
trophoblast layer, the chorionic basement membrane and the reticular layer [107]. The trophoblast 
layer of chorion connects fetal membranes to the decidua via a mass of chorionic trophoblast cells 
loosely arranged with large intracellular spaces. These cells are attached to the chorionic basement 
membrane, a dense connective tissue, and then to the reticular layer that forms the main bulk of the 
chorion. As in the amnion, chorion contributes to the prostaglandin synthesis within the uterus 
associated with labour.  
The placenta is a feto-maternal organ through which the mother supplies the nutrients and oxygen to 
the fetus [108]. As mentioned above, the maternal component of placenta develops from 
decidualisation of the endometrium and the fetal component from the chorionic sac. The placenta is a 
neuroendocrine organ, comprised of lymphoid and non-lymphoid cells and it contributes to the 
maintenance of gestation and the timing of parturition [109]. It is capable of producing high 
concentrations of hormones including progesterone, oestrogen, and gonadotrophins, which play 
significant roles in the maintenance of pregnancy [110]. The placenta also mediates the production of 
corticotrophin-releasing hormone (CRH) with advancing gestational age [111] and there is increasing 
evidence supporting the role of CRH in regulating the time of labour onset [112].  
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1.3. Inflammation – a hallmark of parturition 
The processes involved in the onset of labour are not yet defined, however, there is increasing 
evidence supporting the significance of inflammation in both term and preterm parturition [113-115]. 
During the onset of labour, there is a global increase in a number of proinflammatory factors 
including prostaglandins, cytokines and manganese superoxide dismutase [116-118]. Previous 
microarray and suppression subtractive hybridisation studies demonstrated that this global increase is 
not only confined to the myometrium [119, 120] but it is also seen in the uterine cervix [121] and the 
fetal membranes [122].  
Parturition has been typically associated with elevated levels of interleukin-1β (IL-1β), IL-6 and 
tumor necrosis factor-α (TNFα) in amnion, myometrium, and choriodecidua [123, 124] and 
downregulation of anti-inflammatory cytokines such as IL-10 in placenta [125]. This may be due to 
the influx of inflammatory cells such as neutrophils, macrophages and T-lymphocytes into the 
labouring uterine tissues [114], which results in increase in production of proinflammatory cytokines. 
The role of IL-1 and TNFα in the onset of labour has been studied extensively. In several animal 
models, the levels of IL-1β has been shown to increase with advancing gestation [126] and systemic 
administration of IL-1β can drive both term and spontaneous preterm delivery, which is can be 
reversed with the use of IL-1β antagonist [127, 128]. The proinflammatory cytokines also trigger the 
activation of secondary mediators of inflammation such as prostaglandins and IL-8, which itself can 
contribute to the onset of labour. Other than promoting uterine activation during the onset of labour, 
proinflammatory cytokines may also promote inhibition of signalling pathways that are involved in 
maintaining uterine relaxation. For example, TNFα has been shown to inhibit cAMP production via 
Gαs expression and inhibit the relaxation of myometrium during pregnancy [129]. 
In addition, inflammation has been strongly implicated in the infection-driven preterm labour [130]. 
As discussed before, infection is a frequent cause of preterm delivery. Insults such as exposure to 
microorganisms trigger inflammation, which leads to delivery of macrophages, neutrophils and 
lymphocytes, similar to that in normal term labour. Recent findings demonstrated that a key signal for 
the initiation of uterine inflammatory response at term may be the increase in surfactant lipids and 
proteins released by the maturing fetal lung [131]. In mice, they have shown an increase in surfactant 
protein-A (SP-A) release from fetal lung and this was found to drive the influx of macrophages into 
the amniotic fluid. Subsequently the macrophages produce inflammatory cytokines, which migrate to 
the uterus to stimulate uterine contractions [132]. The findings from various studies over the last two 
decades have given rise to the notion that parturition is an inflammatory process. 
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1.3.1. Triggers of labour 
1.3.1.1. Corticotrophin-releasing hormone (CRH) 
CRH has been reported to play a role in the process of labour. CRH is a peptide hormone produced in 
the hypothalamus but also found in intrauterine tissues including placenta, chorio-decidua and amnion. 
In domestic ruminants such as sheep and cows, CRH is produced by the fetal hypothalamus to act as a 
primary factor in the onset of labour [133, 134]. This involves activation of fetal hypothalamic-
pituitary-adrenal (HPA) axis during term, which leads to increased adrenal cortisol synthesis. The 
fetal cortisol then regulates the placental 17α-hydroxylase/17,20-lyase (CYP17) activity and catalyze 
the metabolism of pregnenolone to 17β-estradiol [135]. Increase in oestrogen alters the oestrogen and 
progesterone ratio at term, and promotes uterine prostaglandin production and labour onset. However, 
this was not observed in human parturition as the placenta lack the CYP17 enzyme [136]. Despite the 
fact the fetal-derived CRH are not associated with human labour, there were hypotheses proposed for 
the role of CRH in labour onset by acting as a „placental clock‟. This was mainly due to the findings 
showing increases in placental CRH production and maternal CRH levels throughout advancing 
pregnancy, peaking at term [137].  
The precise roles of CRH during pregnancy still remain undefined. However, the presence of specific 
CRH receptors (CRH-Rs) in various intrauterine tissues such as the myometrium, deciduas, and 
placenta has led to the speculation that CRH may directly target these tissues to exert important 
functions in the onset of labour [138-140]. CRH has been shown to result in different physiological 
outcomes depending on the type of receptor it activates [140]. In human myometrium, it has been 
demonstrated that CRH-R1 increases in expression in the lower segment during labour, but remain 
unchanged in the fundus [99]. The activation of CRH-R1, predominantly linked to Gαs proteins, lead 
to upregulation of myometrial intracellular signals such as cAMP, cGMP and NO, which generally 
believed to act as a relaxant in the myometrium [141, 142]. This ability of CRH to maintain uterine 
quiescence in pregnant myometrium was confirmed by isometric contractility studies on human 
myometrial strips [143]. This effect of CRH is suppressed with the onset of labour as there is a 
significant down-regulation of Gαs protein [144], and OT-induced protein kinase C (PKC) activation 
inhibits the activity to cAMP-linked CRH-R, which creates a microenvironment for myometrial 
contractility [145]. The specific activation of CRH-R2 by local CRH and CRH-related peptides such 
as urocortin-1 and -2 in the myometrium has been suggested to contribute to uterine contractility 
[146]. More recent findings reported that the onset of labour alters the expression of CRH-R1 splice 
variants in the myometrium, which subsequently impairs CRH-induced cAMP production to enable 
the induction of uterine contractility [147].  
Other than directly contributing the uterine contractility, CRH may also affect uterine activity 
indirectly by regulating the expression of proinflammatory mediators. Local production of CRH has 
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been found to participate in promoting the production of prostaglandins by human placenta, deciduas 
and fetal membranes [148]. This increase in prostaglandins can subsequently contribute to the onset of 
labour as it has been reported to be involved in various stages of human parturition including cervical 
ripening and uterine contractions. Moreover, CRH has been suggested to inhibit production of 
progesterone by placenta trophoblasts [149], which supports the role of CRH in uterine transition 
from quiescent to contractile state. 
1.3.1.2. Mechanical factors 
Previous studies have suggested stretch as a factor contributing to the time of labour. Uterine 
distension in unilaterally pregnant animals is one of the key regulators of labour as it drives 
expression of CAPs, ultimately resulting in uterine contractions. Experiments in rats have provided 
evidence that preterm labour might result from mechanical stretch that induces expression of OTR 
and other genes activated within the pregnant uterus [150]. These changes were achieved with the use 
of an inert cylinder implanted into an empty horn of a pregnant rat. The expression of genes induced 
by mechanical stretch, such as CX-43 and CX-26, was not affected in the control, unstretched horns. 
In sheep, the increases in COX-2 and OTR mRNA were significantly higher in the gravid than the 
non-gravid horns [151]. Similar to this, studies in human myometrial cells have been shown to 
increase the expression of IL-8 [152], OTR [153] and prostaglandin synthetic enzyme, COX-2 [154], 
with mechanical stretch. Stretch also stimulated production of inflammatory cytokines and PGs in 
both cervical cells [155] and amnion epithelial cells [105, 156]. These data indicate that towards the 
end of pregnancy, the increase in fetal growth presses down into the lower segment of the uterus 
leading to stretch in the uterine walls, fetal membranes and the cervix. This subsequently results in the 
activation of contractile and labour-associated proteins (proinflammatory factors) at the time of labour. 
1.3.1.3. Cytokines and chemokines 
1.3.1.3.1. Cytokines 
Cytokines are soluble mediators of the immune response that play a role in immune regulation, 
hematopoiesis and inflammation. Cytokines act as key communicators for immune cells and 
maintaining the delicate balance in their levels is essential for health. Due to the recent findings 
implicating significant role of cytokines in many chronic diseases, it has become a vital diagnostic, 
prognostic and therapeutic tool in human diseases [157].  Originally, cytokines were thought to be 
specific in their function and could be divided into functional classes; lymphocyte growth factors, pro- 
or anti-inflammatory, and others polarizing the immune reponse [157, 158]. However, studies using 
the recombinant molecules demonstrated that some cytokines are multifunctional where one can 
induce various effects depending on the target cell. Typical examples of multifunctional cytokines 
include IL-6, IL-1 and TNFα [159]. This multifunctionality can be explained by the ubiquitous 
expression of specific cytokine receptors, in which case, the cell type can define the effect of the 
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cytokine. For example, both IL-1 and TNFα have been known to activate transcriptional factors such 
as NF-κB to induce COX-2 and PGE2 [160], but in T cells, which lack the expression of COX-2, IL-1 
and TNFα demonstrate co-activating properties to drive IL-2 production [161]. 
Proinflammatory cytokines play a crucial role in both term and preterm parturition. Increase in the 
expression of cytokines is observed in both myometrium and cervix during labour [114], which is 
partly due to the influx of leukocytes expressing cytokines. The placenta and fetal membranes are also 
one of the major sources of a diverse number of cytokines [162]. Inflammatory mediator associated 
with preterm birth, such as IL-1β [163], IL-6 [164], IL-8 [116] and TNFα [165], have all been shown 
to increase in the fetal membranes and amniotic fluid during labour [166]. As mentioned above, IL-1β 
and TNFα work in a coordinated fashion to increase NF-κB activity [167], stimulate arachidonic acid 
release and upregulate COX-2, resulting in PG production in amnion, chorion, decidua and 
myometrium. The regulation of arachidonic acid metabolism and PG production in gestational tissues 
is vital in maintaining pregnancy and the onset of labour in women. Therefore, several studies focused 
on the prostanoid function, changes in their levels and their rate of production prior to and during 
labour. In addition, cytokines can directly alter myometrial function by modulating calcium influx, 
which can increase contractility [168]. IL-1β can also stimulate phosphodiesterase activity to increase 
cAMP metabolism and contribute to the reduction of the inhibition of myometrial contractility [169]. 
Furthermore, IL-1β and IL-6 drive OT synthesis in myometrial cells [170] and in turn, can enhance 
OT-induced contractility of myometrium [171]. Other than uterine contractility, IL-1β stimulates the 
production of metalloproteinases (MMPs) to drive cervical maturation and fetal memebrane rupture 
[172], thus suggesting that cytokines play a crucial role in parturition by directly acting on myometrial 
contractility, cervical ripening and fetal membrane remodelling. 
1.3.1.3.2. Chemokines 
Chemokines are structurally related proteins that regulate the migration of cells to sites of 
inflammation. Chemokines can be divided into different families according to the relative position of 
their cysteine residues [173]. The characterizations of different chemokine families were concentrated 
on two; α- and β-chemokines. The α-chemokines have one amino acid separating the two cysteine 
residues (CXC), and β-chemokines have two cysteine residues besides each other (CC) [174].  
Chemokines and their G-protein-coupled receptors promote trafficking of immune cells to target 
organs. In early pregnancy decidua, chemokine and chemokine receptors are expressed to orchestrate 
the complex cellular migration and interaction of immune cells and trophoblasts [175]. Similar to 
decidua, there is large infiltration of leukocytes, predominantly macrophages and neutrophils, to the 
cervical stroma [176] as well as myometrium during term and preterm labour [177]. Chemokines, 
such as CXCL-8, RANTES and IL-10, attract leukocytes to the site of inflammation and there is 
compelling evidence that the chemokine-driven infiltration of leukocytes contribute to the induction 
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of local inflammatory reactions leading to cervical ripening, decidual activation and myometrial and 
fetal membrane activation during labour [178].  
1.3.1.4. Prostaglandins and cyclooxygenases 
Prostaglandins are bioactive lipids, which belong to the eicosanoid family. They originate from 
arachidonic acids (AA) to exert their function in both paracrine and autocrine manner. Prostaglandins 
bind to their specific G-protein coupled receptors to trigger activation of downstream signalling 
pathways and mediate gene expression.  
The process of PG synthesis is shown in Fig. 1.4. There are three major prostaglandin precursors, 
dihomogamma-linolenic acid, timnodenic acid and arachidonic acid, which comes from desaturation 
of the essential fatty acid linoleic and alpha-linolenic acid. The most abundant precursor is 
arachidonic acid and it is normally stored as complex lipids [179]. Phospholipases A2 (PLA2) exists in 
two different forms; cytoplasmic and secretory forms. These release arachidonic acids from 
phospholipids, which are then converted into prostaglandin H2 (PGH2) by cyclooxygenases (COX) 
particularly type 2. The subsequent conversion of PGH2 to PGE2 is mediated by PGES-1 and -2.  
The levels of prostaglandin production increase within the uterus, myometrium and the amnion [1, 
180, 181]. The single epithelial layer and the mesenchymal layer of amnion are considered to be the 
major site of PGE2 synthesis [180]. COX-2 is the key rate-limiting enzymes for PGE2 biosynthesis 
[182]. There are two major types of COX; constitutively expressed COX-1, and inducible COX-2. In 
mouse models, both cox-1 and cox-2 have been shown to be important in murine parturition [183]. 
Targeted disruption of the cox-1 gene in mice led to delay in labour as well as neonatal death [184], 
whilst disruption of cox-2 resulted in multiple failures in female reproductive processes including 
ovulation, fertilisation, implantation and decidualisation [185]. However, in infection-induced PTL, it 
has been suggested that cox-2, but not cox-1, is involved and that administration of a selective cox-2 
inhibitor can delay labour [186]. The prostaglandin synthesis in fetal membranes is predominantly 
mediated by COX-2 and previous studies have reported a steady increase in COX activity and mRNA 
expression throughout pregnancy in amnion epithelium [187]. Multiple studies have shown that COX-
2 increases in both in term and preterm amnion epithelium. This increase in COX-2 and PG synthesis 
is also present in chorion, however, that increases in decidua occurs with advancing gestation [103, 
188] and it is thought that increase in amnion-derived prostaglandins precedes the onset of labour and 
may cross the chorion to the decidua to facillitate cervical ripening, membrane rupture and uterine 
contractions [1, 189-191]. In vitro studies using radioactive PGE2 demonstrated a significant increase 
in the membrane permeability to PGE2, thus explaining the transfer of prostaglandins from the amnion 
to chorion and the cervix.  
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Figure 1.4. Prostaglandin synthetic pathway. Arachidonic acids are mobilised from membrane phospholipids 
by phospholipase enzymes and cyclooxygenases convert free AA into prostaglandin intermediate, PGH2. The 
PGH2 intermediate is then converted to terminal prostaglandins by specific synthase enzymes. 
 
COX-2 expression is tightly regulated to allow rapid regulation of prostaglandin synthesis when 
required. COX-2 has also been shown to be upregulated by prostaglandins via a positive feedback 
loop [192]. It is thought to be regulated both transcriptionally [193] and post-transcriptionally [194]. 
Proinflammatory stimuli such as cytokines and chemokines can trigger COX-2 expression and the 
promoter region of COX-2 has been shown to contain putative transcriptional factor binding sites for 
CAAT/enhancer binding protein (C/EBP), NF-κB, and AP-1, which have been demonstrated to be 
active and induce COX-2 in various cell types [160, 195, 196]. These transcription factors have been 
shown to work in combination depending on the cell type, stimuli, and the signalling pathways 
involved in their activation. In human pancreatic cancer cells, basal COX-2 expression was found to 
be mediated by both CREB and NF-κB [197], whereas in human fibroblasts, TNF-α results in NF-κB 
binding to COX-2 promoter [198] and phorbol 12-myriate 13- acetate (PMA) induces binding of AP-
1 and C/EBPβ [199].  
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The expression of COX-2 can also be regulated at a post-transcriptional level but there is lack of 
information on the protein factors that regulate the post-transcriptional metabolism of COX-2 mRNA. 
The 3‟-untranslated region (3‟-UTR) of COX-2 mRNA contains multiple adelylate- and uridylate-rich 
(AU-rich) elements (AREs), which have been implicated in posttranscriptional control of gene 
expression by altering mRNA stability [194], and typically, AREs mediate the rate of COX-2 mRNA 
degradation. Previous studies in mammary carcinoma cell line (MDA-MB-231) and human renal 
mesangial cells reported that stimuli such as serum-withdrawal or angiotensin II (AngII) can lead to 
recruitment of cytoplasmic HuR to the AREs in proximal 3‟-UTR of COX-2 mRNA to increase its 
post-transcriptional stability [200, 201], thus suggesting that HuR binding to COX-2 is essential for its 
mRNA stabilisation.  
The synthesis of prostaglandins is one of the key steps involved in the onset of human labour [202]. 
The prostaglandin receptors are present in myometrium and fetal membranes to transform the uterus 
from quiescent to active state. There are various mechanisms of action PGs utilise to trigger labour. 
PGs can lead to cervical ripening and dilation, placental separation [203] and fetal membrane rupture 
by inducing metrix metalloproteinase (MMP) activity [204]. PGs are currently used to induce labour 
and as mentioned in previous section, inhibitors of PG synthesis such as indomethacin, nimesulide 
and celecoxib have been implicated in the management of preterm labour. Knocking out cytosolic 
phospholipase A2 (cPLA2) in mice resulted in the failure to deliver at term [205, 206]. Collectively 
these data implicate that prostaglandins have a critical role in parturition. 
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1.4. Nuclear factor-κB (NF-κB) signalling  
The nuclear factor-κB was first identified in 1986 as a transcription factor that regulates the 
expression of κ light-chain gene in murine B lymphocytes [207]. Since then, there have been 
extensive studies on NF-κB and its role. It has now been established that NF-κB is expressed 
ubiquitously and acts as a central regulator of multiple cellular processes throughout the tissue. The 
NF-κB signalling pathway can be activated by various stimuli such as infection and proinflammatory 
cytokines, which are associated with labour, and drives the expression of a cassette of inflammation-
related genes including those that are pro-labour, suggesting that NF-κB may play a pivotal role in 
parturition. 
1.4.1. Subunits of NF-κB 
NF-κB is a complex of heterogeneous dimers of various subunits from the Rel/NF-κB family. The 
Rel/NF-κB family consists of RelA, RelB, c-Rel, p100/p52 and p105/p50, which share a Rel 
homology domain (RHD). The RHD is important in the process of NF-κB dimerization, DNA binding, 
nuclear translocation and IκB interaction. Each NF-κB subunit can form a homodimer or heterodimers 
with one another, except RelB, which does not dimerize with c-Rel and itself. There are a dozen 
different dimer variants, however, the classical and ubiquitously expressed dimer is the combination 
of RelA and p50, which form the primary inflammatory mediators [208]. The inactivated NF-κB 
subunits are present in the cytoplasm as homo- or hetero- dimers and they are tightly regulated by an 
inhibitory protein from IκB family, which prevents nuclear translocation of NF-κB. This family is 
comprised of four canonical members; IκBα, IκBβ, IκBε, and Bcl3, that contain multiple ankyrin 
repeat domains for protein/protein interaction [209]. Moreover, p105 and p100 precursor proteins can 
act as IκB-like proteins as they contain ankyrin repeat domains.  
1.4.2. Different types of NF-κB signalling pathways 
There are three distinct types of NF-κB signalling pathways, all of which involve sequential activation 
of kinases and nuclear translocation of NF-κB dimers (Fig. 1.5). The classical NF-κB pathway is 
typically triggered by proinflammatory stimuli such as cytokines and lipopolysccharides (LPS). 
Following the ligand-specific receptor activation, the downstream signalling activates IκB kinase 
(IKK) complex. The IKK complex, comprised of IKKα, IKKβ, and NF-κB essential modulator 
(NEMO), phosphorylates IκBα on serines 32 and 36 [210]. IKKα and IKKβ are structurally similar, 
but have different functions. IKKα has been shown to phosphorylate IκB in response to morphogenic 
signals whereas IKKβ acts in response to proinflammatory stimuli and stress [211]. The 
phosphorylated IκBα undergoes tertiary structure changes, which expose motifs recognised by SCF 
ubiquitin ligases and becomes a target for ubiquination at lysines 21 and 22 [212]. This results in 
degradation of IκBα by 26S proteosome and frees NF-κB dimers to enter the nucleus.  
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The alternative pathway has been shown to be activated by several non-inflammatory stimuli, such as 
B cell activating factor of the TNF family (BAFF), lymphotoxin β (LTβ) and CD40 ligand [213, 214]. 
The alternative pathway is NEMO- and IKKβ-independent, depending on the stimuli, RelB dimerize 
with p50 or p52 to drive the signalling pathway. In a simplified model, p100 precursor functions as 
IκB to maintain RelB/p52 or p52/p52 dimers in the cytoplasm of a resting cell. Receptor activation 
triggers increase in IKKα dimer activity, which phosphorylates p100. This elicits degradation of p100 
to p52, thus releasing RelB/p52 or p52/p52 dimers for transcriptional activity [213, 214]. Notably, the 
alternative pathway activation is slower in comparison to the classical pathway due to the absence of 
strong negative feedback mechanism by the typical IκB proteins [208].  
The third type of NF-κB signalling pathways is atypical pathway, which is IKK-independent. Stimuli 
such as DNA damage, hydrogen peroxide or pervanadate can phosphorylate IκB via p38-activated 
casein kinase II (CK-2) [215].  
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Figure 1.5. Three distinct NF-κB signalling pathways. NF-κB can be activated by classical, alternative or 
atypical pathways. In the classical pathway, extracellular signals such as TNFα, IL-1 or Lipopolysaccharide 
(LPS) enable the receptor to recruit the adaptor protein MyD88, and the kinases IRAK4 and IRAK1. These 
associate with IKK complex to stimulate activation. Degradation of IκB by phosphorylation and ubiquitination 
leads to the release of NF-κB p65/p50 heterodimers and nuclear translocation. The atypical pathway triggered 
by DNA damage results in phosphorylation of IκBα via casein kinase-II (CK2) and tyrosine kinase-dependent 
pathways. This results in dissociation of IκB from NF-κB. In the alternative pathway, LPS, lymphotoxin-β (LT-
β) or CD40 activate IKKα via TRAF3/NIK-dependent pathway which then phosphorylates p100 to generate p52. 
RelB/p52 heterodimers translocate to the nucleus and regulate expression of target genes that are distinct from 
those regulated by the classical pathway (modified from [216, 217]).  
 
Although these pathways have been studied extensively, the activation mechanism still remains 
somewhat unclear. This is mainly due to the fact the NF-κB response to a given stimulus may involve 
more than one NF-κB pathway. In particular, the classical and alternative pathways occur in a 
42 
 
completely independent way, requiring distinct signalling molecules [214], however, these pathways 
have been shown to be highly integrated as they can both contribute to the expression of a common 
set of genes. For example, in dendritic cells LPS-, IL-1β- and TNFα-activated classical NF-κB 
pathway can lead to late recruitment of RelB and this can subsequently exert redundancy or complete 
opposite effects [218]. This cross-talk between the different NF-κB pathways often occurs during 
long-lasting NF-κB activation, and it is more complex than initially thought.  In addition, recent 
studies reported cross-talk between NF-κB and other signalling cascades as several kinases such as 
mitogen activated protein kinases (MAPKs) and protein kinase C (PKC) can directly activate NF-κB 
[219]. Such cross-talk can occur at various stages of NF-κB signalling cascade, including at the level 
of NF-κB subunit modification, coactivator recruitment and the target gene promote, thereby enabling 
cell type- and stimulus-specific NF-κB responses. 
1.4.3. Multiple levels of NF-κB regulation 
There are hundreds of substances and physiological conditions known to activate NF-κB and it 
regulates numerous genes involved in a plethora of cellular processes including cell-to-cell 
communications, cell survival, proliferation, apoptosis, cell adhesion, inflammation, immune 
responses and tissue remodelling [208]. Therefore the regulation and the specificity of NF-κB 
signalling pathway are crucial. 
As mentioned before, IκB proteins are essential for NF-κB signal responsiveness as they are important 
in stabilizing DNA-bound NF-κB dimers and regulating the efficacy and duration of their 
transcriptional responses, whilst acting as transcriptional coactivators. The typical IκBs (IκBα, IκBβ 
and IκBε) are involved in the classical signalling of NF-κB. They have conserved serine residues, 
which get phosphorylated by IKKβ and targeted for ubiquitin ligases ultimately resulting in complete 
degradation by proteosomes. IκBα has been studied extensively and it is predominantly found 
associated with p65/p50 heterodimers to mediate the rapid, stimulus-induced response. Traditionally, 
it is thought that p65/p50/IκBα complex is retained in the cytosol when inactive. However, more 
recent crystallographic structure analysis studies have revealed that the actual events are more 
complex. The IκBα was only found to sequester the nuclear localisation sequence (NLS) of p65 but 
not p50 [220]. With the NLS of p50 and the nuclear export sequence (NES) of IκBα exposed, there is 
constant shuttling of p65/p50/IκBα complexes whilst the equilibrium appears to be exclusively 
cytosolic. This equilibrium is only shifted when IκBα is degraded, eliminating the effect of the NES 
and exposing the NLS of p65. IκBα is also important in the negative feedback regulation of NF-κB 
response. IκBβ has similar NF-κB binding specificity to IκBα and can completely replace IκBα 
functionally, but it also has some unique properties. It functions as a chaperone for NF-κB, indicating 
a possible regulatory function in the nucleus, and it can prolong stimulation by preventing IκBα 
association [221, 222]. Both IκBβ and IκBε have significantly delayed kinetics compared to IκBα 
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when it comes to degradation and re-synthesis in response to NF-κB. The roles of IκBε are less well 
established, however, its expression and function has been reported to be limited to hematopoetic cell 
types.  
Alternatively, NF-κB precursor proteins such as p100 and p105 can serve the function of IκB proteins 
due to their carboxy-terminal ankyrin repeats [223]. These precursor proteins undergo distinct 
processing mechanisms to generate p52 and p50. The precursor protein p105 is constitutively 
processed to p50, maintaining the p105:p50 ratio constant [224]. In case of p105 associated with NF-
κB, it can be degraded completely upon phosphorylation by IKKβ [225]. In contrast to p105, p100 
processing is stimulus-dependent and mediates the alternative NF-κB signalling pathway. As shown 
in Figure 1.5, p100 binds to RelB-containing dimers to maintain their stability. Following 
phosphorylation of p100 by IKKα, p100 is partially degraded to release active p52/RelB heterodimers. 
There is also evidence that p100 associates with p65-containing complexes to dampen the p65-
dependent responses via a negative feedback loop, thus mediating not only the alternative but also the 
classical NF-κB signalling pathway [226].  
The NF-κB response can be regulated via post-translational modifications of NF-κB subunits. Specific 
post-translational modifications can lead to changes in coactivator binding, nuclear localisation, and 
degradation of NF-κB dimers [225].  The most thoroughly investigated post-translational 
modifications are that of p65 subunit. There are diverse modification sites detected in p65, which can 
contribute to the fine-tuning of its transcriptional activity. Phosphorylation of p65 at Ser 276 is 
thought to promote acetylation at Lys310 by histone acetyltransferases (HAT) to facilitate DNA 
binding and the recruitment of transcriptional coactivators such as p300 and CBP (CREB-binding 
protein) [227]. Several kinases, including IKKβ, have been shown to target Ser536 of p65 subunit to 
augment transcriptional activity [225]. In contrast to this, inhibitory effects were observed with 
acetylation of Lys122 and Lys123 in p65 [224]. Moreover, ubiquitination of p65 results in 
proteosomal degradation, thereby promoting transcriptional silencing [218]. Alternative mechanisms 
for NF-κB response termination include IKKα-induced acceleration of p65 and c-Rel turnover and 
removal from proinflammatory gene promoters [228]. There has been tremendous progress in 
understanding the complex network of multifactorial regulatory mechanisms involved in the NF-κB 
response, yet still there are areas that remain to be discovered and thus it will continue to attract future 
investigations. 
1.4.4. Role of NF-κB in parturition 
The downregulation of NF-κB in T cells of pregnant women throughout the gestation has been shown 
to be essential for maintaining the balance in the levels of cytokines required for successful pregnancy 
[229]. The expression of NF-κB is lower in the pregnant myometrium in comparison to non-pregnant 
controls [230]. Moreover, the activation of NF-κB has been reported to trigger the onset of labour as it 
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is highly inducible by multiple factors including proinflammatory cytokine/chemokines and infection. 
In addition, NF-κB regulates the expression of a cassette of genes including proinflammatory 
cytokines/chemokines, such as IL-1β, IL-6, TNFα, IL-8 and CCL5 [231], therefore creating a positive 
feedback loop that results in further NF-κB activation. The NF-κB-regulated cassette of genes also 
includes a number of other prolabour genes; OTR, COX-2 and MMPs (specifically MMP-9, MMP-3 
and MMP-2), which can modulate uterine contractility. NF-κB can indirectly interfere with uterine 
quiescence by affecting the activity of progesterone receptor (PR) [132].  
There is compelling evidence that the use of NF-κB antagonists in preterm labour is more effective in 
delaying labour as well as improving fetal outcomes compared to the currently available tocolytics 
[232]. Future studies on determining the components of the labour-specific NF-κB signalling, and 
selective targeting of this pathway may potentially provide new therapies for preterm labour. 
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1.5. Oxytocin/Oxytocin receptor in human parturition 
1.5.1. OT 
Oxytocin (OT) is classically considered to have a fundamental role in the mechanism of human labour. 
In  1906, it was first noted that the posterior pituitary extract had the ability to drive uterine 
contractions [233]. Subsequently, the active factor was identified to be oxytocin, which had a potent 
contractile activity in the pregnant uterus (from the Greek oxus, meaning sharp and tokos, referring to 
childbirth). Thus OT was soon introduced into clinical practice as a uterotonin to stimulate labour 
within 1940s [234]. By 1953, the biochemical structure of OT was determined [235], and the gene 
was cloned 30 years later [236].  
OT is a nonapeptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) with a disulfide bridge 
between the two cysteines. As shown in Figure 1.8, the presence of a disulfide bridge results in a six-
amino acid cyclic part and a COOH-terminal α-amidated three-residue tail. This structure of OT is 
very similar to other nonapeptide neurohypophysial hormones. These can be classified into two 
families; vasopressin and OT families, depending on their amino acid at position 8, where vasopressin 
family contains a basic amino acid (Lys, Arg) and OT family contains a neutral amino acid. It has 
been reported that OT and vasopressin genes are on the same chromosome locus in opposite 
directions and therefore arose as a result of common ancestral gene duplication. However, the 
variance in these key amino acids can promote differences in the polarity of the peptides, enabling 
them to bind to their respective receptors [237].  
In mammals, it has been established that OT is synthesized in the magnocellular neurons of the 
paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus [238]. The produced peptide 
is then transported down the axons of the posterior pituitary gland where it is released to modulate its 
function. Rossoni et al. have demonstrated that some of the OT from the hypothalamus is transported 
to the dendrites in order to regulate the firing patterns of the oxytocin neuronal network [239]. 
Moreover, OT has been found to be synthesized locally in humans to contribute to the processes of 
labour [240].  
The role of OT/OTR system in parturition will be discussed further later in this chapter, however, 
apart from mediating parturition, OT is also important for milk ejection during lactation [241],  
maternal behaviour, sexual receptivity and partnership bonding [242], thereby facilitating species 
propagation. OT is also involved in the regulation of a variety of social and non-social behaviours in 
both animal models and humans. The social behaviours influenced by OT include social recognition, 
aggression, and sexual, parental behaviours. Study in rats illustrated that OT infusion facilitates social 
recognition, where this effect was abolished by the use of an oxytocin receptor antagonist [243]. This 
was subsequently demonstrated in humans as OT was found to influence face recognition at early 
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stages of perceptual processing as well as previously seen faces [244, 245]. Aggressive behaviour 
seems to be highly dependent on the species, sexual status and age. There are contrasting evidences in 
the role of OT in controlling aggression in animal models but recent human studies have suggested 
that OT may act to decrease aggression by increasing recognition and feelings of affiliation [246], 
whilst decreasing anxiety. Increase in OT and OTR during pregnancy and nursing has been shown to 
elicit higher maternal behaviour responses in female rats as OT interact with the dopamine and 
serotonin systems [247]. Parental behaviour in males is much less known as only small number of 
species care for their young, however, there are reports of increase in plasma OT levels in expectant 
male California mice in comparison to virgin males [248]. The effect of increase in OT levels on 
paternal behaviour is yet to be assessed. In addition, OT is implicated in the regulation of sexual 
behaviours. In male rodents, OT can bring penile erections and accelerated ejaculation in the presence 
of testosterone [249] and this can be inhibited by injecting an oxytocin antagonist [250]. Studies in 
humans reported that there are increases in plasma OT levels during sexual arousal, indicating a role 
for OT in sexual behaviours [251, 252]. 
1.5.2.  OTR 
To date, only one type of oxytocin receptor (OTR) has been identified whereas a very similar 
nonapeptide, vasopressin, has been shown to have three difference subtypes of receptors. The human 
OTR gene is present in chromosome 3p25 - 3p26.2, and contains multiple putative binding sites for a 
variety of transcription factors including c-myb, AP-2, AP-1 and C/EBPβ in the 5‟-flanking region 
[253]. There is an absence of complete estrogen responsive element (ERE) in human OTR, whereas 
mouse [254] and rat [255] OTR contains classical ERE along with other transcription factor binding 
sites. However, there are partial palindromic motifs of ERE present at the 5‟-flanking region of human 
OTR gene [253], suggesting a role for estrogen in the regulation of OTR gene expression. 
OTR is a 389-amino acid polypeptide with 7 transmembrane domains and belong to the rhodopsin-
type (class I) G protein-coupled receptor family (Fig. 1.6). Similar to other GPCRs, activation of OTR 
drives conformational changes in the relative orientation of the transmembrane domains to enable G 
protein binding. On the basis of the amino acid sequence, the molecular mass of OTR can be 
calculated to be ~40-45 kDa. However, previous studies in guinea pig myometrial membranes 
identified OTR as a 68- to 80-kDa protein [256], and photoaffinity labelling experiements in rat 
mammary gland and rabbit amnion cells found OTR to be 65 kDa [257, 258]. Such discrepancy in the 
molecular mass of OTR in various tissues may be due to their differential glycosylation patterns, with 
each glycosylation core accounting for approximately 10 kDa. The OTR has been found to have two 
or three putative N-glycosyltion sites depending on the species. Human OTR has three potential 
glycosylation sites as shown in Figure 1.6. Despite the differential glycosylation patterns, OTR 
47 
 
expression, ligand binding affinity and its function are not affected as recombinant deglycosylation 
mutants of OTR showed unaltered functional properties [259].  
As discussed above, vasopressin is a nonapeptide that has a similar structure to OT. Due to the similar 
cyclic part of the hormones, vasopressin is able to act as a partial agonist on the OTR. It has been 
reported that OTR has only 10-fold higher affinity for OT in comparison to vasopressin [260]. Postina 
et al. demonstrated that the ligand selectivity of OTR is dependent on the NH2 terminus and the first 
and second extracellular loops (shown in red Fig.1.6), with the cyclic part of OT interacting with the 
second extracellular loop [261].  
 
 
Figure 1.6. Schematic structure of the human oxytocin receptor. The amino acid residues are shown in one-
letter code, where the residues conserved between OT and vasopressin families shown in grey and those 
conserved for the whole GPCR family in black. The N-glycosylation sites are marked “Y” and domains 
interacting with OT are highlighted in red (modified from [262]). 
 
Persistent stimulation of typical GPCR leads to receptor desensitisation, which can occur at 
transcriptional, translational and protein levels. The rapid desensitisation of GPCR involves 
phosphorylation of COOH-terminal tail of the receptor by GPCR kinases (GRKs) and recruitment of 
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arrestin proteins, subsequently resulting in G protein uncoupling and receptor internalisation, or 
sequestration. It has been suggested that OTR undergoes similar homologous receptor desensitization 
process following persistent stimulation [263]. Studies in human embryonic kidney (HEK) 293 cells 
expressing human OTR demonstrated that OTR internalisation occurs mainly via a clathrin-mediated 
pathway, with greater than 50% of total receptor loss after 5 minutes of OT stimulation [264]. In this 
model system, OTR internalisation involved phosphorylation by GRK-2 and facilitate internalisation 
via dynamin-driven formation of clathrin-coated vesicles. The fate of internalised OTR largely 
unknown, however, the receptor can be targeted for degradation by lysosomes or recycling to cell 
membrane. Transcriptional or translational suppression of OTR was shown in human myometrial cells 
where prolonged exposure to OT resulted in a significant decrease in OTR mRNA level and upto 10-
fold reduction in OT binding capacity [265].  
1.5.3.  Control of OT and OTR expression  
The regulation of OT gene expression has been suggested to involve estrogen; both rat and human OT 
promoter was found to contain a functional estrogen -responsive element (ERE) [266, 267] and 
increases in estrogen [268] as well as the rate of estrogen production [269] are observed at the time of 
parturition in humans. Previous study in amnion-chorion-decidua in vitro explants demonstrated  that 
estrogen triggers the upregulation of OT gene expression [240] and increases in plasma OT 
concentrations in women [270].  
Similar to regulation of OT gene expression, sex steroids such as estrogen and progesterone have been 
shown to be associated with OTR gene expression. Soloff et al. [271] demonstrated an increase in 
OTR levels in the rat uterus with estrogen stimulation, which can be suppressed by administration of 
progesterone [272]. Studies using estrogen receptor-α knockout mice failed to demonstrate an 
increase OTR expression by estrogen as observed in wild-type mice [273], suggesting a nonredundant 
role for estrogen in the control of OTR expression. Progesterone has been shown to inhibit the role of 
OTR via both genomic and nongenomic mechanisms as it reduces the uterine OT binding [274] and to 
downregulation of OTR without affecting its gene expression [275]. Unlike rat and mouse OTR, 
human OTR promoter does not contain any full consensus estrogen or progesterone response elements. 
However, it is possible that estrogen can act on the half-palindromic EREs present in the 5‟-flanking 
region of OTR to mediate its expression [276] or involve additional factors that act or bind on 
alternative functional promoter elements [277].  
The human OTR promoter contains several other putative transcription factor-binding sites in its 
promoter region, specifically for CCAAT/enhancer-binding protein (C/EBP) and NF-κB, which are 
frequently associated with inflammation.  The direct regulatory effects of NF-κB and C/EBP have 
been demonstrated in previous studies [278, 279] whereas a regulatory role of sex steroids is yet to be 
understood. Both C/EBP and NF-κB are highly inducible by several inflammatory cytokines such as 
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IL-1β, IL-6 and TNFα, as well as lipopolysccharides (LPS)-mediated bacterial infection [280]. Given 
that increases in these inflammatory cytokines are associated with both term and preterm labour when 
OTR expression is also upregulated, it has been postulated that C/EBP and NF-κB may mediate 
labour-associated increase in OTR expression. Previous studies in our group demonstrated that IL-1β 
increases OTR expression via C/EBP and NF-κB, which work in synergy to dramatically increase 
OTR promoter activity [281, 282]. Moreover, C/EBP has been found to stimulate c-fos expression 
[283]. In breast cells, activation of c-fos has been reported to be associated with GABP (GA-binding 
protein transcription factor) α/β-induced endogenous OTR gene expression [284], however this was 
not observed in cultured myometrial cells.  
As discussed previously, another stimulus that contributes to the induction of OTR gene expression 
during the onset of labour is stretch. In rats, increase in OTR expression is observed only in the gravid 
horn of the uterus and the OTR expression in nongravid horn can be induced by stretch using a 3-mm 
plastic tube [150]. Similarly, Terzidou et al observed increased expression of OTR in stretched 
myometrial cells [153]. Mechanical stretch resulted in approximately 35% increase in C/EBP binding 
to OTR promoter which led to 4- to 5-fold increase in the promoter activity. It is hypothesized that the 
increased stretch in multiple pregnancies can increase uterine sensitivity to OT via OTR expression, 
which may account for the greater risk of preterm labour in multiple pregnancies. 
1.5.4. Role of OT/OTR in parturition 
There are several evidences supporting the role of OT in the initiation of parturition. Firstly, OT is one 
of the strongest uterotonin available and it is routinely administered to pregnant women to stimulate 
uterine contractions during late gestation. The key prolabour responses induced by OT are 
indistinguishable to that of normal spontaneous labour. Moreover, there is significant increase in 
uterine sensitivity to OT, with increase in OTR expression, in both rats and humans during the onset 
of labour [3, 285, 286]. Last but not least, recent studies in rats [287-289], non-human primates [290-
292] and in humans [293, 294] reported that oxytocin antagonists can inhibit late gestational uterine 
contractions and the process of parturition. However, there are conflicting results on the role of OT in 
parturition. In rodents, OT is believed to play a significant role in the initiation and maintenance of 
parturition [285, 295], whereas in humans, circulating OT does not seem to be essential for the 
initiation and maintenance of labour [241]. Normal parturition has been observed in the absence of 
OT in mice [241]  as well as in cases of clinical pituitary gland dysfunction [296]. There is no good 
evidence for an increase in maternal or fetal OT concentrations with the onset of, or during labour 
[297].  
A hypothesis proposed to explain the absence of OT increase during labour was that it is not the 
peripheral OT but a local OT synthesis that initiates labour. As with the principal actions of OT in a 
paracrine system, any significant changes in the levels of OT may not be reflected in the maternal 
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circulation. The initial suggestion of OT synthesis in peripheral tissues was made with detection of 
high OT concentrations in ovine corpus luteal tissues [298] and subsequent studies have demonstrated 
synthesis of OT mRNA in luteal tissues [299]. In 1993, mRNA of OT was isolated in human uterine 
tissues in late gestation [240]. A semi-quantification analysis revealed that OT mRNA is principally 
localised/or identified in deciduas but also found in the chorion and amnion. Interestingly, 
significantly greater concentrations of OT mRNA were detected in the chorio-decidua after 
spontaneous onset of labour (at the expulsive stage of parturition) compared to before the onset of 
labour at term [240, 300, 301]. Post labour chorio-decidua samples showed similar levels of OT 
mRNA to that of spontaneous labour, indicating the maximal level of gene expression. However, 
prelabour samples showed substantial variation due to samples being taken at varying intervals before 
spontaneous labour [240]. These findings demonstrated that localised synthesis of mRNA encoding 
OT increased around the time of labour onset and may play a role in the physiology of human labour.  
Moreover, the uterine sensitivity to OT markedly increases at the onset of labour. This is associated 
with an upregulation of OTR mRNA levels and a strong increase in the density of myometrial OTRs 
reaching a peak during early labour [302]. This was first described in rats [285], and subsequently 
demonstrated in rabbits and humans [3, 303].  In both species, OTRs are present in the endometirum 
as well as the myometrium, chorio-decidua and amnion [3, 304]. This increase in OTR is one of the 
most consistent findings in the study of parturition in several species, which introduces the possibility 
that the changes in the expression or function of the OTR, not only the peptide, are important for the 
onset of labour. In addition, a more recent gene association study showed that maternal genetic 
variation such as single nucleotide polymorphisms (SNPs) in OTR coding region may be associated 
with gestational age-dependent susceptibility to preterm birth [305]. This finding is in line with the 
hypothesis that OTR has a significant role in the process of labour onset. 
1.5.4.1. OT/OTR in pregnant uterus 
In general, the OT/OTR system within the pregnant uterus serves two distinct physiological functions, 
stimulation of contractions and production of PGs. Contraction and relaxation of myometrium are 
regulated by phosphorylation and de-phosphorylation of the 20kd light chain of myosin. Myosin is the 
primary protein of smooth muscle thick filaments and is composed of two heavy chain subunits 
(approximately 200 kd each) and two of each type of light chain subunits (20 and 17kd respectively). 
At least three distinct components can be discerned in the effect of oxytocin on human uterine smooth 
muscle; increase in frequency of contractions, initial transient increase in the base tone (incomplete 
relaxation), and long-lasting increase in the amplitude and duration of phasic contractions.  
Activation of OTRs located on smooth muscle cells, such as uterine myometrial cells or mammary 
gland myoepithelial cells, induce contraction, which is triggered by an increase in intracellular Ca
2+
 
that leads to a calmodulin-mediated activation of myosin light chain kinase (MLCK) [306] (details in 
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Fig. 1.7). Binding of OT to the OTR activates the heterotrimeric protein complex of a G-protein 
consisting of an α, β and γ subunits [307]. OTR couples to G-proteins of the Gαq/11 subfamily [308], 
which stimulates phospholipase C, specifically, phospholipase Cβ (PLCβ) isoform. This enzyme 
hydrolyzes phosphatidylinositol-4, 5-bisphosphate (PIP2) to inositol-1, 4, 5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 then releases Ca
2+
 from the sarcoplasmic reticulum into the cytoplasm. The 
increase in intracytoplasmic Ca
2+
 is further attenuated by a Ca
2+
 influx from the extracellular space 
through membrane Ca
2+
 channels [309]. The DAG generated by the actions of PPLCβ on PIP2 
stimulates protein kinase C (PKC). The mitogen-activated protein kinase (MAPK) system seems to be 
one of the important substrates for PKC. OT stimulation of cultured human myometrial cells induces 
activation of MAP kinases through a G-protein-mediated mechanism [310]. This effect is partially Gi 
dependent and is attenuated by β-adrenergic agonists [311]. Inhibition of MAPK activation does not 
affect OT-induced intracellular Ca
2+
 mobilisation, but it has been reported that it partly inhibits OT-
induced contraction in the pregnant rat uterus [312].  
The increase in intracellular Ca
2+ 
results in a variety of cellular events. The formation of the Ca
2+
-
calmodulin complex triggers activation of neuronal and endothelial isoforms of NO synthase. NO, in 
turn, stimulates the soluble guanylate cyclise to produce cGMP. In smooth muscle cells, the Ca
2+
-
calmodulin system triggers the activation of MLCK activity, which initiates smooth muscle 
contraction. In neurosecretory cells, rising Ca
2+ 
levels control cellular excitability and lead to 
transmitter release. Further Ca
2+
-promoted processes include gene transcription and protein synthesis. 
In addition to regulating smooth muscle contractility by electromechanical coupling, membrane 
potential independent, pharmacomechanical coupling can also be accounted for the physiological 
mechanisms that regulate contractions [313]. Activation of OTR in human myometrium can convert 
inactive RhoA-GDP to its active form, RhoA-GTP through guanine nucleotide exchange factors 
(GEFs). RhoA-GTP acts via Rho kinase (ROK) to phosphorylate the regulatory subunit of MLC, 
leading to contractions. There have been records of RhoA and ROK upregulation in human 
myometrium during pregnancy [314] and ROK has been shown to mediate OT-induced myometrial 
contractions [315]. Another alternative pathway (and parallel) to induce myometrial contraction may 
be through activation of the enzyme CPI-17 by protein kinase C. 
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Figure 1.7. OT/OTR signalling pathways involved in myometrial contraction. Oxytocin binds to OTR and 
OTR coupled with Gα q/11 leads to activation of PLC, which hydrolyses PIP2 to DAG whilst causing release of 
Ca
2+
 from the sarcoplasmic reticulum. Both OTR and DAG activate PKC to initiate MAPK cascade which in 
turn causes increased cPLA2 activity and PG synthesis. OTR also triggers RhoA/ROK cascade and results in 
increase in MLC kinase activation. Intracytoplasmic Ca
2+
 increases further via membrane Ca
2+
 channels and 
these combined with calmodulin activates MLC kinase. The increase in PG synthesis and MLC activation 
induce myometrial contractions. OT: oxytocin, OTR: oxytocin receptor, PLC: phospholipase, PIP2: 
phosphatidylinositol 4,5-bisphosphate, DAG: diacylglycerol, PKC: protein kinases type C, MLC: myosin light-
chain, MAPK: mitogen-activated protein kinase, cPLA2: cytosolic phospholipase A2, ROK: RhoA associated 
protein kinase (modified from [316]). 
 
It has been noted that OT stimulates an increase in cytoplasmic phospholipase A2 activity and induces 
COX-2 expression in Chinese hamster ovary cells [317] as well as in cultured human myometrial cells. 
These are two major enzymes required for PG synthesis (details in Fig. 1.3). In human myometrium, 
OTR coupling with Gq leads to activation of PLC and PKC which in turn phosphorylates ERK1/2 
MAP kinase and promote PG synthesis.  
A well described action of PGs is their role in promoting myometrial contractility. PGF2α induced 
contractions are partly mediated by electromechanical coupling as well as pharmacomechanical 
coupling, resembling that of OT-induced contractions [318]. Activation of decidual and OTRs induces 
PGF2a release, which results in enhanced uterine contractions whilst driving cervical ripening and 
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luteolysis. Inhibition of PG synthesis decreases the upregulation of OT binding sites as well as the 
effect of OT on promoting myometrial contractions [189].  
1.5.4.2.  OT/OTR in human amnion 
Labour is preceded by changes in the fetal membranes [189], which are composed of amnion and 
chorion. The amnion is the innermost translucent structure surrounding the amniotic fluid and the 
chorion is the outer layer attached to the decidua [319]. Following the degradation of the extracellular 
matrix [320] and physical separation of the amnion from the choriodecidua, rupture of fetal 
membranes leads to labour onset [321]. Human labour is associated with increased PG synthesis and 
inflammatory cytokine release in the uterus [322], and amnion is a major source of inflammatory 
cytokines and PGs, especially PGE2 which increases both before and during labour [181, 323].  
A previous study in rabbit amnion has shown up-regulation of OTR at the end of pregnancy and OT-
stimulated production of PGE2 [324]. This was also observed in the primary amnion cells as PGE2 
release was increased significantly by 40-fold with OT stimulation [181], thus proposing a role for 
OT/OTR system in the activation of human amnion at the time of labour. 
Increased PG synthesis occurs first in the region overlying the cervix where it is thought to mediate 
cervical ripening. The mechanism for this regionalization is not yet clear but it has been suggested 
that stretch through pressure from the fetal head plays a role [105]. Prostaglandin synthesis in the 
amnion is principally via cyclooxygenase type 2 (COX-2) whose expression is mediated by NF-κB 
[231], and the activation of NF-κB itself is regulated by inflammatory cytokines such as IL-1β.  
There are three distinct NF-κB pathways described to date; classical, alternative and atypical, as 
mentioned above. The NF-κB signalling pathway relies on series of activated kinases, formation of 
DNA-binding homo- or hetero-dimers of the Rel family proteins such as p50, p65, c-Rel, p52 and 
RelB, and inducing transcription of NF-κB target genes. In general, basal NF-κB resides in 
association with a member of IκB protein family in the cytoplasm of resting cells [216, 325]. 
However, with the activation of NF-κB via inducers such as IL-1β, NF-κB is able to translocate into 
the nucleus to regulate expression of target genes [326]. It regulates a group of immune/inflammatory 
genes including IL-1β, IL-6, IL-8, PTX3 and chemokines such as CCL2, CCL5, CCL20, CCL11 and 
CXCL2 [231]. Increase in IL-8 has previously been associated with labour [327] which induces 
chemotaxis of inflammatory cells and trigger acute inflammatory response [328]. Increase in CCL20 
synthesis in the uterus has also been associated with both term and preterm labour [329]. It binds 
specifically to CC-chemokine-receptor 6 to recruit dendritic cells and memory B lymphocytes. These, 
combined with the effects of other chemokines that are upregulated by NF-κB activity are responsible 
for the inflammatory infiltration in intrauterine tissues seen with labour [330]. 
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Mechanical stretch of human amnion epithelial cells has been shown to lead to the activation of AP-1 
and NF-κB systems and in turn increase COX-2 and PG expression [105]. AP-1 is a proinflammatory 
transcription factor that contributes to the initiation of the inflammatory response in several disease 
states [331, 332]. AP-1 binding sites are found in the promoter regions of many pro-inflammatory 
genes, including cytokines, adhesion molecules and cell proliferation growth factors. The AP-1 family 
of transcription factors function as either homodimers of the Jun family members or heterodimers of 
Fos and Jun family proteins. These homo- and hetero- dimers have different DNA-binding and 
transcriptional activation characteristic. The OTR, COX-2 and Cx-43 genes contain AP-1 binding 
sites in their promoters and temporal correlation has been demonstrated between the expression of c-
fos and Cx-43 in rat myometrium during labour. Stretching of human amnion cells as well as 
myocytes in vitro can drive PG synthesis, which is one of the main factors driving labour onset. It is 
hypothesised that the increased stretch generated from a multiple pregnancy could stimulate greater 
expression of OTR, suggesting that stretch or other local factors can contribute in the regulation of 
local OTR concentrations. 
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1.6. Oxytocin/Oxytocin receptor antagonists 
1.6.1. Peptide OTR-A 
Selective inhibition of OTR has been shown to directly block contractions and decreases PGF2α 
synthesis in human uterine smooth muscle cells [333, 334]. OTR antagonists may be peptides or non-
peptides. Many OTR antagonists have been synthesized by alteration or substitution of various amino 
acid residues in the oxytocin molecule. This results in a wide variety of compounds with various 
degrees of antagonistic properties and various degrees of specificity for OTR and vasopressin 
receptors.  
Atosiban is a combined oxytocin/vasopressin receptor antagonist registered for human use as a 
tocolytic in Europe and other countries. It is an oxytocin analogue (d[D-Tyr(Et)
2
,Thr
4
,Orn
8
]-oxytocin) 
with modifications at tyrosine in position 2, threonine substitution at position 4 and substituting the 
basic arginine with less basic ortnithine at position 8 [335]. Atosiban has high specificity for the 
uterus and its affinity to arginine vasopressin receptor 1A (AVPR1A) is approximately 100-fold 
greater than to oxytocin receptors (4.7 nmol/l and 397 nmol/l respectively) despite the fact that 
atosiban is often referred to as an „oxytocin antagonist‟ [293]. The oxytocin antagonistic properties of 
atosiban rapidly decrease contractions and has been demonstrated to be effective in delaying delivery 
for at least 48 hours with minimal adverse effects [336]. Its AVPR1A anatagonistic properties can add 
to the tocolytic effects. Clinically, atosiban is safer than beta-mimetics [337] and COX inhibitors [77], 
as it is associated with fewer maternal adverse drugs reactions requiring cessation of treatment [338]. 
However, the efficacy of atosiban is debatable as numerous studies have reported lack of reduction in 
preterm births with atosiban administration. There are several disadvantages of using atosiban as a 
tocolytic. Due to its limited bioavailability and high affinity to AVPR1A , atosiban requires 
hospitalization and can cause undesirable side effects such as nausea, headache, dizziness, tachycardia, 
hypertension, hyperglycemia and allergic reactions [339]. Moreover, there have been concerns about 
the effects of atosiban on neonatal outcome. In a randomised double blinded trial of OTR antagonists 
for tocolysis in the management of women in labour between 20 and 36 weeks gestation, atosiban 
resulted in lower birth weight and an increase in infant deaths at 12 months of age [78]. 
Limitations of atosiban have led to the discovery of new peptide OT specific antagonists for the 
management of preterm labour. Barusiban is a peptidyl OTR-specific antagonist (Fig. 1.8) with higher 
potency and longer duration of action than atosiban. It blocks OT-induced myometrial contractions of 
preterm and term myometrium in a concentration dependent manner [340]. Despite the promising 
results in non-human primates, in which barusiban inhibited OT-induced contractions and prolonged 
pregnancy successfully [341], a recent study in pregnant women did not show satisfactory clinical 
effectiveness. Although barusiban did not raise any safety concerns with respect to the mother, fetus, 
neonate, or infant, there was no reduction in uterine contractility or delay of delivery [342]. 
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New generation OT peptide antagonists with significantly high affinity for human OTR receptor are 
still being evaluated at an experimental level. These include d(CH2)5[Tyr(Me)
2
,Thr
4
,Tyr-NH2]OVT, 
desGly–NH2,d(CH2)5[D-2-Nal
2
,Thr
4
]OVT, desGly–NH2,d(CH2)5[2-Nal
2
,Thr
4
]OVT, d(CH2)5[D-2-
Nal
2
,Thr
4
,Tyr–]OVT, and d(CH2)5[2-Nal
2
,Thr
4
,Tyr–]OVT as candidates for next generation tocolytic 
agents [343]. 
1.6.2.  Non-peptide OTR-A 
Since peptide antagonists have high affinity to AVPR1A and lack bioavailability, nonpeptide OTR-
specific antagonists were developed. Retosiban, also known as GSK221149A (2′-methyl-1′,3′-oxazol-
4′-yl morpholine amide derivative, Fig. 1.8), is a nonpeptide oxytocin antagonist developed by a 
pharmaceutical company which is more than 15-fold more potent at the human OTR compared to 
atosiban [344]. Administration of retosiban by i.v. and orally decreases both OT-induced and 
spontaneous uterine contractions in late-term rats in a concentration dependent manner [345]. 
Retosiban is currently in a Phase II clinical trial for the prevention of preterm labour. 
Other nonpeptide oxytocin antagonists include L-368,899 (1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-
(methylsulfonyl) butyramido) bicyclo [2.2.1]-heptan-1(S)-yl)methyl) sulfonyl)-4(2methylphenyl) 
piperazine), SSR-126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-
2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride), and 
relcovaptan (SR49059) (Fig. 1.8). L-368,899 was shown to be a potent in pregnant rhesus monkeys by 
inhibiting spontaneous nocturnal uterine contractions [346], however, due to its brain penetrant 
properties, it demonstrated a change in maternal and sexual behaviour in non-human monkeys [347]. 
SSR-126768A acts as a competitive antagonist and oral administration delayed significantly delayed 
parturition of labouring pregnant rats by over 24 hours [333]. Being a competitive antagonist, its 
effects were dose-dependent. Unlike the previous nonpeptide OTR antagonists, relcovaptan is an 
orally active arginine vasopressin/OT antagonist with higher affinity to AVPR1A compared to OTR 
(7.2 nmol/l and 340 nmol/l respectively) [293]. Relcovaptan was reported to inhibit uterine 
contractions in vitro as well as in vivo, and demonstrated significant clinical effectiveness in 
decreasing contractions in preterm labour patients [348]. Relcovaptan has also revealed positive 
results against Raynaud‟s disease, dysmenorrhoea, and ischemic brain damage, however it has not yet 
been approved for clinical use [349]. 
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Figure 1.8. Structures of oxytocin and oxytocin receptor antagonists [350].  
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1.7. Hypothesis and aims 
There are multiple factors associated with preterm birth, however there has not been a significant 
reduction in preterm birth due to the poor understanding of the precise mechanisms involved in 
human parturition. The role of myometrial OT/OTR system in the onset of labour has been studied 
extensively but recent reports indicate that this is not limited to the myometrium but also seen in 
amnion. As amnion is not a contractile tissue, the role of OT/OTR will be fundamentally different to 
that of the myometrium.  
The aims of this study are; 
 To investigate the changes in the expression of OT and OTR in human amnion during the 
onset of labour and their effect on the regulation of labour-associated genes such as PG. This 
will provide new insight into the role of OT/OTR system beyond uterine contractions. 
 To elucidate the mechanisms initiated by OT/OTR system to drive inflammation and PG 
synthesis in human amnion.  
 OTR is a GPCR which can activate a complex network of multiple downstream signalling 
pathways that can be regulated dynamically. We aim to explore the G protein signaling 
involved in the OT-induced pro-labour effects. 
 OTR-A are anticipated to result in the down-regulation of OT-mediated effects. Therefore, it 
is proposed to determine the efficacy of currently available OTR-As, OVT and atosiban, in 
the prevention of the OT-induced pro-labour effects. 
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2. Materials and Methods  
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2.1. Materials 
2.1.1. Chemicals and solvents 
 
Absolute Ethanol VWR 
Acrylamide Sigma-Aldrich 
Agarose Invitrogen 
SYBR safe DNA gel stain Invitrogen 
Ammonium Persulphate (APS) VWR 
β-Mercaptoethanol Sigma-Aldrich 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol Blue Bio-Rad 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
Dithiothreitol (DTT) Bio-rad 
Glycerol BDH 
HEPES Sigma-Aldrich 
Isopropanol Fisher Scientific 
Methanol VWR 
NP-40 Alternative Calbiochem 
Non-fat dried milk powder Applichem 
TEMED Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
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2.1.2. Antibodies 
 
Antibody Epitope Catalogue number Supplier 
Primary Antibody 
α-tubulin sc-8035 Santa Cruz 
β-actin ab6276 Abcam 
COX-2 sc-1745 Santa Cruz 
cPLA2 2832 Cell Signaling 
G alpha i 2 ab55117 Abcam 
G alpha i 3 ab89639 Abcam 
G alpha q/11 sc-46972 Santa Cruz 
GAPDH MAB374 Chemicon Int 
IκBα sc-371 Santa Cruz 
Lamin B (Ab-1) NA12-100UG Oncogene Research 
OTR (C-20) sc-8102 Santa Cruz 
P50 sc-7178 Santa Cruz 
P50 X (EMSA) sc-1190X Santa Cruz 
P65 sc-8008 Santa Cruz 
P65 X (EMSA) sc-109X Santa Cruz 
Phospho-cPLA2 (ser505) 2831 Cell Signaling 
Phospho-ERK (thr202/tyr204) 9101 Cell Signaling 
Phospho-HSP27 (ser82) 9709 Cell Signaling 
Phospho-IKKα/β (ser176/180) 2681 Cell Signaling 
Phospho-JNK (thr183/tyr185) 9252 Cell Signaling 
Phospho-p38 (thr180/tyr182) 9211 Cell Signaling 
Phospho-p65 (ser536) 3031 Cell Signaling 
RelB sc-226 Santa Cruz 
TATA binding protein ab818 Abcam 
Secondary Antibody 
Donkey anti-goat IgG sc-2020 Santa Cruz 
Goat anti-mouse IgG sc-2005 Santa Cruz 
Goat anti-rabbit IgG sc-2054 Santa Cruz 
Anti-rabbit IgG  7074 Cell Signaling 
Alexa Fluor 488 dye A11001 Invitrogen 
Alexa Fluor 594 dye A11037 Invitrogen 
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2.1.3. Treatments and inhibitors 
 
2.1.4. siRNA 
 
DHARMAFECT 2 transfection reagent Dharmacon T-2002-0 
ON-TARGETplus Non-Target siRNA Dharmacon D-001810-01-05 
ON-TARGETplus SMARTpool for Gαq Dharmacon L-008562-00-0005 
ON-TARGETplus SMARTpool for Gαi-2 Dharmacon L-003897-00-0005 
ON-TARGETplus SMARTpool for Gαi-3 Dharmacon L-005184-00-0005 
ON-TARGETplus SMARTpool for OTR Dharmacon L-005688-00-0005 
ON-TARGETplus SMARTpool for p65 Dharmacon L-003533-00-0005 
 
Atosiban Sigma-Aldrich 
ATP Applied Biosystems 
ERK inhibitor (U0126) Cell Signaling 
Forskolin Sigma-Aldrich 
IL-1β R&D systems 
JNK inhibitor (SP600125) Calbiochem 
Ornithine vasotocin (OVT; 051-08) Phoenix peptides 
Oxytocin Alliance 
P38 inhibitor (SB203580) Tocris 
Phosphatase inhibitor cocktail Fisher Scientific 
Protease inhibitor cocktail Sigma-Aldrich 
Protease inhibitor tablet Sigma-Aldrich 
sc-514 Calbiochem 
IKK inhibitor (TPCA1) Sigma-Aldrich 
Pertussis toxin (PTX) ENZO Lifesciences 
GF109203X (GFX) ENZO Lifesciences 
PLC inhibitor (U-73122) ENZO Lifesciences 
Broad spectrum PKC inhibitor (Go6983) Tocris 
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2.1.5. Reagents and buffers 
 
General buffers 
 
  
Phosphate Buffered Saline (PBS) 
 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 
10mM Na2HPO4 
pH 7.2 
  
Tris Buffered Saline (TBS) 
 
50mM Tris-HCl 
150mM NaCl 
pH 7.5 
 
  
Tris-EDTA (TE) Buffer 
 
10mM Tris-HCl 
1mM EDTA 
pH 8.0 
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Cell culture materials and media 
 
Protein extraction buffers 
 
Cytosolic Buffer A 
 
10mM HEPES 
10mM KCl 
0.1mM EDTA 
0.1mM EGTA 
2mM DTT 
1% (v/v) NP-40 
Protease inhibitor tablet 
(Sigma-Aldrich) 
 
Nuclear Buffer B 
 
10mM HEOES 
0.1mM EDTA 
0.1mM EGTA 
2mM DTT 
200mM NaCl 
Dulbecco‟s Modified Eagles‟ Medium (DMEM) Sigma-Aldrich 
DMEM/Nutrient Mixture F-12 HAM Sigma-Aldrich 
Penicillin/Streptomycin Sigma-Aldrich 
L-glutamine Sigma-Aldrich 
Fetal calf serum Sigma-Aldrich 
Trypsin/EDTA Sigma-Aldrich 
Collagenase X or 1A Sigma-Aldrich 
Dispase Gibco 
Tissue Culture Plastic-ware Corning, Falcon, Orange 
Cell strainer (70µm) Falcon 
Filter Unit (0.20µm) Appleton woods 
DMEM/F12 Gibco 
Horse Serum Invitrogen 
EGF Sigma-Aldrich 
Hydrocortisone Sigma-Aldrich 
Cholera Toxin Sigma-Aldrich 
Insulin Sigma-Aldrich 
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1% (v/v) NP-40 
Protease inhibitor tablet 
(Sigma-Aldrich) 
 
RIPA whole-cell protein extraction buffer 
 
1% (v/v) Triton X-100 
1% (w/v) Sodium deoxycholate 
0.1% (v/v) SDS 
150mM NaCl 
10mM Tris, pH 7.4 
1mM EDTA 
1mM PMSF 
Protease and phosphatase 
inhibitor cocktail 
 
Western Blotting reagents and buffers 
 
Pre-stained protein markers Fermentas 
PVDF membrane Millipore 
ECL Plus Western blotting reagent Fisher Scientific 
ECL Western blotting reagent Fisher Scientific 
Supersignal Western blotting reagent Fisher Scientific 
ECL plus hyper film Amersham Biosciences 
Whatman 3MM paper Bio-Rad 
30% Acrylamide/Bis Sigma-Aldrich 
  
Tris-Glycine running buffer 
 
25mM Tris-base 
250mM glycine 
0.1% (w/v) SDS 
pH 8.3 
 
Transfer Buffer (TB) 
 
39mM glycine 
48mM Tris-base 
20% (v/v) methanol 
 
Blocking Buffer 
 
0.01% (v/v) Tween-20 
5% (w/v) non-fat milk 
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in TBS-T 
 
Washing Buffer (TBS-T) 
 
0.01% (v/v) Tween-20 
in TBS 
 
 
EMSA reagents and buffers 
 
T4 polynucleotide kinase Promega 
T4 kinase buffer Promega 
MicroSpin sephadex columns Amersham Biosciences 
poly(dI-dC) Amersham Biosciences 
32P(γATP) 9.25 Mbq Amersham Biosciences 
BioMax MS-1 Kodak film Sigma-Aldrich 
Sample loading buffer Promega 
Consensus NF-κB Promega 
Consensus Oct-1 Promega 
  
Annealing buffer 10mM Tris-HCl, pH7.5 
5mM NaCl 
1mM EDTA 
 
Binding buffer 20% (v/v) glycerol 
5mM MgCl2 
2mM EDTA 
50mM Tris-HCl 
250mM NaCl 
2mM DTT 
 
TBE running buffer 0.9M Tris-Borate 
20mM EDTA 
pH8.0 
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2.1.6. Kits 
 
Protein assay Kit Bio-Rad 
Human inflammation antibody array 3 RayBio 
PGE2 ELISA Kit R&D Systems 
IL-6 ELISA Kit R&D Systems 
CCL5 ELISA Kit R&D Systems 
Amaxa Nucleofector Kit Lonza 
First strand cDNA synthesis  Invitrogen 
SYBR Green master mix Sigma-Aldrich 
QIAquick PCR purification Kit Qiagen 
IPOne HTRF assay Kit CisBio 
Fluo-4 Direct Calcium assay Kit Invitrogen 
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2.2. Methods 
2.2.1. Patient selection 
Samples were collected from patients who gave informed consent to the use of tissues for research 
purposes with the approval from the local ethics committee (RREC 2002-6283). Fetal membranes 
were obtained from two groups of patients. The first group consisted of women undergoing elective 
caesarean section at term (38
+0
 - 39
+6
 weeks of pregnancy), prior to the onset of labour (L-), and the 
second group after the onset of labour (L+). Women who had their labour induced were excluded in 
this study as well as those with pre-existing diseases, pre-eclampsia, or multiple pregnancies. 
2.2.2. Primary amnion epithelial cell culture 
Primary amnion cell cultures were established as previously described [351]. Amnion tissue was 
separated from the fetal membrane and washed in phosphate buffed saline (PBS) three times before 
cutting into small strips and incubating in 0.5mM EDTA in PBS for 15 minutes. The strips of amnion 
were washed twice in fresh PBS and digested in 2.5mg/ml dispase (Gibco) in PBS for 45-50 minutes 
at 37°C. Then, in order to dissociate the cells, the strips were shaken vigorously in Dulbecco‟s 
Modified Eagles‟ Medium (DMEM, Sigma-Aldrich) with 10% fetal calf serum (FCS, Sigma-Aldrich) 
for 4 minutes. The remaining strips were discarded and the cell suspension was centrifuged at 175 x g 
for 10 minutes. The pellet of amnion cells were re-suspended in fresh DMEM with 10% FCS, 2mM 
L-glutamine (LG), and 100U/ml Penicillin/streptomycin (PS), and cultured at 37°C, 5% CO2. 
2.2.3. Primary myometrial smooth muscle cell culture 
Term human myometrial biopsies were collected from the lower segment of the uterine incision at the 
time of elective caesarean section. All specimens were obtained after fully informed and written 
patient consent with the approval of local ethics committee (RREC 1997-5089).  
Myometrial tissues were washed three times in PBS and dissected into fine pieces. Tissue samples 
were then digested in filter-sterilised collagenase solution with 1mg/ml collagenase 1A (Sigma-
Aldrich), 1mg/ml collagenase X (Sigma-Aldrich), and 2mg/ml BSA (Sigma-Aldrich) in 50% serum-
free DMEM and 50% DMEM/Nutrient Mixture F-12 HAM (Sigma-Aldrich) for 45 minutes at 37°C. 
DMEM containing 10% FCS was added to the collagenase solution to inactivate the enzymes. The 
cell suspension was filtered through a cell strainer (70µm) and centrifuged at 3000 rpm for 5 minutes. 
The pellet was resuspended in DMEM containing 10% FCS, 2mM LG, and 100U/ml PS and seeded 
into a T25 culture flask (Corning) to grow at 37°C, 5% CO2. Once the cells reach ~95% confluence, 
they were washed in PBS and trypsinised in 0.25% trypsin containing 0.02% EDTA in PBS. DMEM 
containing 10% FCS was added to inactivate the enzyme and the cell suspension was centrifuged and 
diluted in fresh DMEM containing 10% FCS, 2mM LG and 100U/ml PS to be re-seeded in cell 
culture flasks or plates. Cells were used between passage numbers 1-4. 
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2.2.4. MCF-10A mammary epithelial cell culture 
MCF-10A cells are common model system for investigating epithelial cell biology. These cells are an 
immortalized, normal breast epithelial cell line derived from human fibrocystic mammary tissue, 
which require exogenous growth factors for proliferation. The cells were kindly donated by Professor 
Bob Brown‟s group of Imperial College London. MCF-10A cells were grown in growth media 
containing 5% (v/v) horse serum, 20ng/ml epidermal growth factor (EGF), 0.5mg/ml hydrocortisone, 
100ng/ml cholera toxin, 10µg/ml insulin, and 1% (v/v) PS in DMEM/F12 (Sigma-Aldrich). The cells 
were passaged every 4 days and were used for experiments before reaching passage 20. Prior to any 
treatment, MCF-10A cells were serum depleted in DMEM/F12 containing 2% (v/v) horse serum and 
all the additives except EGF. 
2.2.5. Protein extraction 
2.2.5.1. Whole cell protein extraction with RIPA buffer 
The monolayer of confluent primary amnion epithelial cells was scraped and lysed in modified RIPA 
buffer containing 1% Triton x 100, 1% Sodium Deoxycholate, 0.1% SDS, 150mM Sodium Chloride, 
10mM Tris (pH 7.4) and 1mM EDTA with 1mM of PMSF and protease inhibitor cocktail (Sigma-
Aldrich). Whole cell proteins were obtained by centrifuging the lysate at 13,000 x g for 30 minutes at 
4°C and extracting the supernatant.  
2.2.5.2. Nuclear/Cytosolic protein extraction 
Primary amnion epithelial cells were grown to confluence and they were rinsed in PBS, then scraped 
in buffer containing 10mM HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 2mM DTT and 
complete protease inhibitor (Sigma-Aldrich). The cells were lysed with addition of 1% NP-40 and 
cytosolic protein extracts were obtained by centrifugation of the lysate for 30 seconds at maximum 
speed at 4°C. For nuclear protein extraction, the pellet was re-suspended in a different buffer 
containing 10mM HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 2mM DTT, 400mM NaCl, 1% 
NP-40 and complete protease inhibitor tablet (Sigma-Aldrich). The nuclear lysate was then shaken 
vigorously for 15 minutes at 4°C and centrifuged at maximum speed for 5 minutes.  
2.2.5.3. Protein assay 
All protein extracts were quantified by Lowry method using Bio-Rad protein assay reagents (Bio-
Rad), following the manufacturers protocol. The protein samples were aliquoted appropriately to 
contain 50µg of protein and stored at -80°C in order to avoid freeze-thaw cycles. 
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2.2.6. Western Blot and Immunodetection 
Proteins were denatured at 100°C for 10 minutes with loading dye which consists of 3% glycerol, 3% 
SDS, 1% Bromophenol Blue, and β-mercaptoethanol. Equal amount of proteins (50µg) were run on a 
10% SDS-Polyacrylamide gel for 80 minutes at 120V, and were transferred to polyvinylidene 
difluoride (PVDF) membranes (Millipore) for 90 minutes at 300mA. The membranes were then 
incubated in 5% blocking buffer for 1 hour at room temperature and hybridized with primary antibody 
overnight at 4°C. Incubation with secondary antibody was carried out the following day and 
immunodetection using ECL, Supersignal, or ECL plus detection reagent (Fisher Scientific). 
2.2.7. RNA extraction 
Total RNA was extracted using a guanidium thiocyanate-phenol-chloroform extraction RNA STAT-
60 (Tel-Test, Inc, Texas) according to the manufacturer‟s instructions. RNA STAT-60 is known to be 
able to disrupt cells and dissolve cellular components whilst maintaining the stability of RNA during 
cell lysis or tissue homogenization. For RNA-mRNA isolation, firstly, cells were homogenized in 1ml 
of RNA STAT-60 per 5-10 X 10
-6
 cells. Then RNA was extracted by adding 0.2 volume of 
chloroform to 1 volume of homogenate and precipitated using 0.5 volume of isopropanol. Following 
RNA precipitation, the pellet was washed in 75% ethanol, air-dried briefly and re-suspended in 
RNase-free water. The concentration and purity of RNA were analysed by measuring OD230, OD260 
and OD280 on a NanoDrop Nd-1000 spectrometer. The 260/280 ratio was expected to be between 1.8 
and 2.0 and 260/230 ratio at 2.0-2.2 for RNA. If the ratios were below the expected value, it may 
indicate possible contamination. All RNA extracts were stored at -80°C until further analysis. 
2.2.8. DNase treatment and first-strand cDNA synthesis 
Prior to reverse transcription of total RNA to generate cDNA, any DNA contaminations in the RNA 
samples were eliminated through a DNase treatment. With total reaction volume of 10µl, 2µg of total 
RNA was digested with 1µl of DNaseI (Invitrogen) in 1x DNaseI reaction buffer and DEPC-treated 
water at room temperature for 15 minutes. Once the digestion is complete, the reaction was stopped 
by incubating at 65°C for 10 minutes with 1µl of 25mM EDTA, and the whole reaction was used for 
first-strand cDNA synthesis.  
The DNase treated RNA was incubated at 65°C for 5 minutes with 1µl dNTP mix (10mM of dATP, 
dTTP, dGTP and dCTP each) and 1µl Oligo(dT)12-18 (0.5µg/µl), then incubated in ice for 1 minute. 
Following the addition of 1x reverse transcriptase buffer (Invitrogen), 2µl 25mM MgCl,  1µl 0.1M 
DTT and DEPC-treated water to attain the total reaction volume of 20µl, the reaction mix was then 
incubated at 42°C for 2 minutes.  Reverse transcriptase SuperScript II (Invitrogen) was added to the 
reaction mix and incubated at 42°C for 50 minutes. Termination of reverse transcription was carried 
out by heating at 70°C for 15 minutes, and by incubating at 37°C for 20 minutes with 1µl RNase H 
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(Invitrogen), any remaining RNA fragments were removed. Resulting cDNA was then stored at -20°C 
until further analysis. 
2.2.9. Real-time PCR 
Real time quantitative polymerase chain reaction (RTQ-PCR) was carried out using ABI StepOne 
Real Time PCR system (Applied Biosystems) for quantification of target cDNA. SYBR Green I dye 
was used for RTQ-PCR. SYBR Green generates fluorescence when incorporated into double-stranded 
DNA, thus an increase in the accumulation of PCR product leads to higher emission of SYBR Green 
fluorescence which is detected by the Real Time PCR system throughout the cycle. Amplification is 
carried out using specific primers (Table 2.1) for the target DNA, and then the software determines 
the baseline of fluorescence and generates a baseline-subtracted amplification plot by calculating a 
mathematical trend of the normalized fluorescent reporter signal. The cycle number at the point of 
amplification plot where it crosses the threshold, defined as the Ct value, is used as a quantitative 
measurement of the input target. A decrease in the Ct value is seen as an increase in the target cDNA. 
The target Ct values were normalised to L-19 for analysis and any significant changes in target cDNA 
level was determined using ANOVA. 
 
Name Forward Sequence Reverse Sequence RefSeq number 
L-19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA NM_000981 
COX-2 TGTGCAACACTTGAGTGGCT ACTTTCTGTACTGCGGGTGG NM_000963 
OTR GATGGGAAGGGTGGT CAAGGACCCCAGCATTTGTT NM_000916 
IL-8 GCCTTCCTGATTTCTGCAGC CGCAGTGTGGTCCACTCTCA NM_000584 
cPLA2 HTATIP AAGCGAAAATCGAATTGTTTGG GTGGTGCTGACGGTATTCCA NM_182710 
cPLA2 alpha TGCATTCTGCACGTGATGTG CACCATGGCTCGGAAACC NM_024420 
cPLA2 beta GCCTGATCTGGAATCCCATGT GTTCACAGCATCGGGCATCT NM_001114633 
cPLA2 gamma CCAGGACCTCCCTGGAAAA CAAGTTACTGAGTGAGCCTTTCCTT NM_001159322 
cPLA2 delta TCCTGATCCAAGAAACGTCAGA GCTCTCGGGCCACAATGA NM_178034 
cPLA2 epsilon CAATGGCGTGCTGGTGTCT TCCTCCGCCTCCTGGATT NM_001206670 
cPLA2 zeta CAGATCCATGGTGCTGTGAAGA GTCGCTGCCCAGGATGTC NM_213600 
CCL2/MCP-1 TCTGTGCCTGCTGCTCATAG AGATCTCCTTGGCCACAATG NM_002982 
CCL5/RANTES CCATATTCCTCGGACACCAC TGTACTCCCGAACCCATTTC NM_005270 
IL-6 CCTTCCAAAGATGGCTGAAA AGCTCTGGCTTGTTCCTCAC NM_000600 
SOD-2 TTGGCCAAGGGAGATGTTAC AGTCACGTTTGATGGCTTCC NM_000636 
PGES-1 TCTTAGCCCCTTGGATTCCT ATTCTTAGCCCGGGATTCAG NM_004878 
PGES-2 GGAGAAAGCTCGCAACAACT TTCCCACCATACACTTGCTG NM_025072 
AVPR1A TGTGTCAGCAGCGTGAAGTC GTTGCATGAATGCAAGGC NM_000706 
GNAI-1 AGCACTGAGTGACTACGACCTG GGATGTATCTGTAAACCACTTGTTG NM_002069 
GNAI-2 CTTGTCTGAGATGCTGGTAATGG CTCCCTGTAAACATTTGGACTTG NM_002070 
GNAI-3 CACTCCACCTGTGCCACAGACA GTCTGGTCTCAACACTCCACAC NM_006496 
 
 Table 2.1. Sequences of PCR primers used in real-time PCR. 
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2.2.10. Polymerase chain reaction (PCR) 
Polymerase chain reactions (PCR) were performed using Phusion high-fidelity DNA polymerase 
(New England Biolabs). PCR reaction mix prepared following the manufacturer‟s protocol. Each 50µl 
reaction included 200µM of each dNTP (dATP, dCTP, dGTP, dTTP), 50nM of each forward and 
reverse primer, 50ng template DNA, 1xPhusion HF buffer containing 1.5mM MgCl2 and 0.5µl of 
Phusion high-fidelity DNA polymerase. Template DNA were initially denatured for 30 seconds at 
98°C, then the reaction was subjected to 30 thermo-cycles of 98°C for 10 seconds, primer annealing at 
60°C for 30 seconds and extension at 72°C for 30 seconds. This was followed by the final extension 
step of 72°C for 10 minutes. PCR products were then analysed by agarose gel electrophoresis. 
2.2.11. Agarose gel run 
The final products of PCR were analysed using 1.5 – 2% agarose gels (w/v). Gels were prepared by 
dissolving appropriate amount of agarose in fresh 1 x TBE and heating until agarose goes into 
solution. The solution was then cooled to approximately 50°C, at which point, SYBR safe (Invitrogen) 
was added prior to pouring the gel into a suitable gel mould. Once the gel has set, it was submerged in 
1 x TBE buffer and DNA samples containing 1 x DNA loading buffer (Promega) were loaded into the 
wells. Depending on the size of the gels, electrophoresis was carried out at 90 – 120V until the dye 
front reaches the end of the gel. The size of DNA fragments were estimated by using a 100bp or 1kb 
DNA markers (Bioline) which contain restriction fragments of known sizes. The bands were imaged 
using a dark reader (Dark Reader transilluminator, Clare Chemical Research). 
2.2.12. DNA purification and sequencing 
To prepare PCR products for sequencing analysis, they were purified using a QIAquick PCR 
Purification Kit (Qiagen). PCR purification was carried out using a microcentrifuge, following the 
manufacturer‟s protocol. 1 volume of PCR sample and 5 volumes of Buffer PB were placed into a 
QIAquick spin column. To bind DNA, the columns were centrifuged for 1 minute at 10,000 x g. The 
columns were washed with 0.75ml of Buffer PE and centrifuged for another minute. In order to 
remove any residual ethanol from Buffer PE, discard the flow-through and for an additional minute at 
maximum speed. The purified DNA were then eluted from the column by adding 50µl of Buffer EB, 
containing 10mM Tris-Cl, pH 8.5, or RNase-free water to the centre of the QIAquick membrane and 
centrifuging for 1 minute. The resulting DNA sample concentrations were measured using NanoDrop 
Nd-1000 spectrometer.  Sequencing was carried out by Beckman Coulter Genomics. 
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2.2.13. Transfection 
2.2.13.1. Dharmafect transfection reagent 
For transfection using Dharmafect 2 transfection reagent (Dharmacon), the amnion cells were cultured 
in PS- and LG-free, 10% FCS DMEM medium (Sigma-Aldrich) until 50-60% confluence. The 
transfection reagent was prepared for each well of a 6-well plate by mixing 4µl of Dharmafect 
transfection reagent with 196µl of serum-, PS- and LG-free DMEM without phenol-red (Sigma-
Aldrich) and incubating at room temperature for 5 minutes. The mixture was then combined with 
siRNA (10µl of 20µM siRNA and 190µl of serum-, PS-, LG- and phenol-red-free DMEM) and 
incubated for 20 minutes at room temperature. The cells were grown in total of 400µl of the reaction 
mixture and 1600µl of 10% FCS DMEM (Sigma-Aldrich) for 72 hours for RNA extraction and 4-
5days for protein. 
2.2.13.2. Amaxa electroporation 
Transfection using electroporation was performed according to the manufacturer‟s protocol (Amaxa 
Lonza, Germany). Primary amnion cells were seeded in culture flasks to reach 90-100% confluence, 
and then dissociated from the flaks using trypsin for 10-15 minutes. The cell suspension was 
centrifuged and diluted in PBS prior to electroporation. Transfected cells were washed after 24 hours 
and serum-depleted prior to treatment.  
The efficiency of transfection was tested using two different techniques described above using GFP 
(Figure 2.1). Transfecting by electroporation showed higher transfection efficiency in comparison to 
using Dharmafect transfection reagent despite the fact that it led to higher cell death post-transfection. 
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Figure 2.1. Transfection efficiency comparison between Lonza Amaxa electroporation and Dharmacon 
transfection reagent. Pre-labour amnion cells were transfected with 3µg of GFP using electroporation or 
transfection reagent. Total of 5 different electroporation programs were tested as suggested by the manufacturer. 
The level of fluorescence was detected for two following days. 
 
2.2.14. Fluorescent immunocytochemistry 
Term, non-labouring primary amnion cells were grown on multi-chamber slides until fully confluent. 
Following overnight serum-depletion (16-18 hours), the cells were stimulated with IL-1β (1ng/ml) or 
OT (100nM) for 30 minutes. Treated cells were fixed with methanol and target proteins were 
incubated in primary antibody for 1-2 hours and washed thoroughly with PBS. Following the washing 
steps, cells were incubated with fluorescently conjugated secondary antibodies for 1 hour at room 
temperature. The slides were washed and mounted with Vectashield (Vector Laboratories) that 
contains 4‟,6-diamidino-2-phenylindole (DAPI) for visualisation of the cell nuclei as it produces a 
blue fuorescence with excitation at ~360nm and emission at ~460nm when bound to DNA. IgG 
control was incorporated for each experiment as a negative control.  
Slides were observed on a Leica SP5 confocal microscope (Zeiss) using x 60 objective. High 
resolution images of amnion epithelial cells were captured and saved in JPEG format using LAS-AF 
program. 
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2.2.15. Electrophoretic mobility shift assay (EMSA)  
Consensus and non-consensus double-stranded oligos were end-labelled with 0.37MBq 
32P (γATP) by 
incubating for 30 – 60 minutes at 37°C with T4 polynucleotide kinase (Promega). The labelled oligos 
were cleaned by centrifugation at 3000 rpm for 5 minutes through MicroSpin G-25 sephadex columns. 
Total of 5µg nuclear proteins were incubated for 1 hour on ice with non-radiolabelled non-specific 
oligos (Oct-1) in an EMSA binding buffer containing 20% glycerol (v/v), 5mM MgCl2, 2mM EDTA, 
50mM Tris-HCl (pH 7.5), 250mM NaCl and 54mM DTT. Proteins were then incubated with 
0.035pmol 
32P (γATP)-end labelled probes for 40 minutes on ice. The resulting protein/DNA 
complexes were separated in a 4% non-denaturing acrulamide gel in 1 x TBE buffer. The gel was then 
dried and transferred to a filter paper under vacuum at 80°C, and exposed to X-ray film overnight at -
80°C. For supershift analysis, 2µg p65 or p50 antibodies (Santa Cruz) were incubated with the 
samples prior to probe binding. Non-radiolabelled oligos were used for specific and nonspecific 
competition for DNA binding. 
2.2.16. Enzyme-linked immunosorbent assay (ELISA) 
Concentrations of PGE2, IL-6 and CCL5 were determined by a standard enzyme-linked 
immunosobent assay (ELISA). Primary amnion epithelial cells were grown to confluence and treated 
for 1 hour, 2 hours, 4 hours, and 6 hours with OT (10
-7
M) or Atosiban (10µM). Supernatant was 
collected and immediately frozen at -20°C for analysis by ELISA. PGE2, IL-6 and CCL5 ELISA kits 
were used according to manufacturer‟s instructions (R&D systems).  
2.2.17. IPOne HTRF assay 
Direct quantitative measurement of myo-Inositol 1 phosphate (IP1) was performed using IPOne 
HTRF assay kit (Cisbio). The principle behind this assay technique is illustrated in Fig 2.2. Total of 
20,000 primary amnion epithelial cells were seeded in each well of a white, 384 well small-volume 
plate (Greiner). Prior to treatment, cells were washed in IP1 stimulation buffer which contains 10mM 
HEPES, 1mM CaCl2, 0.5mM MgCl2, 4.2mM KCl, 146mM NaCl, and 5.5mM glucose, in pH 7.4.The 
treatment compounds were diluted in 1 x StimB, provided by the kit. Cells were treated in duplicates 
for 1, 5, 15, 30, 45 and 60 minutes. After stimulation with compound, HTRF reagents were added (1
st
 
distribution IP1-d2 then 2
nd
 distribution Ab-Crypt) then incubated for 1 hour at room temperature. 
Plate reading was carried out using an HTRF compatible reader, PHERAstar plus (BMG Labtech). As 
for all HTRF assay, results were calculated from the 665nm/620nm ratio to eliminate possible 
photophysical interference.  
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Figure 2.2. IPOne HTRF assay. The IPOne HTRF assay (Cisbio) is a competitive immunoassay based on a 
new HTRF technology involving antibody specific for IP1, labelled with Lumi4
TM
-Tb cryptate. Presence of 
lithium chloride (LiCl) in the cell stimulation buffer causes the acculation of IP1in the cells when receptor is 
stimulated. The native IP1 accumulated in the cells competes with IP1 which is coupled to the dye d2 to bind to 
anti-IP1 cryptate Tb. The FRET signal is inversely proportional to the concentration of IP1. 
 
2.2.18. Fluo-4 direct Calcium assay 
Primary amnion epithelial cells were plated onto single chamber glass bottomed dishes (MatTek 
Corporation). Cells were grown to reach 80-90% confluence in DMEM containing 10% FCS, 2mM 
LG, and 100U/ml PS. Prior to Calcium assay, cells were serum depleted in DMEM containing 2% 
FCS, 2mM LG and 100U/ml PS overnight. Equal volume of Fluo-4 direct calcium reagent loading 
solution (Invitrogen) and culture medium were loaded directly to the wells containing cells, and 
incubated at 37°C for 30 minutes, then at room temperature for another 30 minutes. Culture dishes 
were then placed for live cell imaging on the Leica SP5 confocal microscope (Zeiss), using the LAS-
AF program to capture images every 1.315 seconds. Cells were imaged at optimum gain and exposure 
points. Initially, the fluorescence was measured for 2 minutes without any treatment to obtain a basal 
value. After addition of the agonist/antagonist, the fluorescence was measured for 10 minutes. The 
data produced from the program provides histogram values based on the fluorescence emitted by the 
experiment. The average basal value was subtracted from these values and analysed in Excel. Control 
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experiments were done using 10µM BAPTA-AM, which is an intracellular calcium chelator, and 
8mM EGTA, an extracellular calcium chelator. 
2.2.19. Statistical analysis 
All data were initially tested for normality using a Kolmogorov-Smirnoff test. Normally distributed 
data were analysed using ANOVA followed by Bonferroni or Dunnett‟s post hoc test for three groups 
or more. Where appropriate, Student‟s t-test for paired or unpaired data was used to calculate the 
significance of the differences of the means. Non-normally distributed data were analysed using 
Wilcoxon matched pars test for paired data and Mann-Whitney u test for unpaired data when 
comparing two groups. For three or more groups, Friedman‟s Test with a Dunn‟s Multiple 
Comparisons post hoc test was used. All data were presented with SE and p<0.05 was considered 
statistically significant. 
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3. Oxytocin/oxytocin receptor expression and its role in 
prostaglandin synthesis during the onset of labour  
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3.1. Introduction 
Human labour strongly resembles an inflammatory reaction [113], with global increases in a number 
of proinflammatory factors including prostaglandins and cytokines [116-118]. Inflammatory 
cytokines such as IL-1β, IL-6, IL-8 and TNFα, which increase during labour have been shown to 
activate MAPK, NF-κB, C/EBP and AP-1 [352-354]. There are series of published data which shows 
that coordinated upregulation of IL-1β, IL-8, PG, and COX-2 expression occur just prior to labour, 
suggesting they may play a role in the initiation of labour [137, 355-357]. Amnion is one of the major 
sites of PG and cytokines synthesis during human labour. Secretion of these factors by the fetal 
membranes increases with labour [356, 358-360] and in response to stimuli such as TNF-α, IL-6 and 
IL-1β [361, 362].  
In most mammalian species, parturition is preceded by a rise in oestrogen, a decline in progesterone 
concentrations in maternal plasma [268] and upregulation of myometrial OTR expression [363], as 
well as an increase in neurohypophyseal OT in the maternal circulation [364]. However, there is 
considerable doubt about the role of OT in normal human parturition due to the lack of evidence in 
the increase in plasma OT before labour onset [297, 365] and the absence of apparent correlation 
between plasma OT levels and myometrial activity [366]. It was hypothesized that local synthesis of 
OT within the intrauterine tissues may play a role in regulating normal human parturition. The 
increase in local OT levels was demonstrated in amnion, chorion and deciduas at the time of labour 
onset, supporting the hypothesis that a paracrine system involving OT in intrauterine tissues can 
contribute to the onset of labour without being reflected in the maternal circulation [240].  
The role of oxytocin and its receptor in the amnion during the onset of labour is not as well 
established as that in the myometrium, however, previous work in rabbit amnion showed that OT 
stimulates PGE2 production, with OTR expression increasing up to 200-fold towards the end of 
pregnancy [367]. This marked increase in PGE2 synthesis with OT stimulation was later demonstrated 
in pre-labour human amnion epithelial cells [181]. As mentioned previously, PG biosynthesis starts 
with the liberation of the substrate, which involves the release of arachidonic acid (AA) from 
membrane glycerophospholipids by the actions of phospholipases [368]. Cytosolic phospholipases A2 
(cPLA2) is one of the most studied in human uterine tissues and has been postulated to play significant 
role in the process of parturition [369, 370]. The next step involves the conversion of substrate to 
product. In PGE2 synthesis, PGES-1 and -2 activity coupled to that of COX-2 to metabolize 
arachidonate into prostanoids [371-373].   
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3.2. OT synthesis in human amnion during labour 
Previous studies have demonstrated an increase in OT mRNA expression with labour, specifically in 
chorio-decidua. In this study, we have investigated whether there are any changes in OT mRNA levels 
in human amnion in respect to the onset of labour.  
Pre-labour amnion cells were cultured from women undergoing elective caesarean section at term 
(38
+0
 - 39
+6
 weeks of pregnancy), prior to the onset of labour (L-), and labouring amnion cells were 
cultured from women undergoing emergency caesarean section or vaginal delivery after the onset of 
labour (L+). The expression of OT mRNA was analysed using real-time PCR. The result showed 
significantly higher basal expression of OT in labouring amnion cells compared to non-labouring 
(p<0.05; Fig. 3.1). This indicates there is an increase in OT mRNA expression in human amnion with 
the onset of labour. 
 
 
 
 
 
 
Figure 3.1. Labour-associated increase in OT mRNA expression. Total RNA extracted from labouring (L+) 
and non-labouring (L-) amnion tissues were subjected to qRT-PCR analysis. Transcript levels were normalised 
to the housekeeping gene, L19, to quantify the relative abundance of OT mRNA (n=6 from 6 independent 
samples; * p<0.05 vs L-, ANOVA).  
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3.3. Expression of OTR increases with labour in human amnion 
The uterine sensitivity to OT increases markedly during the onset of labour, which is associated with 
increase in both OTR mRNA levels and myometrial OTR density during early labour [374]. This was 
first described in rats [285], and subsequently demonstrated in rabbits and humans [3, 303].  The role 
of OT/OTR system in human myometrium is well understood as OT is one of the major mediators of 
uterine contractions. The increase in OTR expression is not restricted to the myometrium. In both rats 
and humans, OTRs are present in the endometirum as well as the myometrium and chorio-decidua [3, 
304]. In rabbit amnion, there is up to 200-fold increase in expression of OTR towards the end of 
pregnancy [324] and OTR binding to OT significantly increases in human fetal membranes during the 
onset of labour [375]. Also, previous study in human myometrial smooth muscle cells has illustrated 
an increase in OTR mRNA expression with IL-1β treatment, peaking at 4 hours [278]. Increase in 
OTR is one of the most consistent findings in the study of parturition across several species, which 
can imply that the changes in the expression or function of the OTR, as well as the peptide, are 
important for the onset of labour.  
Pre-labour and labouring primary amnion epithelial cell cultures were established from samples taken 
at the time of Caesarean section from patients with informed consent. Basal OTR mRNA expression 
was significantly higher in the labouring samples compared to pre-labour (p<0.01; Fig. 3.2 A).  OTR 
protein levels were also higher in labouring samples compared to non-labouring (p<0.05; Fig. 3.2 B). 
These results suggest increase in sensitivity to OT in human amnion during labour. 
 
Figure 3.2. Expression of OTR increases both with labour. Total RNA and proteins extracted from labouring 
(L+) and non-labouring (L-) amnion tissues were subjected to qRT-PCR analysis (A) and western blot (B). 
Transcript levels were normalised to the housekeeping gene, L19, to quantify the relative abundance of OTR 
mRNA. Control with β-actin confirmed equal protein loading (n=3 from 3 independent samples; * p<0.05, ** 
p<0.01 vs L-, ANOVA).  
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3.4. OT increases expression of PG synthetic enzymes; cPLA2, COX-2, PGES-1, and -2 
To study the effect of OT on the expression of PG synthetic enzymes, cPLA2, COX-2, PGES-1, and -
2, in human amnion epithelial cells, cultured pre-labour primary amnion cells were treated with OT 
(100 nM) and total RNA were extracted at 1 h, 2 h, 6 h and 24 h. The changes in enzyme mRNA 
expressions were measured over time. Stimulation of amnion with OT induced significant increases of 
the enzyme mRNA levels compared to non-stimulated control (NS). Upon OT stimulation, the mRNA 
levels of cPLA2 and PGES-2 increased by 3.8- and 6.4-fold respectively, peaking at 2 h (p<0.01; Fig. 
3.3 A and D). PGES-1 increased by 6.9-fold after 6 h (p<0.05; Fig. 3.3 C), and COX-2 by 2.7-fold 
after 2 h (p<0.05; Fig. 3.3 B). By 24 h of OT stimulation, the mRNA expression of cPLA2, COX-2, 
PGES-1, and PGES-2 returned to basal level. 
 
Figure 3.3. Effects of OT on the expression of prostaglandin synthetic enzymes. Pre-labour amnion 
epithelial cells were treated with OT (100 nM) for 1 h, 2 h, 6 h and 24 h. The expression of cPLA2, COX-2, 
PGES-1 and -2 were analysed using qRT-PCR. Transcript levels were normalised to the housekeeping gene, 
L19 (n=6 sets of amnion epithelial cells isolated from 6 patients; * p<0.05 vs NS, ANOVA).  
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3.5. OT increases PGE2 synthesis 
As mentioned above, cPLA2, COX-2, PGES-1, and -2 are PG synthetic enzymes. Therefore, it can be 
postulated that the increase of their mRNA expression with OT stimulation would be coupled with an 
increase of PGE2 secretion. Pre-labour amnion cells were treated with OT (100 nM) for 1 h, 2 h, 4 h 
and 6 h, and the supernatants were collected to measure PGE2 levels by ELISA. The PGE2 ELISA 
showed that OT treatment significantly increased the synthesis of PGE2, with approximately 15-fold 
increase after 6 h of stimulation (p<0.01; Fig. 3.4). Thus, suggesting that OT actives PG synthetic 
enzymes; cPLA2, COX-2, PGES-1, and -2, to mediate PGE2 production. 
 
 
 
Figure 3.4. Synthesis of PGE2 increases upon OT stimulation. Pre-labour amnion epithelial cells were serum 
depleted overnight and treated with OT (100 nM) for 1 h, 2 h, 4 h and 6 h. The culture medium was collected for 
PGE2 EIA analysis (n=6; * p<0.05, ** p<0.01  vs NS, ANOVA).  
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3.6. Summary and discussion 
There are several lines of evidence to support an important role for OT in the initiation of parturition. 
As discussed before, the first evidence being that OT is one of the most potent uterotonins currently 
available and is able to induce labour in pregnant women during late gestation that is indistinguishable 
from normal labour [376]. Second, OT antagonists designed to manage preterm labour have been 
demonstrated to inhibit late gestational uterine contractions in several species including humans [289, 
291, 293]. There is a study which reported an increase in OT concentrations in maternal plasma 
during labour [301]. However, there are contrasting evidences as many investigators failed to show 
any significant changes in maternal plasma concentrations of OT [103, 297, 365], and no direct 
correlation has been shown between maternal plasma OT and myometrial activity [366, 377]. This led 
to the hypothesis that OT may be playing a role in parturition via a paracrine/autocrine system instead 
of acting as an endocrine hormone. A previous study demonstrated an increase in OT mRNA 
expression in intrauterine tissues during the onset of labour, which enables OT to aid the processes of 
labour via a paracrine/autocrine system [240]. Similar pattern of increase OT mRNA was observed in 
intrauterine tissues during late gestation in rats [378] and cows [379]. Our data complements previous 
findings as we have shown elevated basal expression of OT mRNA in labouring compared to non-
labouring amnion (Fig. 3.1). This marked increase in OT mRNA expression in late gestation occurs in 
close proximity to the target tissues, including the endometrium and the myometirum, providing a 
strong support to the hypothesis that OT may act as a local mediator rather than a circulating hormone 
to regulate the timing of parturition. 
Despite evidence supporting the role of OT in the initiation of parturition, the significance of its role 
is still in question. This is due to the fact that OT-knockout mice undergo normal parturition [241] and 
that uterine sensitivity to OT varies greatly between patients [380]. Appropriate timing of OT use is 
the key to successful induction of labour. One of the suggested explanations for this is that OTR 
expression may mediate the uterine responsiveness to OT. One of the most consistent findings in the 
study of parturition is the increase in OTR expression in intrauterine tissues before the onset of labour. 
The increase in OT binding in the uterus has been found to be associated with the increased sensitivity 
to OT via upregulation of OTR mRNA expression in both humans [3, 381] and rats [285, 363], which 
introduces a role for OTR in the initiation of labour. There is evidence in rats showing that 
progesterone inhibits OT binding by preventing OTR function via both genomic and non genomic 
mechanisms [274, 382, 383], thereby implying that the functional withdrawal of progesterone may 
contribute to increase in OT/OTR activity prior to initiation of labour. The increase in OTR mRNA 
expression before the onset of labour has also been found in deciduas and fetal membranes. The 
greatest increase in OTR expression with labour was seen in rabbit amnion cells with approximately 
200-fold increase [384]. Subsequently, we have shown a 16-fold increase in OTR mRNA expression 
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as well as increase in OTR protein level with the onset of labour in human amnion epithelial cells (Fig. 
3.2 A and B). 
The production of PGs is one of the key steps in the biochemistry of human labour [202]. 
Prostaglandins have been studied extensively in their role in promoting myometrial contractility 
during labour onset [323]. There is increasing evidence supporting that PGs play a role at various 
stages of human parturition. They lead to increase in metalloproteinase-9 activity associated with 
rupture of fetal membranes [204], and there is large literature supporting the role of PGs in cervical 
ripening and dilation [190, 191, 385]. In addition, PGs have been reported to be associated with 
placental separation [386] and uterine involution [387].  
Prostaglandins, specifically PGE2, have been found to accumulate in the amniotic fluid with 
increasing gestation and the enzymes involved in its synthesis increase in both expression and activity 
in amnion cells prior to labour onset [355]. For biosynthesis of PGE2, three major enzymatic reactions 
are required, which involves cPLA2, COX-2, PGES-1 and -2. PGES-1 and PGES-2 (also known as 
microsomal PGE synthase-1 and -2). PGES-1 and PGES-2 are functionally coupled with COX-2 [373] 
and they have been shown to be upregulated in response to proinflammatory stimuli [388, 389] as 
well as labour in human myometrial cells [390]. In this study, OT stimulation resulted in the transient 
upregulation of multiple PGE2 synthetic enzymes, including PGES-1, PGES-2, COX-2 and cPLA2 
(Fig. 3.3), and the consequent PGE2 production. Stimulation with OT resulted in significant increase 
in the mRNA levels of PG synthetic enzymes after 2 h, which returned back to basal levels by 24 h. 
This transient response has been reported previously in HEK-293 and ECV304 cells, where a 
common proinflammatory stimuli, IL-1, induced rapid but transient activation of PGES-1, -2 and 
COX-2 transcription [373, 391]. Similar our data, IL-1β-driven upregulation of COX-2 in human 
myometrium rapidly declined after peaking at 4 h, returning to basal level by 24 h of treatment [392]. 
In addition, OT has been shown to upregulate cPLA2 and COX-2 expression in both rat [393] and 
human uterus [394]. The transient increase in the expression of PG synthetic enzymes by OT may be 
explained by the functional desensitisation of OTR. G protein coupled receptors, such as OTR, are 
able to undergo desensitisation after a prolonged or repeated stimulation. Interestingly, studies in 
myometrial cells demonstrated a time-dependent decrease in OT binding and OTR mRNA expression 
during prolonged exposure to OT, with the significant reduction occurring from 6 h exposure [265, 
395].  
The data presented here demonstrated that the induction of OTR expression by OT in human amnion 
correlates with the increase in PG synthetic enzyme levels as well as PGE2 production, suggesting a 
role for OT/OTR system in amnion during the onset of labour. Such correlation has also been 
demonstrated in rats, where the increase in the sensitivity to OT and the increase in PG production 
occurred in close temporal proximity [396]. Studies in rat models showed that PGs are important 
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stimulants of  OTR expression [397, 398], and that OTR upregulation can be blocked by PG synthesis 
inhibitors [399]. Thus it is possible that OTR and PGs may work in a positive feedback system within 
the uterus to induce myometrial contractility during labour. Our data does not show whether it is OTR 
or PGs that is driving the positive feedback system, however, there is evidence that OTR is the 
primary driver of this positive feedback loop as Fang et al. showed increase in OTR peptide prior to 
PG synthesis [400].  
In summary, the data suggests a pro-inflammatory role of amnion OT/OTR system in the onset of 
labour. During the initiation of labour, where there is an increase in OT as well as the sensitivity to 
OT, the OT/OTR system not only triggers uterine contractility but also mediate PGE2 synthesis in 
amnion. The PGs produced mediate various physiological events of parturition including membrane 
rupture, cervical dilation, myometrial contractility, placental separation and uterine involution.   
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4. Effects of OT on mediators of inflammation and downstream 
pro-labour gene expression 
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4.1. Introduction 
The production of PGs by amnion is fundamental in the onset and the continuance of labour. It has 
been established that PGE2 is produced in amnion via the COX-2-dependant pathway [373, 401, 402]. 
The onset of labour promotes COX-2 mRNA and protein expression in human myometrium as well as 
amnion [403, 404]. In human amnion, OT has been shown to drive PGE2 synthesis, suggesting a role 
for amnion OT/OTR system in the onset of labour. PGE2 synthesis has been shown to be strongly 
associated with the upregulation of COX-2 [181]. COX-2 is highly regulated both transcriptionally 
and post-transcriptionally [405-407]. Previous work in both myometrial and amnion cells have 
implicated NF-κB, AP-1 and MAPKs in regulating COX-2 expression induced by mechanical stretch 
and inflammatory cytokines [105, 154, 231, 408, 409]. Here we investigated the signalling pathways 
involved in OT-induced COX-2 expression and PGE2 synthesis. 
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4.2. OT activates NF-κB  
The promoter region of the human COX-2 gene contains various putative transcriptional regulatory 
elements, including binding sites for NF-κB, cyclic AMP responsive element (CRE), SP-1, AP-1, AP-
2 and NF-IL6 (CCAAT/enhancer binding protein β; C/EBPβ) [410]. Among these elements, the 
positive transcriptional regulators of COX-2 are CRE, C/EBPβ and NF-κB [160, 411, 412]. Our group 
has previously shown that NF-κB activity in human amnion increases with labour and that one of the 
most significantly upregulated genes is COX-2 [413], which suggests a role for NF-κB in regulating 
COX-2 expression in human amnion. To investigate whether NF-κB signalling pathway is involved in 
the OT-mediated expression of COX-2, we initially focused on the effects of OT on NF-κB.  
4.2.1. OT leads to nuclear translocation of p65 subunit but not p50 or RelB 
Nuclear/Cytosolic proteins were extracted from pre-labour amnion cells treated with OT (100 nM) for 
15 min, 30 min, and 1h. The efficacy of nuclear and cytosolic protein separation was confirmed using 
TATA binding protein (TBP) and α-tubulin, which are only expressed in the nucleus and cytosol, 
respectively. We have demonstrated the translocation of the p65 NF-κB subunit from cytosol to 
nucleus after 30 min of OT stimulation (p<0.05; Fig. 4.1 A), however, there were no nuclear 
translocation of p50 or RelB subunits observed (Fig. 4.1 B). Fluorescent immunocytochemistry was 
used to confirm the nuclear translocation of p65 subunit upon OT stimulation. Pre-labour amnion cells 
were treated with OT (100 nM) for 30 min and subsequently fixed with methanol. Using a 
fluorescently-tagged secondary antibody specific for the p65 primary antibody, its subcellular location 
was studied. We have found an increase in fluorescence in the nucleus of OT treated cells compared 
to non-stimulated cells (Fig. 4.1 C), indicating nuclear translocation of p65 subunit upon OT 
stimulation.   
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Figure 4.1. Nuclear translocation of NF-κB subunits with OT treatment. Pre-labour primary amnion cells 
were stimulated with OT (100 nM) for 15 min, 30 min, and 1 h. Western blotting of nuclear and cytosolic 
protein extracts illustrates nuclear translocation of different NF-κB subunits, p65 (A), p50 and RelB (B). 
Membranes were probed with α-tubulin and TATA binding protein (TBP) to confirm separation of nuclear and 
cytosolic extracts (n=4; * p<0.05 vs NS, ANOVA). Cultures were treated with OT for 30 min and then fixed and 
immunostained for the NF-κB subunit, p65, and visualized with TRITC. IgG was used as the negative control. 
Scale bar, 25µm (C).   
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4.2.2. OT activates the canonical NF-κB signalling pathway involving p65 homodimers 
There are three main NF-κB signalling pathways that have been described; classical, alternative and 
atypical, which involves a trigger, sequential activation of kinases leading to the release of NF-κB 
dimers from IκB proteins, nuclear translocation, and binding to NF-κB responsive genes. To 
determine which pathway is utilized by OT, we focused on looking at activation of different subunits 
of NF-κB signalling pathway. Pre-labour amnion cells were treated with OT (100 nM) for 15 min, 30 
min, 1 h, 2 h and 4 h. Treatment with OT resulted in increased expression of phosphorylated IKKα/β 
and p65, and degradation of IκBα after 15 min and 30 min of stimulation (Fig. 4.2). This resembles 
the canonical NF-κB signalling pathway, which involves activation of IKKα/β, degradation of IκBα, 
phosphorylation of p65 and nuclear translocation of NF-κB dimers. However, as we have not seen 
nuclear translocation of p50 subunit with OT treatment (Fig. 4.1 B), we hypothesized that instead of 
classical p50-p65 heterodimer translocation, p65-p65 homodimers are involved in OT-induced NF-κB 
activation.  
Further experiments using EMSA showed increase in NF-κB-DNA binding upon OT stimulation for 
30 min (Fig. 4.3). Supershift analysis was used to examine the composition of the NF-κB complexes 
binding to its consensus probe. There was a supershift of NF-κB-DNA binding with the addition of 
p65 antibody, but no shift was observed in presence of p50 antibody (Fig. 4.3). This suggests that the 
NF-κB bound to the consensus probe consists only of p65 subunits, supporting the hypothesis that 
p65-p65 homodimers are predominatly involved in OT-induced NF-κB activation. 
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Figure 4.2. Oxytocin activates NF-κB subunits involved in the classical signalling pathway. Pre-labour 
primary amnion cells were grown to reach confluence and serum depleted overnight prior to treatments. The 
cells were stimulated with OT (100 nM) for 15 min, 30 min, 1 h, 2 h and 4 h. Whole cell lysates analysed by 
Western blot demonstrated activation of NF-κB p65 and IKKα/β, and degradation of IκBα upon OT stimulation. 
Control with β-actin confirmed equal protein loading (n=6; * p<0.05 vs NS, ANOVA).  
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Figure 4.3. Treatment with OT increases DNA binding of NF-κB p65 but not p50. Pre-labour amnion 
epithelial cells were treated with OT for 30 min and nuclear proteins were extracted for binding studies. EMSA 
study demonstrated increase in nuclear protein binding to DNA sequence containing binding sites for NF-κB 
upon OT stimulation. Specificity of NF-κB binding was confirmed by co-incubation with non-labelled non-
competing (Oct-1 consensus; 5‟- TGTCGAATGCAAATCACTAGAA -3‟) and non-labelled competing (NF-κB 
consensus; 5‟-AAGAGAAGGGGCTTGCCCAAGG-3‟) oligos. Unbound probes appeared as double bands 
possibly due to single and double stranded forms of the labelled probe. Co-incubation with antibodies to NF-κB 
p65, but not p50, resulted in a band supershift in OT treated samples, indicating increase in NF-κB p65 DNA 
binding.  
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4.2.3. OT drives the expression of proinflammatory NF-κB regulated genes 
NF-κB has been found to regulate the expression of a cassette of proinflammatory genes [231, 413]. 
Having shown that OT leads to NF-κB activation in human amnion, we aimed to assess the effects of 
OT on the expression of downstream NF-κB-regulated genes. Pre-labour amnion cells were treated 
with OT for 1 h, 2 h, 4 h, 6 h, and 24 h, and total RNA was collected for qRT-PCR analysis. 
Stimulation with OT led to significant increase in IL-8 and CCL2 mRNA expression by 6- and 4-fold 
respectively, peaking after 2 h (p<0.05; Fig. 4.4 A and C). COX-2 and CCL5 mRNA levels were also 
upregulated within 2 h and 4 h of OT stimulation, respectively (p<0.05; Fig. 4.4 B and D). The 
mRNA levels of IL-6 and SOD2 showed a similar trend with an increase after 2 h stimulation (p<0.01; 
Fig. 4.4 E and F). The increase in protein levels of IL-6 and CCL5 with OT stimulation was further 
confirmed using ELISA, which demonstrated a significant increase in IL-6 after 4 h (p<0.01; Fig.4.4 
G) of OT stimulation and CCL5 after 6 h (p<0.01; Fig.4.4 H).  
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Figure 4.4. Increase in the expressions of pro-labour, downstream NF-κB-regulated genes with OT 
stimulation. Pre-labour primary amnion cells were treated with OT (100 nM) for 1 h, 2 h, 4 h and 6 h and the 
expression of downstream NF-κB-regulated genes, IL-8 (A), COX-2 (B), CCL2 (C), CCL5 (D), IL-6 (E) and 
SOD2 (F) were analysed using qRT-PCR. Transcript levels were normalised to the housekeeping gene, L19 
(n=6; * p<0.05, ** p<0.01 vs NS, ANOVA). IL-6 (G) and CCL5 (H) protein levels were examined using ELISA 
from the collected culture media collected (n=3; ** p<0.01 vs NS, ANOVA).  
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4.2.4. Activation of NF-κB upon OT stimulation is cell type-specific 
It is well established that the components involved in the activation of NF-κB signalling cascade are 
specific to both the stimulus and the type of the cell or tissue. To determine whether the ability of OT 
to activate NF-κB is specific to amnion, the effect of OT was examined in two different cell types; 
MCF-10A mammary epithelial cells and primary myometrial smooth muscle cells. The MCF-10A 
cells were treated with OT for 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h and 6 h. Whole cell 
proteins were used to confirm expression of OTR in MCF-10A cells. Despite the fact that OT is 
capable of inducing NF-κB signalling in amnion, MCF-10A cells showed no significant changes in 
the levels of phospho-p65 upon OT stimulation (Fig. 4.5). This indicates that OT-mediated activation 
of NF-κB is cell type-specific. 
Unlike in MCF-10A cells, OT treatment in primary myometrial smooth muscle cells led to nuclear 
translocation of p65 and p50 NF-κB subunits (p<0.01; Fig. 4.6 A), suggesting the involvement of 
p65-p50 heterodimers as seen in a typical classical NF-κB signalling pathway. Notably, the 
components involved in the NF-κB signalling cascade were different to that of the amnion. 
Stimulation with OT resulted in activation of p65 (p<0.05; Fig. 4.6 B), with no significant changes in 
OTR expression. The probability that OT may be driving tissue-specific NF-κB signalling cascades to 
regulate downstream gene expression indicates a complex proinflammatory role of OT. 
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Figure 4.5. The effect of OT on NF-κB p65 subunit in MCF-10A stably expressing OTR. The monolayer 
culture of MCF-10A mammary epithelial cells treated with OT (100 nM) for 5 min, 10 min, 15 min, 30 min, 1 h, 
2 h, 4 h and 6 h were extracted and Western blot analysis performed to study the effects of OT stimulation on p-
p65 and OTR expression. Control with β-actin confirmed equal protein loading (n=3).  
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Figure 4.6. Activation of NF-κB in human myometrial smooth muscle cells upon OT stimulation. Pre-
labour human myometrial smooth muscle cells were cultured from biopsies taken from patients undergoing 
elective caesarean section at term. Myometrial cells treated with OT (100 nM) for 15 min, 30 min, and 1 h were 
extracted and Western blotting of nuclear cytosolic extracts demonstrated nuclear translocation of NF-κB p65 
and p50 upon OT stimulation (A). Membranes were probed with α-tubulin and TATA binding protein (TBP) to 
confirm separation of nuclear and cytosolic extracts (n=4; * p<0.05 ** p<0.01 vs NS, ANOVA). Western blot 
analysis of whole cell extracts was performed to study the effects of OT stimulation on p-p65 and OTR 
expression (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05 vs NS, ANOVA).  
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4.3. NF-κB activation is required for COX-2 upregulation 
NF-κB has been described to be one of the key regulators of COX-2 expression in both human 
myometrium and amnion [105, 231, 409, 413]. We have shown above that OT activates IKKα/β, and 
promote degradation of IκBα and phosphorylation of p65 to allow nuclear translocation of p65 
homodimers to mediate gene expression. We then investigated the role of NF-κB pathway in OT-
induced COX-2 expression using amnion cells. Pre-labour primary amnion cells were grown to 
confluence and pre-incubated in TPCA1, an IKKβ inhibitor, for 1 h. These cells were stimulated with 
OT for 30 min and 6 h. IL-1β treatments were used as a control. There was a significant decrease in 
both IL-1β- and OT-induced p65 activation in presence of TPCA1 (p<0.05; Fig. 4.7 A). Unlike IL-1β, 
OT-induced COX-2 expression was suppressed in presence of TPCA1 (p<0.05; Fig. 4.7 B), thus 
demonstrating that OT requires the activation of IKKβ to regulate COX-2 expression whereas IL-1β-
induced COX-2 expression is not dependent on IKKβ activation. 
To further confirm the role of NF-κB in COX-2 regulation, targeted siRNA knockdown studies were 
carried out. Pre-labour amnion cells were grown to confluence and transfected with NF-κB p65-target 
siRNA via electroporation prior to OT stimulation. The cells were treated with OT (100 nM) for 6 h 
and mRNA and proteins were extracted. The knockdown of p65 expression was confirmed using both 
qRT-PCR (p<0.01; Fig. 4.8 A) and Western blot analysis (p<0.01; Fig. 4.8 C). Only those samples 
with greater than 70% knockdown were used in this study. Successful knockdown of p65 subunit led 
to significant decrease in OT-mediated COX-2 expression at both mRNA and protein levels (p<0.05; 
Fig. 4.8 B and C), indicating that p65 NF-κB subunit is required in regulation of OT induced COX-2 
expression. These data combined together demonstrate that OT drives COX-2 expression in human 
amnion via the canonical NF-κB signalling pathway. 
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Figure 4.7. IKKβ plays a role in OT-induced activation of NF-κB and COX-2 expression. Prelabour amnion 
epithelial cells were pretreated with IKKβ inhibitor (TPCA-1) for 2 h prior to OT (100 nM) or IL-1β (1 ng/ml) 
stimulation. Whole cell lysates were extracted for Western blot analysis. The presence of TPCA-1 inhibited both 
IL-1β- and OT-induced phosphorylation of NF-κB p65 (A), but only reduced OT-induced COX-2 expression 
(B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01  vs NS, § p<0.05 vs OT, ≠ 
p<0.05 vs IL-1β, ANOVA).  
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Figure 4.8. NF-κB is essential in OT-induced COX-2 expression. Prelabour amnion epithelial cells were 
subjected to transfection with non-target siRNA or p65-target siRNA (30 pmol) via electroporation prior to OT 
treatment. QRT-PCR was used for gene expression analysis of p65 (A) and COX-2 (B) in cells transfected with 
non-target siRNA or p65-target siRNA, treated with OT (100 nM) for 6 h. Transcript levels were normalised to 
the housekeeping gene, L19 (n=3; * p<0.05, ** p<0.01, *** p<0.001, § p<0.05 non-target siRNA+OT, 
ANOVA). Western blot analysis for p65 and COX-2 (C). Control with β-actin confirmed equal protein loading 
(n=3; * p<0.05, ** p<0.01, *** p<0.001, § p<0.05 non-target siRNA+OT, ANOVA).  
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4.4. OT activates ERK1/2, p38 kinase, and JNK 
MAPKs are important transcriptional and translational regulators. Numerous GPCRs, including OTR, 
have been found to result in downstream activation of MAPKs via both G-protein-dependent and -
independent mechanisms [414]. OT has been shown to activate MAPKs in rabbit amnion to regulate 
PG synthesis [367] and with this in mind, our initial experiments were designed to study the effect of 
OT on MAPKs in human amnion. Cultured amnion epithelial cells were treated with OT (100 nM) for 
15 min, 30 min, 1 h, 2 h, and 4 h, and whole cell lysates were analysed using Western blot. The levels 
of phosphorylated ERK1/2 and p38 kinase increased in response to OT after 15 min and 30 min, 
respectively (p>0.001, p>0.05; Fig. 4.9). Phosphorylation of JNK increased at 15 min and 30 min of 
OT treatment, peaking at 30 min (p>0.05;  Fig. 4.9).  
 
 
Figure 4.9. Oxytocin activates ERK1/2, p38 kinase and JNK. Pre-labour primary amnion cells were treated 
with OT (100 nM) for 15 min, 30 min, 1 h, 2 h and 4 h, and Western blot analysis was performed to study the 
effects of OT stimulation on p-ERK1/2, p-p38 and p-JNK expression. Control with β-actin confirmed equal 
protein loading (n=6; * p<0.05 vs NS, ANOVA).  
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4.5. MAPKs are required for COX-2 upregulation 
In amnion-derived WISH cells, MAPKs; p38 kinase and JNK in particular, have been shown to play a 
role in regulating COX-2 expression [415, 416]. In contrast to these findings, data from rabbit amnion 
and human amnion cells suggested that only ERK1/2 is involved in OT-mediated COX-2 expression 
[181, 367]. As we have previously shown that OT can activate ERK1/2, p38 kinase, and JNK, we 
aimed to determine the role of MAPK activation on OT-induced COX-2 expression using ERK1/2 
inhibitor (U0126; 10 µM), p38 kinase inhibitor (SB203580; 10 µM) and JNK inhibitor (SP600125; 10 
µM). Pre-labour amnion epithelial cells were treated with the different MAPK inhibitors for 2 h prior 
to 6 h OT stimulation. The presence of ERK1/2 and p38 kinase inhibitors attenuated OT-induced 
COX-2 protein expression, suggesting that ERK1/2 and p38 activation by OT/OTR signalling is 
essential for COX-2 expression (p<0.05; Fig.4.10 A). The efficacies of the different MAPK inhibitors 
were confirmed by Western blot analysis (Fig. 4.11). 
4.6. MAPKs play a role in OT-induced activation of NF-κB 
Activation of MAPK pathways combined with NF-κB activation are involved in the regulation of 
proinflammatory cytokine synthesis [417]. Since we established a role for OT in activating both 
pathways, we then explored the association between the activation of MAPK and NF-κB in the 
regulation of COX-2 expression. Pre-labour amnion cells were pre-treated with MAPK inhibitors; 
U0126 (10 µM), SB203580 (10 µM) and SP600125 (10 µM), for 2 h and stimulated with OT (100 nM) 
for 30 min. We found a dramatic decrease in OT-induced p65 phosphorylation in the presence of 
ERK1/2 and p38 kinase inhibitors, U0126 and SB203580 (p<0.05; Fig. 4.10 B), indicating that OT-
induced activation of NF-κB is MAPK-dependent. This demonstrates a cross-talk between the OT-
induced activation of MAPKs and NF-κB signalling cascades. 
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Figure 4.10. OT-induced expression of COX-2 requires MAPK dependent NF-κB activation. Pre-labour 
primary amnion cells were incubated in the presence of the ERK1/2 inhibitor (U0126; 10 µM), p38 kinase 
inhibitor (SB203580; 10 µM) or JNK inhibitor (SP600125; 10 µM) for 2 h prior to OT (100 nM) stimulation for 
30 min and 6 h. Whole cell lysates were extracted for Western blot analysis of COX-2 (A) and p-p65 (B). 
Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** p<0.001 vs NS, § p<0.05 
vs OT, ANOVA).  
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Figure 4.11. Efficacy of different MAPK inhibitors. Pre-labour primary amnion cells were incubated in the 
presence of the ERK1/2 inhibitor (U0126; 10 µM), p38 kinase inhibitor (SB203580; 10 µM) or JNK inhibitor 
(SP600125; 10 µM) for 2 h prior to OT (100 nM) stimulation for 30 min. Whole cell lysates were extracted for 
Western blot analysis of p-ERK, p-HSP27, and p-JNK.Control with β-actin confirmed equal protein loading.  
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4.7. Effect of IL-1β on NF-κB signalling and COX-2 expression 
In this study we report a novel mechanism for OT activation of NF-κB, which involves activation of 
IKKα/β, degradation of IκBα, phosphorylation of p65 and nuclear translocation of p65 homodimers 
alone. OT-induced activation of NF-κB therefore resembles a classical NF-κB signalling pathway 
triggered by IL-1β stimulation in amnion cells [353]. To compare and contrast our findings, we used 
IL-1β stimulated pre-labour amnion epithelial cells as a control.  
As reported previously, IL-1β led to nuclear translocation of NF-κB p65 and p50 subunits after 15 
min and 30 min of stimulation (p<0.001; Fig. 4.12 A and B) and there was a delayed nuclear 
translocation of RelB after 1 h (p<0.05; Fig. 4.12 B). This was further confirmed by fluorescent 
immunocytochemistry (Fig. 4.12 C). To demonstrate that IL-1β activates the classical NF-κB pathway 
in human amnion, we focused on looking at activation of different subunits of NF-κB signalling 
pathway. Pre-labour amnion cells were treated with IL-1β (1ng/ml) for 15 min, 30 min, 1 h, 2 h and 4 
h. IL-1β stimulation resulted increases in phosphorylation of IKKα/β and p65, and degradation of IκBα 
after 15 min, 30 min and 1 h, before returning to basal level at 2 h (p<0.05, p<0.001 and p<0.05; Fig. 
4.13). This resembles the classical NF-κB signalling pathway, which involves activation of IKKα/β, 
degradation of IκBα, phosphorylation of p65 and nuclear translocation of p65/p50 heterodimers. 
NF-κB is a key modulator of COX-2 expression in amnion [325]. Consistent with this we provided 
evidence that OT-induced COX-2 expression in the amnion is NF-κB-mediated, however, inhibition 
of IKKβ using TPCA1 had no effect on IL-1β-induced COX-2 expression. Previous reports have 
shown that IL-1β-mediated COX-2 expression involved MAPKs, specifically ERK1/2 and p38 
kinases, in cardiac myocytes [418] as well as mesangial cells [419], therefore, we aimed to 
demonstrate the role of MAPKs on IL-1β-induced COX-2 expression. Pre-labour amnion epithelial 
cells treated with IL-1β showed significant increase in ERK1/2, p38 and JNK phosphorylation, 
peaking after 30 min (Fig. 4.14). Preincubating the cells with MAPK inhibitors; U0126 (10 µM) and 
SB203580 (10 µM), for 2 h showed significant reduction in IL-1β-induced COX-2 expression (p<0.05; 
Fig. 4.15 A). This was not observed in presence of JNK inhibitor, SP600125. Despite the evidence of 
cross-talk between NF-κB and MAPK pathways in OT-mediated COX-2 expression, this was not 
shown in IL-1β-treated amnion cells (Fig. 4.15 B).  
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Figure 4.12. Nuclear translocation of NF-κB subunits with IL-1β treatment. Pre-labour primary amnion 
cells were stimulated with IL-1β (1ng/ml) for 15 min, 30 min, and 1 h. Western blotting of nuclear and cytosolic 
protein extracts illustrates nuclear translocation of different NF-κB subunits, p65 (A), p50 and RelB (B). 
Membranes were probed with α-tubulin and TATA binding protein (TBP) to confirm separation of nuclear and 
cytosolic extracts (n=4; * p<0.05, ** p<0.01, *** p<0.001 vs NS, ANOVA). Cultures were treated with IL-1β 
for 30 min and then fixed and immunostained for the NF-κB subunit, p65, and visualized with TRITC. Scale bar, 
25µm (C).  
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Figure 4.13. IL-1β activates NF-κB subunits involved in the classical signalling pathway. Pre-labour 
primary amnion cells were grown to reach confluence and serum depleted overnight prior to treatments. The 
cells were stimulated with IL-1β (1ng/ml) for 15 min, 30 min, 1 h, 2 h and 4 h. Whole cell lysates analysed by 
Western blot demonstrated activation of NF-κB p65 and IKKα/β, and degradation of IκBα upon IL-1β 
stimulation. Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01 vs NS, ANOVA).  
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Figure 4.14. IL-1β activates MAPKs, ERK1/2, p38 kinase, and JNK. Pre-labour primary amnion cells were 
treated with IL-1β (1ng/ml) for 15 min, 30 min, 1 h, 2 h and 4 h, and Western blot analysis was performed to 
study the effects of IL-1β stimulation on p-ERK1/2, p-p38 and p-JNK expression. Control with β-actin 
confirmed equal protein loading (n=6; * p<0.05, *** p<0.001 vs NS, ANOVA).  
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Figure 4.15. IL-1β-induced expression of COX-2 requires independent activation of MAPKs and NF-κB. 
Pre-labour primary amnion cells were incubated in the presence of the ERK1/2 inhibitor (U0126; 10 µM), p38 
kinase inhibitor (SB203580; 10 µM) or JNK inhibitor (SP600125; 10 µM) for 2 h prior to IL-1β (1ng/ml) 
stimulation for 30 min and 6 h. Whole cell lysates were extracted for Western blot analysis of COX-2 (A) and p-
p65 (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** p<0.001 vs NS, ≠ 
p<0.05 vs IL-1β, ANOVA).  
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4.8. Summary and discussion 
The simultaneous increase in the sensitivity to OT and PG synthesis in the amnion during the onset of 
labour has led to the concept that OT/OTR system in the amnion enacts events requisite to parturition 
that is separate from inducing uterine contractions. The physiology of human labour resembles that of 
an inflammatory process. PGs has been reported to play a key role in the generation of the 
inflammatory responses whilst orchestrating fetal membrane rupture, cervical ripening and uterine 
contractions [420]. It has been established that COX-2 is a key regulator of PG production and a 
central mediator of inflammation [421]. In human amnion, COX-2 is present at low levels throughout 
gestation and highly expressed during the onset of labour to drive PG synthesis [403]. Inflammatory 
cytokines, such as IL-1β, has been shown to upregulate the expression of COX-2 through MAPKs 
[367, 416] and NF-κB [409, 416, 422, 423] in various cell types. However, little is known about the 
detailed mechanisms involved in the regulation of the OT-mediated COX-2 expression in human 
amnion cells. Here, we utilised our primary human amnion epithelial cell model to demonstrate that 
both the OTR-dependant activation of MAPKs (ERK1/2 and p38 kinase) and subsequent activation of 
NF-κB signalling cascade are required for OT-induced COX-2 expression. 
The NF-κB transcription factor family is a key regulator of inflammatory responses following 
exposure to extracellular stimuli, and it has been found to play an important role in the expression of a 
variety of genes involved in inflammatory responses as well as cell survival [208]. It has been 
established that the activation of NF-κB is strongly associated with parturition as it regulates 
expression of contraction-associated proteins whilst antagonising the relaxatory effects of 
progesterone [325]. There is evidence in mouse models that during the onset of labour, NF-κB is 
activated by the release of surfactant proteins from fetal lung, which indicate pulmonary maturity. 
Inhibition of NF-κB activity in mouse delays the onset of normal labour [131] and infection-
associated preterm labour [424]. In human, there is increase in NF-κB activity in amnion during the 
onset of labour [325, 413], and NF-κB has been shown to play a critical role in the regulation of 
COX-2 expression and in the development of inflammatory response. Therefore, we investigated the 
effect of OT on NF-κB signalling pathway in human amnion. Treatment with OT resulted in nuclear 
translocation of p65 subunit, but not p50 or RelB (Fig. 4.1 A and B). This was further confirmed by 
immunofluorescence studies (Fig. 4.1 C). Moreover, we demonstrated that OT stimulates 
phosphorylation of IKKα/β and p65, and degradation of IκBα (Fig. 4.2). These data clearly indicate 
that OT activates the classical NF-κB signalling cascade, which resembles that activated by IL-1β 
(Fig. 4.12 and 4.13). However, the absence of p50 nuclear translocation and p50 supershift upon OT 
stimulation indicate that unlike IL-1β, OT-induced activation of NF-κB signalling cascade involves 
p65 homodimers and not p50-p65 heterodimers (Fig. 4.3).  
112 
 
The role of p65 homodimers in the regulation of gene expression has been suggested in previous 
studies. Early initial studies had suggested that only p50 subunit of NF-κB can bind to DNA [425], 
however, later investigations demonstrated that the p65 NF-κB subunit also possesses intrinsic DNA 
binding activity [426]. Fujita et al. showed that p50 and p65 homodimers are both transcriptional 
activators, but activation is dependent on different parameters [427]; where activation by p65 
homodimers are dependent on their carboxy-terminal region and that of p50 is dependent on its 
conformation. The presence of p65 homodimers have been shown in human T cells where it was 
found to be capable of associating with IκBα under certain physiologic conditions [428]. Similar to 
our findings, a proinflammatory mediator, thrombin, has been shown to induce ICAM-1 expression in 
endothelial cells via NF-κB signalling pathway involving p65 homodimers binding to ICAM-1 
promoter region [429]. 
Activation of NF-κB by OT is not confined to the amnion but also seen in the myometrium. Although 
we did not observe any activation of NF-κB in MCF-10A cells expressing OTR, human myometrial 
smooth muscle cells showed activation of p65 NF-κB subunit upon OT stimulation (Fig. 4.5 and 4.6). 
The components of the NF-κB signalling cascade activated by OT in amnion and myometrium had 
slight differences. OT resulted in the nuclear translocation of both p65 and p50 in myometrium 
whereas only p65 translocation was observed in amnion. The involvement of p65/p50 heterodimers in 
OT-induced NF-κB pathway in myometrium requires further analysis. However, the presence or 
absence of p50 NF-κB subunit activation can introduce a previously unsuspected element of 
specificity in regulation of gene expressions as the dimers of p65 and p50 (hetero- or homo-dimers) 
have been shown to possess variable DNA-binding affinity to NF-κB binding sites of different genes. 
For instance, in HeLa cell extracts, the IFNβ NF-κB binding site showed no transcriptional activity 
with p50 homodimers but responded to p65 homodimers and p65/p50 heterodimers [427]. Therefore, 
this tissue-dependent activation of NF-κB pathway by OT may enable it to control the expression of 
different cassette of genes in amnion compared to myometrium. 
We have demonstrated that OT increases COX-2 expression in amnion. The OT-induced COX-2 
expression was completely abolished in the presence of a selective IKKβ inhibitor TPCA1 (Fig. 4.7), 
which indicates that NF-κB is essential in OT-induced COX-2 expression. This was further confirmed 
via NF-κB p65 siRNA knockdown experiments (Fig. 4.8) where successful knockdown of p65 
expression led to a marked decrease in both basal and OT-induced COX-2 mRNA and protein levels. 
These results were consistent with COX-2 expression induced by hypoxia, or LPS in various cell 
types including amnion cells [430, 431]. Opposite to previously studies that demonstrated a role for 
NF-κB in IL-1β-induced COX-2 expression, we found that IKKβ activation is not required for IL-1β-
induced COX-2 expression [353, 423].  This discrepancy in the results may be due to the difference in 
the NF-κB subunits inhibited in each study as we have used IKK inhibitor whereas Lee et al. used 
siRNA p65-targeted knockdown and Ackerman et al. used inhibitor of IκBα degradation. 
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In addition to COX-2, we demonstrated that OT increases the expression of several downstream 
proinflammatory genes including IL-8, IL-6, CCL2, CCL5 and SOD2 (Fig. 4.4), which are included 
in the cassette of immume/inflammatory genes regulated by NF-κB in human pregnant myometrium 
[231]. The major genes upregulated at the time of labour are from inflammatory pathways [432] and 
these genes have considerable overlap with those upregulated by NF-κB pathway in human 
myometrium. The gene with the highest increase in expression in these studies was IL-8, which was 
most highly expressed cytokine in OT-treated amnion cells [417]. In both human and animal models, 
prolonged exposure to OT has been shown to drive systemic anti-inflammatory effects via depression 
of proinflammatory cytokine expression, especially TNFα and IL-6, in macrophages, lymphocytes 
and neutrophils [433, 434]. However, a recent study in human macrophages and monocytes has failed 
to observe any anti-inflammatory effects of OT [435]. Interestingly, our data demonstrate a novel role 
of OT in activating NF-κB signalling cascade through which it induces proinflammatory 
cytokines/chemokines and PG production that can contribute to the onset of labour. 
There are several lines of evidence demonstrating that MAPKs can be activated by GPCR agonists 
[436]. MAPK activation has been implicated in the expression of COX-2 induced by various 
extracellular stimuli in different cell types. In macrophages, LPS activates ERK1/2 and p38 kinase to 
induce the transcription factor C/EBPβ and CREB and in turn, mediate the initial stages of COX-2 
transcriptional activation [437, 438]. Several proinflammatory cytokines such as IL-1, IFNγ or TNFα 
have also been shown to induce COX-2 expression via MAPK activation. IL-1- and IFNγ-induced 
COX-2 expression involved p38 kinase activation [439] whilst TNFα-induced COX-2 expression was 
heavily regulated by ERK1/2 and NF-κB [440].   
In this study, we demonstrated stimulus-specific activation of MAPKs in amnion cells. Both IL-1β 
and OT triggered the activation of ERK1/2, p38 kinase and JNK (Fig. 4.9 and Fig. 4.14); however, the 
MAPK response to IL-1β was more prominent. Recent study reported the significance of MAPK 
pathways in the onset of labour as they demonstrated that increase in activation of MAPKs in term 
pre-labour fetal membranes overlying the cervix play a role in the degradation of the ECM, promoting 
membrane rupture [441]. Pretreatment with the MAPK inhibitors U0126 or SB203580 both markedly 
reduced OT- and IL-1β-induced expression of COX-2 protein (Fig. 4.10 A and 4.15 A). These data 
suggest that in amnion cells, ERK1/2 and p38 kinase are required for OT- and IL-1β-induced COX-2 
expression, consistent with those obtained from various cell types where the upregulation of COX-2 
by OT or IL-1β was via ERK1/2 [394, 442]. For the role of p38 kinase, we are the first to demonstrate 
that p38 kinase plays a critical role in OT-induced COX-2 expression in human amnion epithelial 
cells.  
OT-stimulated NF-κB p65 phosphorylation was significantly inhibited by the MAPK inhibitors 
U0126 or SB203580 (Fig. 4.10 B), indicating OT induced activation of NF-κB is mediated through 
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OT-dependent activation of ERK1/2 and p38 kinase. This cross-talk between MAPKs and NF-κB in 
the regulation of COX-2 expression was not seen with IL-1β stimulation (Fig. 4.15 B), but it has been 
demonstrated in a variety of other cell types. In endothelial [443] and vascular smooth muscle cells 
[444], COX-2 expression induced by thrombin were found to be mediated through MAPK; 
specifically ERK1/2 and p38 kinase, -dependent NF-κB activation. Similarly, Bradykinin (BK) 
induced COX-2 expression and PGE2 release in astrocytes was reported to be via ERK1/2-mediated 
NF-κB activation [445]. However, we are the first to report that OT-induced COX-2 upregulation in 
human amnion cells require sequential activation of MAPK (ERK1/2 and p38 kinase) and NF-κB 
pathways. The details of how MAPKs regulate NF-κB activation are not clear, but there are evidences 
suggesting that MAPKs can act directly on IKKα/β and in turn trigger the NF-κB signalling cascade 
[440]. JNK and p38 kinases have been shown to regulate phosphrylation of IκBα and NF-κB p65 
subunit, repectively [446, 447]. Therefore, this interplay between MAPK and NF-κB pathways in the 
induction of COX-2 needs to be further investigated.   
Several reports indicate that COX-2 expression can have both proinflammatory and anti-inflammatory 
effects depending on the type of prostaglandins it produces. Gilroy et al. [448] showed that during the 
early inflammatory process when there is induction of COX-2 expression and PGE2 levels are high, 
COX-2 functions in a proinflammatory manner. In human colon epithelial cells, it was suggested that 
COX-2-mediated PGE2 release can regulate the transcriptional activity of NF-κB, thus promoting 
inflammatory processes [449]. Therefore, it is possible that OT-induced COX-2 expression and PGE2 
synthesis in human amnion at the time of labour onset can further enhance NF-κB activity and 
subsequently increase inflammation via a positive feedback system. 
To summarise, we have illustrated that OT/OTR system in amnion exerts its effects on COX-2 
expression through a sequential activation of ERK1/2, p38 kinase and NF-κB signalling cascades as 
shown in Figure 4.16. These findings provide new insights into the molecular mechanisms used by 
OT/OTR receptor system to induce proinflammatory responses via PGs and cytokines synthesis 
during the onset of labour in human amnion.  
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Figure 4.16. A model for OT/OTR signalling and action in amnion. OT binding to OTR drives the activation 
of MAPKs, ERK1/2 and p38 kinase, to activate the classical NF-κB signalling cascade involving p65 
homodimers. The NF-κB dimers translocate to the nucleus and binds to κB sites to induce expression of pro-
labour genes such as COX-2 and proinflammatory cytokines. This leads to the increase in PG and cytokine 
synthesis from human amnion cells during the onset of labour.  
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5. Oxytocin receptor/G-protein coupling in human amnion 
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5.1. Introduction 
Oxytocin receptor (OTR) belongs to the group I G-protein coupled receptor family. It has been 
established that OT binding to its myometrial receptor leads to an activation of Gαq/11 and 
phospholipase Cβ (PLCβ) pathway to generate inositol trisphosphate (IP3), which results in increase 
in intracellular calcium levels [308]. This OT-stimulated phosphoinositide hydrolysis has been 
implicated in regulating COX-2 expression [450] as well as myometrial contractility and it has been 
found to involve both pertussis toxin-sensitive and -insensitive G-proteins, members of Gαi and Gαq 
family [451-454]. However, the OTR and G-protein coupling in amnion is yet to be understood. 
Previous work on rabbit amnion showed that, similar to human myometrium, OT binding to its 
receptor leads to activation of Gαq /PLC pathway and increase in intracellular calcium, which in turn 
activates cPLA2 and COX-2 for PGE2 synthesis [367]. We have shown that in human amnion, OT 
regulates PGE2 synthesis via COX-2 expression, which requires activation of both NF-κB and 
MAPKs. Our aim was to identify the OTR and G-protein coupling involved in this process. 
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5.2. OT increases in intracellular calcium levels in human amnion cells 
G-protein coupled receptors are capable of coupling to multiple G proteins, which is important for 
introducing variability in the mechanisms involved in response to a ligand between different cell types. 
The significance in understanding the receptor-G-protein coupling is becoming more apparent as 
promiscuity in receptor-G-protein coupling can give rise to great variability in the effects of receptor 
activation. Therefore the signalling pathways activated by a given GPCR need to be investigated in 
individual cell types. Since we have verified that OTR is present in human amnion and that OT 
stimulation results in PGE2 synthesis, a series of experiments were carried out to determine the 
downstream G-protein signalling pathways involved in this process. 
Increases in intracellular calcium levels by OT via Gαq coupling has been previously shown in CHO-
OTR cells, amnion-derived WISH cells as well as human amnion [317, 455, 456]. Therefore we 
demonstrated the ability of OT to activate calcium signalling in amnion epithelial cells. Pre-labour 
amnion cells were grown to reach confluence and they were loaded with calcium dye Fluo-4 prior to 
OT treatment. Stimulation with OT resulted in a delayed (approximately 450 sec) increase in 
intracellular calcium levels, reaching a peak after 600 sec (Fig. 5.1 A). 
 
Figure 5.1. Oxytocin stimulates calcium mobilisation in human amnion. Pre-labour amnion epithelial cells 
were loaded with calcium-sensitive dye, Fluo-4, before stimulation with OT (100 nM). The changes in the 
intracellular calcium levels with OT stimulation were determined by live cell imaging on the Leica SP5 confocal 
microscope (A). The addition of stimulus is indicated by an arrow. Snapshot of calcium loaded amnion cells 
treated with and without OT (B) (n=3).  
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5.3. Downstream Gαq inhibitors and siRNA knockdown of Gαq do not attenuate the 
proinflammatory effects of OT 
In rabbit amnion, OTR has been shown to couple with Gαq to induce PLC activity and calcium 
mobilisation leading to activation of PKC to regulate cPLA2 phosphorylation and COX-2 expression 
via MAPKs, and in turn, mediate PGE2 production [367]. Our work in human amnion epithelial cells 
demonstrated activation of MAPKs, ERK and p38 kinase, leading to increase in phosphorylation of 
cPLA2 and COX-2 expression upon OT stimulation. To investigate the role of Gαq in this regulatory 
mechanism, pre-labour amnion epithelial cells were pre-treated for 1 h with different downstream Gαq 
inhibitors; U-73122 (PLC inhibitor; U7), GF109203X (PKC-α and -β inhibitor; GFX), and Go6983 
(broad spectrum PKC inhibitor; Go). The presence of U7 did not inhibit the OT-induced activation of 
p65, ERK and p38 kinase, but stimulation with U7+OT had additive effect on the activation of ERK 
and p38 kinase compared to OT alone in a dose-dependent manner (Fig. 5.2 A). This was also 
observed in the upregulation of COX-2 and activation of cPLA2, where U7 was insufficient to 
suppress the effects of OT but U7+OT resulted in an enhanced expression of COX-2 (Fig. 5.2 B). 
Similar results were observed with the PKC-α and -β inhibitor, GFX (Fig. 5.3 A and B), as well as 
broad spectrum PKC inhibitor, Go (Fig. 5.4 A and B). Pre-treating the cells with all these inhibitors 
did not suppress the activation of NF-κB and MAPKs, nor the upregulation of COX-2 and phospho-
cPLA2 upon OT stimulation. Our results indicate that activation of PKC and PLC are not required for 
OT-induced proinflammatory response in human amnion, thereby suggesting that Gαq may not be 
involved in the OT-induced activation of NF-κB, MAPKs, cPLA2, and COX-2. 
These findings were further confirmed via Gαq knockdown studies. Pre-labour amnion epithelial cells 
were grown to confluence in tissue culture flasks and trypsinised to obtain cell suspension. The cells 
were then transfected with 80 nmol Gαq targeted siRNA by electroporation. Transfected cells were 
grown for another 3 days prior to any treatments. The efficiency of the knockdown was validated 
using Western blot analysis. Successful knockdown of Gαq did not suppress the OT-induced activation 
of NF-κB and MAPKs, nor upregulation of COX-2 and p-cPLA2 (Fig. 5.5).  
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Figure 5.2. PLC inhibitor, U73122, does not suppress the proinflammatory effects of OT. Pre-labour 
primary amnion cells were incubated in a downstream Gαq inhibitor, PLC inhibitor (U73122; 5 µM/10 µM), for 
2 h prior to OT (100 nM) stimulation. Whole cell lysates of cells treated with OT for 15 min and 30 min were 
subjected to Western blot analysis for p-p65, p-ERK1/2 and p-p38 (A). The expressions of COX-2 and p-cPLA2  
in amnion cells treated with OT for 4 h and 6 h were analysed using Western blotting (B). Control with β-actin 
confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** p<0.001  vs NS, ANOVA).   
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Figure 5.3. PKC-α and -β inhibitor, GFX, does not suppress the proinflammatory effects of OT. Pre-
labour primary amnion cells were incubated in a downstream Gαq inhibitor, PKC-α and -β inhibitor (GFX; 5 
µM/10 µM), for 2 h prior to OT (100 nM) stimulation. Whole cell lysates of cells treated with OT for 15 min 
and 30 min were subjected to Western blot analysis for p-p65, p-ERK1/2 and p-p38 (A). The expressions of 
COX-2 and p-cPLA2  in amnion cells treated with OT for 4 h and 6 h were analysed using Western blotting (B). 
Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** p<0.001  vs NS, ANOVA).  
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Figure 5.4. A broad spectrum PKC inhibitor, Go6983, does not suppress the proinflammatory effects of 
OT. Pre-labour primary amnion cells were incubated in a downstream Gαq inhibitor, broad spectrum PKC 
inhibitor (Go6983; 5 µM/10 µM), for 2 h prior to OT (100 nM) stimulation. Whole cell lysates of cells treated 
with OT for 15 min and 30 min were subjected to Western blot analysis for p-p65, p-ERK1/2 and p-p38 (A). 
The expressions of COX-2 and p-cPLA2  in amnion cells treated with OT for 4 h and 6 h were analysed using 
Western blotting (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** 
p<0.001  vs NS, ANOVA).  
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Figure 5.5. The role of Gαq protein in the OT-mediated activation of NF-κB and MAPK, and up-
regulation of COX-2 and p-cPLA2 in human amnion epithelial cells. Prelabour amnion epithelial cells were 
subjected to tranfection with non-target siRNA or Gαq-target siRNA (30 pmol) via electroporation prior to OT 
(100 nM) treatment. Western blot analysis was used to examine the efficiency of Gαq knockdown and its effect 
on OT-mediated activation of NF-κB and MAPKs, as well as COX-2 and p-cPLA2 expression. Control with β-
actin confirmed equal protein loading. As with chemical inhibition, siRNA knockdown of Gαq did not markedly 
alter p65 phosphorylation, MAPK activation or COX-2 protein levels (n=3; a p<0.05 vs NS of Nt, b p<0.05 vs 
NS of Gq siRNA, ANOVA).  
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5.4. Pertussis toxin, a Gαi inhibitor, suppresses the OT-stimulated increase in intracellular 
calcium levels 
In previous studies, OTR and Gαi coupling has been shown to result in dissociation of Gβ/γ subunits 
leading to activation of PLCβ and/or calcium channels directly and bring about calcium mobilisation 
[457, 458]. As data shown above indicate that OT/OTR system in human amnion may not require 
coupling with Gαq to mediate its proinflammatory effects, we studied the role of Gαi coupling. Pre-
labour amnion epithelial cells were grown to confluence and incubated in pertussis toxin (PTX; 500 
ng/ml) for 1 h. The cells were then loaded with the calcium dye Fluo-4. The presence of PTX 
completely inhibited OT-induced calcium response (Fig. 5.6 A and B), thus indicating that calcium 
mobilisation by OT is mainly via OTR/Gαi coupling.  
As mentioned previously, the coupling of OTR and Gαi subunit can activate Gβ/γ subunits to induce a 
calcium response. There are two alternative mechanisms that may be used by GPCR to initiate a 
calcium signal via Gαi; a distal activation of calcium via PLCβ and IP3 [459] and a local activation of 
IP3 receptors (IP3Rs) with Gβ/γ subunit via direct binding [457, 458]. In order to determine whether 
PLCβ/IP3 is involved in OT induced calcium response in human amnion, IPOne HTRF assay kit was 
utilised to measure accumulation of IP1 with OT stimulation. Pre-labour amnion epithelial cells were 
plated into white small-volume 384 culture plates with approximately 20,000 cells per well. The cells 
were incubated in a buffer containing Lithium Chloride (LiCl) which leads to accumulation of IP1, an 
IP3 metabolite, upon receptor activation. Amnion cells were treated with a series of OT dilutions 
ranging from 1 pM to 1 µM for 1 h and stimulation with ATP was used as a positive control. We 
found no accumulation of IP1 in presence of OT, even at the highest concentration of 1 µM (Fig. 5.6 
C). This suggests that in human amnion, OT may activate a calcium response via an IP3-independent 
pathway. 
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Figure 5.6. Calcium mobilisation mediated by OT is PTX-sensitive and independent of IP-1 increase. Pre-
labour amnion epithelial cells were pretreated with a Gαi inhibitor, pertussis toxin (PTX; 0.5 µg/ml), and loaded 
with calcium-sensitive dye, Fluo-4, before stimulation with OT (100 nM). The changes in the intracellular 
calcium levels with OT stimulation were determined by live cell imaging on the Leica SP5 confocal microscope 
(A). The addition of stimulus is indicated by an arrow. Preincubation with PTX resulted in complete inhibition 
of OT-induced calcium mobilisation (B). For IPOne HTRF assay, amnion cells cultured in a low-volume white 
384-well plates were stimulated with increasing dose of OT (1 pM - 1 µM) over time, and the IP-1 
concentrations were extrapolated from a standard curve (C). Treatment with ATP was used as a positive control 
(n=3).  
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5.5. The proinflammatory role of OT in human amnion is via OTR-Gαi coupling 
The increased ability of human amnion cells to synthesise prostaglandins is accomplished by 
sequential activation of MAPKs, ERK and p38 kinase, and NF-κB. As amnion OTR couples with Gαi 
to initiate calcium mobilisation, which is considered a pro-labour response, it was postulated that this 
then might regulate the downstream proinflammatory responses exerted by OT. This potential link 
was tested by examining the effects Gαi inhibitor (PTX) and siRNA Gαi-target knockdown may have 
on the activation of NF-κB and MAPK signalling, and COX-2 expression in human amnion cells. 
Initially, the pre-labour amnion epithelial cells were incubated in PTX (0.2 µg/ml and 0.5 µg/ml) for 1 
h prior to OT stimulation. Analysis using Western blot showed significant decrease in OT-induced 
activation of NF-κB and MAPKs in a dose-dependent manner (Fig. 5.7 A). The presence of Gαi 
inhibitor, PTX, also dampened the effect of OT on the expression of downstream genes including 
COX-2 and p-cPLA2 (Fig. 5.7 B), suggesting that OTR-Gαi coupling is required in the regulation of 
OT-mediated expression of COX-2 and p-cPLA2. In addition, pretreatment with PTX had downstream 
effect on PGE2 synthesis upon OT stimulation (Fig. 5.8), indicating that OTR and Gαi coupling may 
act as a key regulator of OT-induced proinflammatory effects in human amnion. 
There are three different subtypes of human Gαi proteins identified to date; Gαi-1, Gαi-2 and Gαi-3 [460]. 
As Gαi proteins play a significant role in regulating the effect of OT in human amnion, the next set of 
experiments were conducted to identify the subtype of Gαi protein involved. Primers were designed for 
the three subtypes of Gαi proteins and their expressions were studied using standard PCR. Total of 5 
pre-labour amnion samples from 5 different patients were used for the PCR, along with two pre- 
labour myometrial samples as positive controls. The result showed low expression of Gαi-1 in 
myometrial cells but none in amnion (Fig. 5.9 A) and a higher expression of Gαi-2 and Gαi-3 in both 
human myometrial and amnion cells (Fig. 5.9 B and C).  
To determine which of the two subtypes expressed in amnion are involved in the regulation of OT 
induced proinflammatory effects, siRNA knockdown of Gαi-2 and Gαi-3 was used. Pre-labour amnion 
epithelial cells were grown to confluence and transfected with Gαi-2 and Gαi-3 -target siRNA using 
electroporation. Knockdown of Gαi-2 significantly inhibited the activation of NF-κB and both ERK 
and p38 kinase by OT (Fig. 5.10). This in turn resulted in suppression of COX-2 expression and 
cPLA2 activation (Fig. 5.10). Similar results were observed with Gαi-3 knockdown to a lesser extent, 
except for activation of p65, which was not affected (Fig. 5.11), implicating that these both Gαi 
subtypes expressed in amnion can couple with OTR to regulate the proinflammatory responses to OT 
in human amnion.   
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Figure 5.7. The proinflammatory effects of OT are PTX-sensitive. Prelabour amnion epithelial cells 
pretreated with PTX (0.2 µg/ml or 0.5 µg/ml) were stimulated with OT over time. Western blot analysis was 
used to examine the effect of PTX on OT-mediated activation of NF-κB and MAPKs (A), as well as COX-2 and 
p-cPLA2 expression (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, *** 
p<0.001 , ANOVA).  
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Figure 5.8. OT-induced PGE2 synthesis is PTX-sensitive. Pre-labour amnion epithelial cells were serum 
depleted overnight and treated with PTX (0.5 µg/ml) prior to OT (100 nM) stimulation. The culture media were 
collected for PGE2 EIA analysis (n=6; ** p<0.01 vs NS, ≠ p<0.05 vs OT 6h, ANOVA).  
 
 
 
 
Figure 5.9. Human amnion expresses different subtypes of Gαi proteins. Prelabour amnion epithelial cells 
were established from 5 different samples. cDNAs were synthesized using total RNA extracted from non-
stimulated amnion cells. Products of PCR reactions with primers specific for Gαi1, Gαi2 and Gαi3 were analysed 
on 2% agarose gel. Gαi1 (A) was not detectable in amnion, however, Gαi2 (B) and Gαi3 (C) were detected. 
Myometrial cDNA was used as positive controls (+) (Gαi1 115 bp, Gαi2 212 bp and Gαi3 154 bp).  
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 Figure 5.10. The role of Gαi2 protein in the OT-mediated activation of NF-κB and MAPK, and up-
regulation of COX-2 and p-cPLA2 in human amnion epithelial cells. Prelabour amnion epithelial cells were 
subjected to tranfection with non-target siRNA or Gαi2-target siRNA (30 pmol) via electroporation prior to OT 
(100 nM) treatment. Western blot analysis was used to examine the efficiency of Gαi2 knockdown and its effect 
on OT-mediated activation of NF-κB and MAPKs, as well as COX-2 and p-cPLA2 expression. Control with β-
actin confirmed equal protein loading. As with chemical inhibition, siRNA knockdown of Gαi2 abated the OT-
mediated activation of NF-κB, ERK and p38, and the consequent COX-2 and p-cPLA2 levels (n=3; a p<0.05 vs 
NS of Nt siRNA, b p<0.05 vs NS of Gi-2 siRNA, c p<0.05 Nt siRNA vs Gi-2 siRNA, ANOVA). 
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Figure 5.11. The role of Gαi3 protein in the OT-mediated activation of NF-κB and MAPK, and up-
regulation of COX-2 and p-cPLA2 in human amnion epithelial cells. Prelabour amnion epithelial cells were 
subjected to tranfection with non-target siRNA or Gαi3-target siRNA (30 pmol) via electroporation prior to OT 
(100 nM) treatment. Western blot analysis was used to examine the efficiency of Gαi3 knockdown and its effect 
on OT-mediated activation of NF-κB and MAPKs, as well as COX-2 and p-cPLA2 expression. Control with β-
actin confirmed equal protein loading (n=3; a p<0.05 vs NS of Nt siRNA, b p<0.05 vs NS of Gi-3 siRNA, c 
p<0.05 Nt siRNA vs Gi-3 siRNA, ANOVA).  
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5.6. Summary discussion 
Oxytocin receptors are coupled to various G proteins including Gαq, Gαi and Gαs and they can regulate 
diverse cellular functions through multiple signalling pathways. Although the subtypes of G proteins 
involved in OT-induced COX-2 expression in certain target cells is well recognised, particularly in 
myometrium [451-454, 461], that in human amnion have not been investigated. The results in this 
study indicate that Gαi, and not Gαq coupling, is involved in the OT-initiated signal transduction in 
human amnion epithelial cells.  
In rabbit amnion, OT binding to OTR typically leads to Gαq coupling and increase in PLC activity 
[367]. This increases both DAG and IP3 formation, resulting in an increase in intracellular Ca
2+ 
levels, 
subsequently favouring PKC activation to stimulate MAPK activation. In human amnion, we have 
shown an influx of calcium upon OT stimulation (Fig.5.1). However, we found that pretreatment with 
U-73122 (PLC inhibitor; U7), GF109203X (PKC-α and -β inhibitor; GFX), or Go6983 (broad 
spectrum PKC inhibitor; Go) was insufficient to interrupt OT-mediated MAPK and NF-κB activation 
and the consequent COX-2 and phospho-cPLA2 expression (Fig. 5.2-4). Interestingly, treatment with 
the inhibitors alone also resulted in increased activation of MAPK and NF-κB, as well as downstream 
COX-2 and phospho-cPLA2 expression. This may be due to the non-selective effects of the inhibitors. 
Previous work in CHO cells have demonstrated that the PLC inhibitor, U-73122 can cause marked 
effects on cell morphology and integrity at higher concentrations of 4-15µM [462]. It is possible that 
the ability for U-73122 to potentiate its effects may be associated to events that are involved in these 
morphological changes. As the cytolysis induced by U-73122 could be cell-dependent, it would be 
important to study these effects in the future. In addition to this, there has been an accumulation of 
reports that indicate undesired side-effects of U-73122. In pancreatic acinar cells and NG108-05 cells, 
it has been shown to activate cation channels and drive oscillations in intracellular Ca
2+
 levels [463, 
464], and it has also been shown to activate tyrosine kinases or inhibit tyrosine phosphatases in 
patelets [465]. Non-specific effects have been reported with PKC inhibitors, GF109203X and Go6983. 
In human platelets, treatment with PKC inhibitors demonstrated enhancement of ligand-induced Ca
2+
 
release as well as Ca
2+
 entry [466]. Therefore, it can be concluded that both PLC and PKC inhibitors 
can have multiple effects and thus using them as a tool to identify the role of PLC/PKC activity in 
cellular events may be limited.  
The role of calcium in OT signalling needs to be investigated further, but these data do not support the 
role of Gαq/PLC or PKC pathways in the regulation of OT-mediated effects. This complements the 
finding from PHM1 cells, where OT-induced activation of ERK1/2 was found to be independent of 
PLC or PKC pathways [467]. In human myometrial cells, OT-induced COX-2 expression and PG 
synthesis were also reported to be independent of PKC activation [394]. In contrast to this, CHO cells 
expressing OTR, demonstrate that activation of both PLC and PKC, as well as calcium increase are 
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essential for OT-induced ERK2 activation and PG synthesis [442]. Therefore, it is possible that the 
relative importance of PLC/PKC in OT signalling is cell type-dependent.  
To further confirm that Gαq signalling is not required for OT to exert its effects in human amnion, Gαq 
targeted knockdown was performed.  Under conditions where Gαq proteins were successfully 
downregulated by targeted siRNA transfection, OT-induced activation of MAPKs and NF-κB and the 
consequent COX-2 expression was not significantly affected (Fig. 5.5), suggesting that OTR-Gαq 
coupling may not be required to drive the effects of OT in human amnion. Krumins and Gilman 
reported that reductions in Gαq protein concentrations are associated with compensatory changes in the 
levels of other G proteins including Gαi [468]. Thus, although we have demonstrated that Gαq targeted 
knockdown has no effect on OT signalling, we cannot eliminate the potential role of Gαq due to the 
compensatory effects. 
Previous report in cultured myometrial cells demonstrated that OT stimulated calcium response, ERK 
phosphorylation and COX-2 expression are PTX sensitive to an extent, indicating a possible 
involvement of Gαi [394, 451, 453, 469, 470]. Therefore, we used PTX (Gαi inhibitor) to disrupt Gαi 
signalling in amnion and studied its effects on OT responses. We observed an inhibitory effect of PTX 
on OT-induced increase in intracellular calcium was observed in human amnion (Fig. 5.6 B), 
consistent with previous findings in rats. However, despite evidence of OT stimulating PLCβ/IP3 
increase to drive accumulation of intracellular calcium in human myometrium [452, 453], such 
increase in IP3 was not observed in amnion (Fig. 5.6 C). Our findings resemble the calcium signalling 
evoked by vasoactive intestinal peptide (VIP) binding to Gαi coupled receptor, which does not elicit a 
measurable increase in IP3 [457]. It has been previously demonstrated that Gαi coupled receptors can 
mediate calcium signalling via Gβ/γ [459], independent of IP3, as Gβ/γ  can directly regulate multiple 
channels including IP3R, inward-rectifying K
+
 channels and the L-type Ca
2+
 channels [471]. Gβ/γ are  
able to regulate adenylyl cyclase [472], PLCβ [473] and cPLA2 [474] directly, however, we did not 
see a PLC/PKC-dependent signalling with OT stimulation. Therefore, a potential explanation for our 
finding is that OTR- Gαi coupling in amnion uses a PLC/IP3/PKC-independent pathway, mediated via 
Gβ/γ, to trigger increase in intracellular calcium levels. Pretreatment with PTX was successful in 
suppressing OT-induced MAPK and NF-κB activation (Fig. 5.7 A) as well as COX-2 and p-cPLA2 
expression at protein level (Fig. 5.7 B), resulting in a decrease in OT-induced PGE2 production (Fig. 
5.8). Activation of cPLA2 requires calcium and phosphorylation at Ser505 by active MAPKs and both 
of which can be regulated by Gαi [475, 476]. In summary, our data indicate that in human amnion OT 
binds to OTR coupled to Gαi, which then activates a calcium response via a PLC/IP3/PKC-
independent pathway to contribute to the sequential activation of MAPK and NF-κB signalling 
cascades, ultimately mediating PGE2 synthesis. 
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Although we have demonstrated a functional coupling of amnion OTRs to Gαi proteins using PTX, it 
is still a matter of debate as PTX treatment alone have been reported to affect cAMP levels in 
myometrial cells [467]. PTX acts by ADP-ribosylation, which irreversibly inhibits Gαi activation, thus 
PTX sensitivity is considered to be an indication for Gαi involvement. However, PTX treatment has 
been shown to lead to inhibition of PLC by increasing cAMP concentrations and activating PKA [311, 
477]. It also inhibits MAPK activation by preventing transmission of signals from Ras to c-Raf [478-
480]. Therefore, inhibition of OT-induced activation of MAPKs and NF-κB, and expression of COX-
2 and p-cPLA2 by PTX pretreatment does not necessarily constitute as proof of OTR-Gαi coupling 
[467]. To overcome this limitation, Gαi targeted siRNA knockdown studies were performed. Prior to 
siRNA knockdown, we first demonstrated expression of different Gαi isoforms in human amnion (Fig. 
5.9). Keeping in mind that we only found expression of Gαi-2 and -3, the involvement of these subtypes 
were confirmed as Gαi-2 targeted knockdown reduced OT-induced activation of MAPKs and NF-κB, 
and expression of COX-2 and p-cPLA2 (Fig. 5.10), and to a lesser extent by Gαi-3 targeted knockdown 
(Fig. 5.11). These data suggest that Gαi-2 predominantly mediates OT-induced responses in human 
amnion. Previous work in rat myometrium has established a strong association between OTR/Gαi 
coupling and cPLA2 [461]. Cohen-Tannoudji et al. showed up to 41% increase in the concentration of 
Gαi-2 in rat myometrium, second to Gαq increase of 2-folds, at the end of gestation whereas Gαi-3 
decreased with advancing gestation [481]. These findings combined provide further support for a 
more prominent role of Gαi-2 compared to Gαi-3 during parturition, as they imply that other than Gαq, 
Gαi-2 is the main form of Gαi associated with OTR at the time of labour.  
The summary of the mechanistic pathways involved in OT induced PG synthesis is shown in Fig.5.12. 
In human amnion, OT binds to OTR and with OTR/Gαi-2 coupling, it drives the activation of ERK1/2 
and p38 kinase, which subsequently trigger NF-κB activation. The p65-p65 homodimers of NF-κB 
transcriptional pathway translocate to the nucleus and result in an increase in COX-2 expression 
whilst activating cPLA2 to promote PGE2 production. The details of how Gαi drives MAPK and NF-κB 
activation is still not clear, the potential involvement of Gβ/γ and direct association between Gαi and 
downstream effectors, such as calcium and cAMPs, need to be studied further.  
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Figure 5.12. A modified model for OT/OTR signalling and action in amnion. OT binding to OTR drives 
Gαi2 signalling, which leads to sequential activation of MAPKs, ERK1/2 and p38 kinase, and NF-κB. The NF-
κB p65 homodimers translocate to the nucleus and bind to κB sites to induce expression of COX-2. This leads to 
the increase in PG synthesis in human amnion cells during the onset of labour. It is hypothesized that the 
PLC/IP3/PKC-independent calcium mobilisation induced by OT is via Gβ/γ proteins, which is capable of 
activating ion channels directly. The combination of calcium influx and MAPK activation triggers 
phosphorylation of cPLA2, another key enzyme in PGE2 synthesis. However, the link between calcium 
mobilisation and activation of MAPK and NF-κB signalling cascades requires further examination.  
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6. Effect of oxytocin receptor antagonists on OT-induced 
proinflammatory effects 
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6.1. Introduction 
Although advances have been made in prediction and prevention of preterm birth in women identified 
as high risk based upon past history, the overall rate has not reduced. The 2012 WHO report “Born 
Too Soon” [482] highlighted the need for effective tocolytic drugs to delay preterm birth in women 
with preterm contractions. There are several classes of tocolytic agents developed including 
magnesium sulphate [76], calcium channel blockers [74], nitric oxide donors [73], COX inhibitors 
[77], betamimetics [75], and OTR antagonists [333].  
Oxytocin is one of the strongest uterotonic agents known to stimulate uterine contractions and there is 
evidence to support that OT plays a key role in the initiation and regulation of both term and preterm 
labour. It has been shown that OT concentrations as well as sensitivity to OT increases markedly in 
both myometrium and fetal membranes prior to the onset of labour, which in turn leads to increase in 
PGF2α and PGE2 synthesis [181, 309]. Thus, there is a strong rationale for designing tocolytics that 
target OT/OTR system to inhibit premature uterine contractions. OTR antagonists are designed to 
block the increase in intracellular calcium levels leading to relaxation of the myometrium [483]. There 
are a number of peptide and nonapeptide OTR antagonists produced, with the most-studied OTR 
antagonist being atosiban. The effectiveness of OTR antagonists has been reviewed previously with 
conflicting results. A randomised, double-blind, placebo-controlled trial using an oxytocin receptor 
antagonist, atosiban, showed that atosiban prolonged the pregnancy for up to 7 days in women at a 
gestational age less than 28 weeks with minimal maternal-fetal adverse effects [336]. However, more 
recent reviews of multiple randomised controlled trials concluded that atosiban did not reduce the risk 
of preterm birth before 37 weeks, 32 weeks or 28 weeks [484], nor improve neonatal outcome [78].  
We have shown in previous chapters that OT not only triggers uterine contractions but also activates 
proinflammatory responses in human amnion to initiate the onset of labour. The aim of the following 
chapter was to confirm that OT exerts its effect via OTR (not via AVPR1A), and to investigate the 
efficiency of different OTR antagonists in inhibiting the OT-induced proinflammatory responses. 
OTR antagonists were anticipated to result in down-regulation of PGE2 and cytokine synthesis, by 
preventing activation of NF-κB and/or MAPK pathways. Currently available OTR antagonists, 
atosiban and ornithine vasotocin (OVT) were employed to study their effectiveness. The proposed 
experiments aimed to expand the knowledge of human parturition and enable rapid progress in the 
management of preterm labour. 
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6.2. Human amnion epithelial cells express vasopressin receptor 
OT binds not only to OTR, but also to vasopressin receptors [485], however, there is limited evidence 
suggesting a role for vasopression receptors in the processes of parturition. The uterus contains 
AVPR1A, but its expression does not change during gestation or labour [486]. Similar findings were 
observed in ovine fetal membranes, where there were no significant changes in the AVPR1A mRNA 
levels throughout gestation [487]. A study by Czaja et al. showed that rabbit amnion membranes were 
completely devoid of AVPR1A [488], however, the presence or absence of AVPR1A in human 
amnion is yet unclear. As both OTR and AVPR1A are capable of coupling to Gαq and Gαi proteins 
[451, 485], we deemed it important to investigate whether human amnion expresses AVPR1A. 
Initially, cDNAs from amnion were subjected to GAPDH PCR amplification to verify their integrity. 
Then they were subjected to PCR amplification using primers targeting AVPR1A, followed by SYBR 
safe stained 1.5% agarose gel electrophoresis. The PCR products were visualised by UV light and a 
AVPR1A PCR amplicon of the expected size (452 bp) was observed in all amnion samples (Fig. 6.1 
A). Placental cDNA were used as positive controls. The PCR amplicons from these samples were then 
purified using QIAquick PCR purification kit and sequenced to confirm specificity. The DNA 
sequence information confirmed the product as AVPR1A (Fig. 6.1 B).  
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Figure 6.1. Human amnion expresses arginine vasopressin receptor 1A. Prelabour amnion epithelial cells 
were established from 5 different samples. cDNAs were synthesized using total RNA extracted from non-
stimulated amnion cells. Products of PCR reactions with primers specific for arginine vasopressin receptor 
(AVPR1A) were analysed on 2% agarose gel. PCR products of expected size, 473 bp, were detected (A). 
Placental cDNA was used as positive controls (P). The PCR product was purified and subjected to DNA 
sequencing. AVPR1A cDNA and PCR product sequences were aligned using BOXSHADE (B).  
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6.3. Ornithine vasotocin suppresses the proinflammatory effects of OT 
There have been numerous studies on structural modification of OT to develop potent in vivo 
antagonists of OT. The du Vigneaud and Rudinger laboratories first reported in vitro OT antagonists 
with structural modifications [489, 490], which were then shown to be fully effective in vivo [491]. 
Later antagonists replaced the Tyr
2
 by Tyr(Me)
2
 and Leu
8
 by Orn
8
, and resulted in significant 
enhancement of in vivo oxytocic antagonism [492]. However, these modified OT antagonists lacked 
specificity with regard to V1 receptors. This led to development of new analogues which replaced the 
Gln
4
 to Thr
4
 and Gly-NH2
9
 to Tyr-NH2
9
, exhibiting similar in vivo oxytocic antagonism as 
[d(CH2)5,Tyr(Me)
2
,Orn
8
] vasotocin, but acting as a much weaker vasopressor antagonists [490]. A 
potent, highly specific OT antagonist, [d(CH2)5,Tyr(Me)
2
, Thr
4
, Orn
8
, Tyr-NH2
9
] vasotocin (OVT), 
was utilised in this study to verify whether the proinflammatory effects of OT in amnion are mediated 
specifically via OTR. Pre-labour amnion epithelial cells were treated with OVT (1 µM) for 30 min 
and stimulated with OT (100 nM) for 5 min, 15 min, 30 min, 1 h, 2 h, 4 h and 6 h. The presence of 
OVT significantly reduced the activation of MAPKs and NF-κB by OT (Fig. 6.2 A), as well as 
reducing OT-induced COX-2 and p-cPLA2 expression to basal level (Fig. 6.2 B). These findings 
support our hypothesis that in human amnion, OT is binding to OTR to activate ERK, p38 kinase, and 
NF-κB, which in turn increases PGE2 and cytokine production. 
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Figure 6.2. OT-induced proinflammatory effects are predominantly via OTR. Prelabour amnion epithelial 
cells pretreated with a potent OTR-A, OVT (1 µM), were stimulated with OT over time. Western blot analysis 
was used to examine the effect of OVT on OT-mediated activation of NF-κB and MAPKs (A), as well as COX-
2 and p-cPLA2 expression (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01, 
*** p<0.001, ANOVA).  
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6.4. Atosiban does not inhibit OT-induced proinflammatory effects 
Atosiban is a currently available competitive OT and vasopressin antagonist and it is one of the most 
studied OT antagonists. Atosiban was developed specifically for the treatment of preterm labour and 
was designed to have uterine specificity thus minimizing multiorgan side-effects. Preliminary studies 
have shown atosiban to be effective in inhibiting uterine contractions in both animal [493, 494]  and 
human [294, 495, 496] in vitro and in vivo models. Despite inital reports of atosiban as a promising 
tocolytic agent, more recent meta-analysis of various clinical trials concluded that atosiban does not 
have a significant effect on the risk of preterm birth, neonatal morbidity or perinatal mortality [78, 
484]. The limited efficacy of atosiban may be due to its mechanism of action and its high affinity to 
vasopressin receptors [483]. 
Having shown that OT exerts its proinflammatory effects via OTR, we aimed to examine the effect of 
OTR-A, atosiban, on OT-induced activation of NF-κB and MAPKs, as well as upregulation of PG 
synthetic enzymes. Pre-labour amnion epithelial cells were pre-treated with atosiban (10 µM and 20 
µM) for 30 min and then stimulated with OT (100 nM) for 5 min, 15 min, 30 min, 2 h, 4 h and 6 h.  
OT consistently activated NF-κB, ERK and p38 kinase after 15 min, 5 min and 30 min of stimulation 
respectively (p<0.05; Fig. 6.3 A). The presence of atosiban did not affect the effect of OT on NF-κB, 
ERK and p38 kinase (Fig. 6.3 A). The upregulation of COX-2 expression as well as the increase in 
activation of cPLA2 by OT was unaffected by atosiban (Fig. 6.3 B). These findings suggest that 
atosiban may be effective in inhibiting uterine contractions to certain extent, but it is insufficient in 
inhibiting the proinflammatory effects of OT in human amnion. 
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Figure 6.3. Atosiban fails to inhibit the proinflammatory effects of OT. Prelabour amnion epithelial cells 
pretreated with atosiban (10 µM or 20 µM), were stimulated with OT over time. Western blot analysis was used 
to examine the effect of atosiban on OT-mediated activation of NF-κB and MAPKs (A), as well as COX-2 and 
p-cPLA2 expression (B). Control with β-actin confirmed equal protein loading (n=6; * p<0.05, ** p<0.01 vs NS, 
ANOVA).  
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6.5. Atosiban activates MAPKs and NF-κB, and upregulates subsequent expression of COX-
2 and cPLA2   
Pretreatment with atosiban was unable to inhibit the proinflammatory effects of OT in amnion. To 
study the effect of atosiban on its own, pre-labour amnion epithelial cells were treated with atosiban 
alone (10 µM) or atosiban and OT together for 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, and 6 h. Western 
blot analysis showed significant increase in phosphorylation of NF-κB p65, ERK1/2 and p38 kinase 
with both atosiban treatment alone (p<0.01; Fig. 6.4 A), and atosiban+OT (p<0.05; Fig. 6.4 A). 
However, there were no significant differences between the effects of atosiban alone and that of 
atosiban+OT treatments. The proinflammatory effects of atosiban were not limited to the activation of 
inflammatory mediators such as MAPKs and NF-κB but it also resulted in the upregulation of 
downstream pro-labour gene expression; COX-2 and p-cPLA2, to similar extent as OT treatments (Fig. 
6.4 B). This suggests that Atosiban may have a proinflammatory effect in human amnion.  
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Figure 6.4. Atosiban activates NF-κB and MAPK, and upregulates inflammatory genes in human amnion 
epithelial cells. Prelabour amnion epithelial cells were treated with atosiban (10 µM or 20 µM) and OT (100 
nM) simultaneously over time. Western blot analysis was used to examine the effect of atosiban and OT on the 
activation of NF-κB and MAPKs (A), as well as COX-2 and p-cPLA2 expression (B). Control with β-actin 
confirmed equal protein loading. Atosiban treatment alone led to significant activation of p65, ERK and p38. 
Similarly, COX-2 and p-cPLA2 levels were increased in atosiban treated cells (n=6; * p<0.05, ** p<0.01, *** 
p<0.001 vs NS, ANOVA).  
145 
 
6.6. Atosiban stimulates expression of downstream NF-κB regulated genes as well as PGE2 
production 
Our data implies that atosiban acts as a selective agonist to induce activation of proinflammatory 
pathways in human amnion. To determine whether atosiban has any effect on the downstream genes 
such as cytokine and prostaglandins, pre-labour amnion epithelial cells were grown to confluence, and 
treated with atosiban (10 µM) for 1 h, 2 h, 4 h, 6 h and 24 h. NF-κB and MAPKs were activated upon 
atosiban treatment to similar extent as OT treatment. The mRNA expression of downstream NF-κB 
regulated genes with atosiban was further studied. Atosiban increased mRNA expression of COX-2 
and IL-6 by approximately 2-fold after 4 h, and CCL5 by 1.8-fold after 2 h (p<0.05; Fig. 6.5 A-C). 
We found increases in IL-6 and CCL5 with atosiban at protein level; IL-6 increased by3-fold, 
reaching a statistical significance after 2 h (p<0.05; Fig. 6.5 D), and CCL5 incread by 2-fold (p<0.05; 
Fig. 6.5 E). The expression of IL-8, CCL2 and SOD2 were not affected by atosiban.   
As previous result showed increase in the expression of PG synthetic enzymes, COX-2 and p-cPLA2, 
with atosiban, the culture media from treated cells were collected and analysed for PGE2 release. The 
PGE2 ELISA showed an increase in PGE2 concentration with atosiban treatment compared to NS 
controls, peaking after 4 h stimulation and reduced back to basal level by 6 h (p<0.05; Fig. 6.6).  The 
details of how atosiban triggers activation of NF-κB and MAPK to regulate expression of different 
genes are yet unclear. Further investigations focusing on confirming the biased agonist effect of 
atosiban and determining the G-protein signalling involved in atosiban-OTR binding can aid the 
future development of tocolytic drugs. 
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Figure 6.5. Upregulation of inflammatory genes by atosiban in human amnion epithelial cells. 
Downstream NF-κB regulated genes, COX-2 (A), IL-6 (B), and CCL5 (C) all showed increased expression in 
response to atosiban (10 µM) treatment as assessed by qRT-PCR. Transcript levels were normalised to the 
housekeeping gene, L19 (n=6, * p<0.05 vs non stim, ANOVA). The collected culture media were used for IL-6 
(D) and CCL5 (E) ELISA (n=3; * p<0.05 vs NS, ANOVA).  
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Figure 6.6. Increase in the production of PGE2 upon atosiban treatment. Pre-labour amnion epithelial cells 
were serum depleted overnight and treated with atosiban (10 µM) over time. The culture media were collected 
for PGE2 EIA analysis (n=6; * p<0.05 vs NS, ANOVA).  
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6.7. OTR-Gαi coupling is involved in atosiban-mediated proinflammatory response  
Recent studies have suggested biased agonist effect of OTR-A, specifically atosiban, where it has 
been shown to inhibitor Gαq signalling whilst acting as a Gαi agonist in cell lines. To elucidate the Gαi 
signalling involved in atosiban-induced proinflammatory effects in human amnion, pre-labour amnion 
cells were pre-incubated in PTX (0.5 µg/ml) and treated with atosiban (10 µM) for 5 min, 15 min, 30 
min, 2 h, 4 h and 6 h. Both OT and atosiban significantly increased phosphorylation of NF-κB and 
MAPKs. Presence of PTX suppressed atosiban-induced activation of NF-κB p65 and ERK1/2 by 64% 
and 69% respectively, reaching basal level (p<0.05; Fig. 6.7 A). The activation of p38 kinase was 
inhibited to some extent but did not reach significance (Fig. 6.7 A). Similarly, atosiban-induced COX-
2 and p-cPLA2 expressions were suppressed in presence of PTX (p<0.05, p<0.001; Fig. 6.7 B), 
indicating a role for Gαi in atosiban-mediated proinflammatory effects. 
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Figure 6.7. Atosiban-induced proinflammatory effects are PTX-sensitive. Prelabour amnion epithelial cells 
pretreated with PTX (0.5µg/ml) for 30 min and stimulated with atosiban (10 µM) over time. Western blot 
analysis was used to examine the effect of PTX on atosiban-mediated activation of NF-κB and MAPKs (A), as 
well as COX-2 and p-cPLA2 expression (B). Control with β-actin confirmed equal protein loading (n=6; * 
p<0.05, ** p<0.01, *** p<0.001, ANOVA).  
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6.8. Summary and discussion 
It has been previously demonstrated that PGE2 synthesised in amnion by inducible COX-2 is involved 
in the onset of labour. OT has been shown to upregulate COX-2 expression via MAPKs and NF-κB 
activation in various cell types. We are the first to demonstrate that OT mRNA level is elevated in 
amnion with labour and OT binding to OTR drives Gαi-2 signalling to activate MAPK-dependent NF-
κB signalling pathway leading to subsequent cPLA2 and COX-2 expression, and PGE2 release.  
OT principally activates OTR which is coupled to various G proteins including Gαq and Gαi [497]. It is 
known that OT binding to vasopressin receptor can trigger downstream signalling [485]. The 
signalling pathways activated by AVPR1A have been studied extensively in several different cell 
types [498-500]. Activation of AVPR1A coupled to G-proteins has been shown to drive calcium 
response and in turn increase PLC and PKC activity resulting in stimulation of transcription factors 
such as c-fos and c-jun [499]. We have shown that human amnion cells express AVPR1A (Fig. 6.1), 
and have confirmed that the downstream proinflammatory effects of OT during the onset of labour are 
through OTR and not AVPR1A. Pretreatment with OVT (specific OTR antagonist) reduced OT-
induced ERK1/2 and p38 kinase activation and the subsequent activation of NF-κB (Fig. 6.2). COX-2 
protein expression as well as phosphorylation of cPLA2 was reduced in presence of OVT, suggesting 
that OTR predominantly mediates OT-induced PGE2 release in amnion cells. Our data are consistent 
with the fact that OT effect is mediated principally by its receptor, OTR,  whereas the effects of 
arginine vasopressin are mediated by both OTR and AVPR1A [497]. Thornton et al. has previously 
demonstrated that AVPR1A expression in human myometrium does not change with progressing 
stages of pregnancy or labour onset [500], indicating that AVPR1A is not involved in the activation of 
the pregnant human uterus. 
As mentioned above, human OTR have the ability to couple to Gαq, Gαi [451-454] and in a smaller 
extent to Gs [461]. Only the signalling pathways induced by Gαq have been studied extensively to be 
exploited for the development of tocolytic drugs. Atosiban, an OTR antagonist currently used for the 
treatment for preterm labour, works by blocking the Gαq signalling pathway and subsequently 
inhibiting PLCβ activation and calcium mobilisation in myometrial cells, subsequently preventing 
uterine contractions [293, 497, 501]. In amnion cells, we have demonstrated that atosiban does not 
inhibit the OT-induced activation of MAPKs and NF-κB, or the expression of COX-2 and 
phosphorylation of cPLA2 (Fig. 6.3).  
We have found that despite being an OTR-A, atosiban activates MAPKs and NF-κB to induce COX-2 
and p-cPLA2 expression via Gαi signalling. In addition, we have demonstrated that atosiban treatment 
alone is capable of stimulating PGE2 synthesis whilst increasing the production of other 
proinflammatory chemokines and cytokines (Fig. 6.5 and Fig. 6.6). The effect of atosiban on the 
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mRNA level of proinflammatory chemokines and cytokines appeared to be similar to the transient 
effect of OT. However, Atosiban-induced PGE2 synthesis rapidly declined after reaching a peak at 4 h, 
whereas OT maintained high levels of PGE2 at 6 h. The significance of such temporal difference in 
PGE2 synthesis between OT and Atosiban is yet to be understood, however, it is possible that OT is 
capable of prolonging its effects further in comparison to Atosiban via post-
transcriptional/translational regulation of PG synthetic enzymes. It would be important to understand 
the role of these differences in the OT and Atosiban effects as the induction of proinflammatory 
effects in human amnion could have detrimental consequences upon the fetus in preterm labour in the 
presence of chorionamnionitis if there is a proinflammatory effect on the fetal brain. Interestingly, the 
principal placebo controlled RCT of Atosiban [336] showed that although Atosiban was ineffective in 
delaying preterm labour at gestational ages below 28 weeks its use was associated with an increase 
risk of fetal/neonatal death in infants below 26 weeks. This was explained in part by uneven 
recruitment at low gestational ages, but also by the presence of chorionamniotis. The authors 
commented that adverse effects at these gestational ages, caused by Atosiban, could not be excluded.   
As atosiban is a competitive antagonist to OTR-Gαq coupling, the proinflammatory effects of atosiban 
may be due to a biased agonist effect. Biased agonism is a term introduced in 1998 to describe the 
behaviour of single ligands that can promote specific receptor conformations capable of differentially 
activating distinct signalling cascades [502]. Recent evidence indicate that G protein-coupled receptor 
signalling does not involve a simple „on‟ and „off‟ switch but instead, different agonists/antagonists 
can activate multiple effectors with varying efficacies [503]. The first report of biased agonism was 
seen in small cell lung carcinoma, where substance P (D-Arg
2
, D-Phe
5
, D-Trp
7,9
, Leu
11
) inhibited the 
Gαq-mediated pathway whilst acting as an agonist to Gαi, resulting in activation of MAPKs, 
particularly JNK, and inhibition of cell growth [502, 504]. Another ligand shown to have biased 
agonist properties is the bradykinin antagonist dimer CU201, which blocks the Gαq-mediated pathway 
and activates G12-13 leading to apoptosis in multiple cancer cell lines [505]. Moreover, the OT/OTR 
system in various cell types has previously been suggested to activate multiple G protein signalling 
pathways which act in synergy [506]. Biased agonist effect has been also observed in the OT/OTR 
system as activation of OTR can drive opposite effects via coupling to different type of G-proteins. In 
the case of neuronal cells, OT can inhibit or stimulate K
+
 conductance via PTX-resistant or -sensitive 
G-protein pathways [507]. An analogue of OT, atosiban, has been shown to have biased agonist effect 
through OTR in neuronal cells as well as in other cell lines. Atosiban acts as a selective agonist upon 
OTR-Gαq coupling to induce cell proliferation whilst acting as a competitive antagonist upon OTR-Gαi 
coupling to inhibit cell growth in MDCK and HEK293 cell lines stably expressing OTR [508, 509]. 
Similar to this, inhibiting Gαi by PTX resulted in a significant reduction in the proinflammatory effects 
of atosiban in human amnion (Fig. 6.7). These studies provide potential explanation for the agonistic 
effect of atosiban via Gαi in human amnion, however, this hypothesis requires further investigation.  
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In conclusion, our data indicate that OT predominantly works through OTR to induce activation of 
MAPKs and NF-κB, to regulate COX-2 expression and cPLA2 activity. Atosiban may possess a 
biased agonist property on amnion OTRs to act as a Gαi agonist, promoting proinflammatory effects 
similar to that of OT. Given that atosiban has already been approved as a tocolytic drug in the 
management of preterm labour, this ability of atosiban to drive proinflammatory effects in amnion is 
worth noting. Inflammation is strongly associated with labour and it is possible that whilst atosiban is 
blocking uterine contractions by acting as a Gαq antagonist, it may be activating an inflammatory 
response in the amnion via Gαi signalling, which could potentially explain the limited efficacy of 
atosiban in delaying labour. The possibility that a drug designed for a therapeutic property can 
stimulate opposite effects in different tissue is a pharmacological oddity that requires attention in the 
future discovery of a target-specific drug. An „ideal‟ OTR antagonist should block pro-contractile 
effects of OT without activating inflammation. The potential for differential effects of OT and OTR-
antagonists has a major clinical implication in the use of OT in induction of labour, and OTR 
antagonists as tocolytics. It will therefore be critical that therapeutics designed to modulate the 
OT/OTR system for the management of term and preterm labour take into account the role of OT in 
the activation of inflammation and the effects of differential G-protein coupling of the OTR. 
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7. Summary and Final Conclusion 
  
154 
 
Oxytocin is widely recognised as playing a major role in promoting myometrial contractility [510]. It 
is the most potent uterotonin currently available and is extensively used in the clinical management of 
dysfunctional labor [234]. However, labor is not only characterised by myometrial contractions. The 
onset of human labor resembles an inflammatory reaction and a substantial body of evidence suggests 
that both preterm and term labor are linked with increased NF-κB activity in all gestational tissues 
[230, 352, 511]. Although labor onset is defined clinically by myometrial contractions, these are 
preceded by activation of NF-κB-mediated inflammatory pathways in gestational tissues leading to 
fetal membrane remodelling and cervical ripening. The fetal membranes (composed of amnion and 
chorion) undergo carefully regulated biochemical changes that modulate functional pathways 
precipitating labor and birth. Just prior to labor, there is an increase in inflammatory cytokine release 
from the amnion [322, 512] as well as increased prostaglandin (PG) synthesis, particularly PGE2 [323]. 
Collectively these changes promote cervical ripening, lower uterine segment remodelling and 
initiation of myometrial contractions [190, 191, 204, 323, 385]. In murine parturition surfactant 
protein A (SP-A) produced by the maturing fetal lung has been suggested to represent the stimulus for 
a cascade of inflammatory signaling pathways leading to labor onset [131]. However in human 
pregnancy the endocrine or mechanical stimuli triggering inflammatory activation are obscure. 
Our group has shown that NF-κB is activated in the human amnion prior to the onset of labour [413], 
leading to the upregulation of prolabour genes including PGs and COX-2. OT is an important 
regulator of PG production in the endometrium, amnion and decidua in several species including 
humans [324, 367, 513-516]. The NF-κB signalling pathway plays a critical role in the regulation of 
inflammation activation in both term and preterm gestational tissues [325]. Consistent with this, 
suppression of NF-κB activity inhibits LPS-induced preterm labour in mice [131] and IL-1β induced 
uterine contractions in Rhesus monkeys [517]. We have previously shown that both labour and 
inflammation increase amnion sensitivity to OT by inducing OTR expression and that this 
subsequently stimulates PGE2 synthesis [181]. In this study we demonstrate a proinflammatory role 
for OT in the amnion whereby specific stimulation of OTR by its ligand drives the sequential 
activation of MAPKs and NF-κB via OTR-Gαi coupling and subsequent prostaglandin and 
proinflammatory cytokine production. This suggests an additional and hitherto unrecognised role for 
OT in the onset of human labor via modulation of the inflammatory pathways leading to amnion 
activation. 
It has been suggested that OT may play an additional role in prostaglandin production in amnion via 
an unknown mechanism. cPLA2 and COX-2 mediate the committing and rate-limiting step of PG 
biosynthesis, generating the PGH2 intermediate that is converted to the terminal PGE2 by PGES-1 and 
-2 [351]. We have demonstrated that OT treatment of amnion cells up regulates the gene expression of 
prostaglandin synthetic enzymes cPLA2, COX-2, PGES-1 and PGES-2, as well as subsequent PGE2 
production. Consistent with these findings, OT has been reported to regulate the expression of cPLA2 
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and COX-2 genes in both rat [393] and in human myometrial cells [394] via the calcineurin/NFAT 
pathway [450]. Combined with our data demonstrating a local production of OT and OTR with the 
onset of labour, we can extrapolate that a paracrine/autocrine effect of OT drives to the synthesis of 
prostaglandins at term, facilitating downstream fetal membrane remodelling, cervical ripening and 
myometrial contractility.    
OT has a well-defined role in stimulating uterine contractions via calcium signalling at term yet we 
have recently shown that labor is antedated by NF-κB activation and inflammatory stimulation in the 
amnion [413]. Amnion epithelial cells are easily isolated and cultured from fetal membranes collected 
after delivery. Sufficient cells can be obtained to undertake experiments without the need for passage 
and these cells retain their pre-labor non-activated, activated or post-labor phenotype for the duration 
of experiments and therefore represents a reasonable model for investigating OT stimulated NF-κB 
activation. It has been proposed that NF-κB plays a key role in the regulation of implantation, the 
menstrual cycle and parturition. However, it is noteworthy that NF-κB does not function in isolation 
from other intra-cellular signaling pathways. Studies have shown that there is cross talk of NF-κB 
with GPCRs [518, 519]. Our data illustrate a novel mechanism for OT in activating NF-κB, 
demonstrated by phosphorylation and nuclear translocation of the p65 subunit upon OT treatment. 
However, OT did not result in nuclear translocation of p50 or RelB, suggesting a possible 
involvement of p65 homodimers. This was confirmed using EMSA where only p65 supershift was 
observed with OT stimulation. In addition to p65 nuclear translocation, OT elicited activation of 
IKKα/β, degradation of IκBα, and phosphorylation of p65. Taken together, the OT-induced activation 
of NF-κB resembles that of the classical NF-κB signalling pathway triggered by IL-1β stimulation in 
amnion cells [353], with the exception that OT-induced activation of NF-κB involves nuclear 
translocation of p65 homodimers and not p65/p50 heterodimers. Pont et al. have recently reported that 
OT induces translocation of NFATC1-EFP in myometrial cells, leading to NFAT activation [450]. 
The NFAT transcription factors are also part of the Rel family and they have similar structure to the 
NF-κB family. They can bind to overlapping DNA sequence elements and have been previously 
shown to demonstrate interdependence in mediating cardiac hypertrophic gene expression as NF-κB 
nuclear translocation induced by IKKβ or p65 enhanced NFAT nuclear localisation [520]. 
NF-κB activation is a key modulator of COX-2 expression in amnion. Consistent with this we provide 
evidence that OT-induced COX-2 expression in the amnion is NF-κB mediated. The presence of IKKβ 
inhibitor (TPCA1) impeded OT-mediated expression of COX-2, implying that IKKβ activity is 
essential in the regulation of COX-2 by OT. Downregulation of the NF-κB p65 subunit using targeted 
siRNA inhibited the expression of OT-induced COX-2 at both mRNA and protein levels, further 
illustrating the significance of NF-κB in the regulation of COX-2. The OT-induced nuclear 
translocation of p65 homodimers also lead to increased expression of downstream NF-κB regulated 
genes including IL-8, CCL2, CCL5, IL-6 and SOD2, thus suggesting that OT can act as an 
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endogenous signalling molecule at labour onset triggering NF-κB activation in the amnion and the 
subsequent up regulation of key “pro-labour” genes involved in the inflammatory cascade preceding 
delivery. 
Ligand activation of GPCRs, including OTR, often leads to rapid downstream activation of MAPKs 
via both G-protein dependent and independent mechanisms [414]. MAPKs are important regulatory 
components of IL-1β-mediated COX-2 expression and changes in their expression and activation are 
associated with the onset of labour [521]. Here we demonstrate that OT stimulation of human amnion 
epithelial cells increased levels of phospho-ERK1/2, phospho-p38 kinase and phospho-JNK. To 
investigate the role of MAPKs in COX-2 expression, different MAPK inhibitors were used. The 
presence of ERK1/2 inhibitor (U0126) and the p38 kinase inhibitor (SB203580), but not the JNK 
inhibitor (SP600125), resulted in suppression of OT-mediated NF-κB activation (measured as 
decreased phospho-p65) and COX-2 expression, thus suggesting that unlike IL-1β stimulation, where 
NF-κB and MAPK pathways function independently to trigger upregulation of COX-2, OT mediate 
activation of NF-κB via ERK1/2 and p38 kinases. 
Typically, OTR couples with Gαq and partly to Gαi. The significance of Gαq signalling was investigated 
using inhibitors for PLC and PKC. Pre-incubating amnion cells with three different inhibitors of Gαq 
(U73122, GFX, and Go6893) had no effect upon OT-mediated phosphorylation of p65, ERK1/2, p38 
kinases nor COX-2 expression and similar results were observed following siRNA knockdown of Gαq. 
To explore alternative G-protein signaling in human amnion, the effect of Gαi inhibitor, PTX, on OT 
induced proinflammatory effects were examined. Pre-treatment with PTX reduced the effect of OT 
upon NF-κB, ERK1/2 and p38 kinases as well as the consequent COX-2 expression and PGE2 
production. Gene expression of Gαi2 and Gαi3, but not Gαi1, were detected and following siRNA 
knockdown of Gαi2 and Gαi3, the proinflammatory effects of OT were significantly reduced. Our work 
indicates that OTR in human amnion couples to Gαi and not Gαq to regulate the downstream signalling 
cascade, ultimately leading to inflammatory cytokine/chemokine and PG synthesis. 
We have ingestigated the hypothesis that OT may be working via the AVPR1A but that was quickly 
discarded as an OTR-specific antagonist, OVT, abolished the effect of OT completely. Subsequently, 
we used alternative OTR-A to examine their effects on OT-induced proinflammatory responses. The 
OTR antagonist, atosiban, has a well-described role in the modulation of myometrial contractility but 
its effect on other gestational tissues is unknown.  Surprisingly, atosiban failed to inhibit the effect of 
OT in human amnion and atosiban treatment alone resulted in activation of NF-κB, ERK1/2 and p38 
kinases, increased expression of COX-2, CCL5 and IL-6 to a similar extent as OT treatment alone. 
While the immediate effect of Atosiban in the myometrium may be OTR antagonism, subsequent 
suppression of Gαq-mediated signalling and decreased uterine contractility, our results suggest 
atosiban concurrently activates inflammation in the amnion and downstream cytokine production via 
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Gαi. Consistent with this notion, Busneli et al. have recently reported that atosiban activates the Gαi3 
but not Gαq subunit in HEK293 cell lines, stably transfected with the human OTR cDNA [503]. Our 
work has demonstrated that atosiban can act as a biased ligand which means that it can differentially 
activate different intracellular pathways. It is crucial that the ligand bias of OT and OTR antagonists 
are determined as antagonists that do not prevent intracellular coupling to all the contraction related 
pathways will not be effective tocolytics. Indeed the clinical effectiveness of OTR-A is markedly 
different, and our study highlights that understanding the alternative signaling pathways activated by 
different GPCR agonists/antagonists is key in designing „next generation‟ tocolytics. 
In conclusion, our results show a novel mechanism of inflammatory activation in human amnion 
mediated by the OT-OTR system, where OT stimulates PGE2 and inflammatory 
cytokines/chemokines release via a mechanism involving specific binding of OT to OTR and the 
sequential activation of MAPKs and NF-κB via the Gαi-2 signalling cascade. OT leads to translocation 
of NF-κB into the nucleus and drives the expression of numerous prolabour genes including COX-2, 
cytokines and chemokines. The consequent upregulation of prostaglandins and inflammatory 
cytokines/chemokines contribute to fetal membrane remodelling, cervical ripening and myometrial 
activation. This provides compelling evidence that OT modulates key inflammatory pathways that 
promote the labouring phenotype and reveal a novel role for OT in the onset of labour.  
Unexpectedly, OTR-A, atosiban, activates inflammatory pathways in amnion in a similar way to OT 
and increases cytokine/chemokine and prostaglandin secretion. This suggests that atosiban can drive 
inflammation in human amnion, which may have detrimental effects upon the fetus in preterm labour 
at early gestational ages. There is no evidence that current tocolytics, which targets uterine 
contractions, improve long-term outcome for preterm infants. It was previously thought that 
prematurity associated brain injury was mediated by hypoxia ischemia occurring during neonatal 
intensive care. It is now recognized that cytokine-mediated cerebral injury represents an important 
cause of prematurity linked handicap, thus infection/inflammation within the uterus is a major risk 
factor for fetal/neonatal CNS damage and poor outcome [522-524]. It was also previously throught 
that delaying preterm birth would be associated with improved neonatal outcome simply because of 
increased gestational age at delivery and the effect of in utero transfer and steroid administration to 
the mother.  However, in the context of established chorioamnionitis, a perfect tocolytic drug could 
act to retain the fetus in an adverse environment and so do more harm than good. Therefore a tocolytic 
drug that stops contractions but does not inhibit infection-related inflammation in the fetal brain may 
delay delivery, but could worsen neonatal outcome. Furthermore, because activation of inflammatory 
pathways is central to the onset of labour, a drug inhibiting both contractions and inflammation is 
more likely to be effective, thus it is important to consider whether future therapeutics designed to 
modulate the OT/OTR system for the management of term and preterm labour stimulate the activation 
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of inflammation in the amnion by ligand directed signalling to minimise the risk of neonatal exposure 
to inflammation. 
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